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Abstract 
Our environment is constantly threatened by large amounts and variations of man-
made chemicals and natural substances. Parts of these substances accumulate and 
contaminate soil and surface water, affecting the organisms living in it and eventu-
ally contaminate the food chain. The European Union (EU) has imposed regulations 
and obliged EU member states to monitor for possible contaminants in the environ-
ment and food. For this, highly sophisticated mass spectrometry (MS) techniques, 
which can nowadays screen >100 contaminants in a single run, are applied. For 
rapid and inexpensive screening of contaminants, bioactivity-based screening as-
says are applied, however, identification of compounds based on their chemical-
physical properties is not possible. As both methods cannot identify emerging and 
unknown bioactive contaminants, there is a need for new tools and concepts. In 
this thesis, new bioaffinity MS (BioMS) concepts, using an antibody, transport pro-
teins and a receptor, are presented for the screening and identification of contami-
nants. In the first concept, monoclonal antibodies (Mabs) against ochratoxins were 
coupled to fluorescent labeled paramagnetic microbeads for high-throughput flow 
cytometric screening of ochratoxins in wheat and cereal. The identification of ochra-
toxins with nano-ultra performance liquid chromatography-quadrupole-time-of-flight-
MS (nano-UPLC-Q-ToF-MS) was achieved in full scan accurate mass mode. In the 
second BioMS approach, the flow cytometer was replaced by UPLC-triple quadru-
pole (QqQ)-MS for rapid screening of thyroid transporter ligands. For this, thyroid 
transport protein transthyretin (TTR) was immobilized onto inexpensive non-colored 
paramagnetic microbeads and a stable isotopic thyroid hormone was used as label 
in the competitive inhibition format. For the identification of TTR-binding endocrine 
disrupting chemicals (EDCs) in process water and urine, nano-UPLC-Q-ToF-MS 
was used. In order to perform high-throughput screening, a microtiter plate-based 
high-throughput BioMS approach was developed with the same beads but coupled 
with recombinant human sex hormone-binding globulin (rhSHBG) for the detection 
of designer steroids in dietary supplements. Following the screening with rhSHBG-
based BioMS using LC-QqQ-MS, the rhSHBG bioaffinity extracts were injected 
onto chip-UPLC-Q-ToF-MS operated in full scan mode and a wide range of steroids 
were identified. The same approach was applied with the estrogen receptor α (ERα) 
in which LC-QqQ-MS, instead of the commonly applied GC-MS, was used for the 
screening of estrogens with a suitable LC-MS-compatible label. The identification of 
estrogens in ERα-purified supplement extracts was achieved with UPLC-ion mobil-
ity (IM)-Q-ToF-MS. These new BioMS concepts present new tools for the screening 
and identification of emerging yet unknown food and environmental contaminants to 
ensure consumer’s health and fair play in sports.
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Food and environmental contaminants
Due to the needs of our society, large amounts of man-made chemical substances 
are being produced by the industry. Some of these substances might contaminate 
the environment by accident or deliberately and can accumulate, contaminating soil 
and surface water, affecting the organisms living in the environment and entering 
the food chain [1-4]. The contamination is not only caused by the industry but also 
by households [5]. Although some substances might not be toxic at low concentra-
tions, due to continuous accumulation their concentrations may increase to a point 
which makes them harmful to the environment and organisms. Next to the apparent 
adverse health effects, the economic impacts are significant when e.g. contaminated 
food has to be removed from the market [6]. The costs of an environmental con-
tamination incident affect both individuals and the industry and therefore the best 
policy is to avoid these contaminants from entering the environment and/or food 
chain. This can be achieved through regulations and through monitoring possible 
contaminants in environment and food matrices. For this, rapid and inexpensive 
screening methods are required which must be capable of detecting known and 
unknown hazardous contaminants  [7]. In this research, various relevant food and 
environmental contaminants were chosen as model compounds. These compounds 
were used to develop novel bioaffinity mass spectrometric (BioMS) concepts for the 
screening and identification of known and yet unknown emerging contaminants. In 
this chapter, these compounds are introduced. The model compounds researched 
in this study are considered as environmental and/or food contaminants and are 
divided in groups based on whether they are man-made or naturally occurring. The 
former group of compounds consists of chemicals derived from an industrial source 
(industrial contaminants) that enter the food chain through the environment or from 
their use in household products and influence the endocrine system. In this group 
also exogenous steroid hormones are included since the man-made steroids are 
being produced for several specific medical applications, but also for the illegal use 
in sports and animal farming. The substances in this group could either threaten 
the consumers’ health through direct uptake or through the contamination of e.g. 
surface water or soil. The second group includes toxins, such as mycotoxins, which 
are secondary metabolites from fungi known to contaminate a variety of food and 
agricultural commodities worldwide. Mycotoxins are recognized as a potential threat 
to humans and animals through either direct contamination of plants or by carry-over 
of mycotoxins into animal tissue, milk and eggs after intake of contaminated feed [8]. 
Endocrine disrupting chemicals
Many industrial xenobiotics are considered endocrine disrupting chemicals (EDCs) 
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as they might disrupt the normal functioning of the endocrine system of wildlife or 
humans [9, 10]. EDCs can mimic or antagonize the effects of the endogenous hor-
mones or disrupt the synthesis and metabolism of endogenous hormones and dis-
rupt the binding of endogenous hormones to transport proteins. The EDCs enter the 
marine environment directly through discharges of industrial and sewage wastewa-
ter, emissions from various marine activities and oil spills and indirectly through riv-
ers, streams and canals that receive untreated wastewater before entering the sea 
[11]. EDCs can end up in food through the environment but also through migration 
from e.g. plastic food containers [12]. EDCs may be present in packaging materials 
as flame retardants, color, flexibility or softness agents. One of these relevant xeno-
biotics (i.e. a man-made chemical contaminant), is tetrabromobisphenol-A (TBBPA) 
which structurally has similarities to natural thyroid hormone L-thyroxine (T4) (See 
Figure 1). 
Figure 1. Molecular structure of TBBPA (A) and T4 (B).
The production and consumption estimates of TBBPA vary from 120,000 [13] to 
150,000 tons/year, including TBBPA derivatives [14]. TBBPA is used as a flame re-
tardant in many products such as electronics equipment, transportation devices, 
sports equipment, and furniture parts [15]. There are no restrictions in the EU to 
produce TBBPA and a preliminary report by the European Food Safety Authority 
(EFSA) found no risk in using TBBPA as flame retardant [16]. However following an 
EU survey, TBBPA was reported to be present in fish, birds, air and dust, surface 
water, plants and food  [16]. TBBPA is reported to have a binding affinity equal to or 
higher than T4 to the transport protein transthyretin (TTR) [17-19]. T4 and its biologi-
cally active metabolite, triiodothyronine (T3), are essential for the modulation of the 
cellular metabolic rate and for the development and differentiation of several organs, 
especially the brain [20-23]. If T4 is displaced from its transport proteins by e.g. 
TBBPA, this could have consequences in fetal development and later in adulthood 
[24, 25]. Another xenobiotic is triclosan (see Figure 2), which is a broad spectrum 
antimicrobial used widely in e.g. disinfectants, soap, toothpaste and shampoo [26], 
but also reported to be a member of the group of EDCs as it competes with thyroid 
hormones for TTR [17].
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Figure 2. Molecular structure of triclosan.
Although triclosan has a lower binding affinity towards TTR compared to T4, due to 
its occurrence at high levels it can compete with T4 [27]. To give an example of the 
presence of this compound, Calafat et al. described triclosan levels between 2.4 
and 3800 µg L-1 in nearly 75% of urine samples collected from a US National Health 
and Nutrition Examination Survey including subjects ≥ 6 years old [28]. The pres-
ence and bioaccumulation of these bioactive chemicals in the food chain and con-
sequently in humans is a cause of health concern and there is an increasing need 
for high-throughput screening and identification methods for chemicals affecting the 
thyroid system at different levels.
Steroid hormones
The pharmaceutical industry is a source which releases steroid hormones into the 
environment, but also humans and animals excrete natural steroid hormones which 
end up in the environment through sewage discharge and animal waste disposal 
contaminating eventually the surface water [29]. Steroid hormones in the environ-
ment may affect not only wildlife and humans but also plants. Steroid hormones can 
enter the food chain also by the legal and illegal use of steroids as growth promot-
ers in livestock. The chemical structure of steroid hormones consists of a polycyclic 
C17 steran skeleton named cyclopentaneperhydrophenanthrene which has three 
condensed cyclohexane rings (A, B and C) and a cyclopentane ring (D). Depend-
ing on the presence and location of methyl and alkyl side chain groups, the parent 
steroid structures are classified as pregnane (C21), androstane (C19) or estrane 
(C18) (Figure 3) [30]. For steroids, systematic as well as trivial names are widely 
used. Systematic names are applied according to the rules for steroid nomenclature 
formulated by the International Union of Pure and Applied Chemistry (IUPAC) [31]. 
In this nomenclature, the parental steroid structure (preg-, androst- and estr-) is the 
basis for denomination and prefixes and/or suffixes are added to indicate the pres-
ence and location of substituents and double bonds. 
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 R1 R2 R3
Pregnane CH3 CH3 C2H5
Androstane CH3 CH3 H
Estrane H CH3 H
Figure 3. The cyclopentaneperhydrophenanthrene structure with the parent structures of pregnane, an-
drostane and estrane list [30].
On basis of biological activity and pharmacological effect, steroid hormones are di-
vided into two groups. One group is sex hormone steroids producing sex differences 
which include estrogens, androgens and gestagens. The other group includes corti-
costeroids which regulate metabolism and functions in the immune system. Another 
way of classification is based on whether the steroid hormones are endogenous or 
exogenous. Endogenous steroid hormones are biosynthesized in the organism and 
exogenous hormones are foreign compounds which have steroidal effect. The exog-
enous can be either man-made or naturally synthesized. In the following paragraph 
estrogens, androgens and gestagens are described in more detail. 
Estrogens are the endogenous C18 female sex hormone. They are mainly produced 
by the reproductive organs and adrenal glands in females and at lower quantities in 
males. Estrogens are responsible for stimulating the female reproductive system, 
secondary sexual characteristics and are also important in mineral, fat, sugar and 
protein metabolism estrogens [32, 33]. The estrogen receptor α and β (ERα and 
ERβ) mediate the most effects of estrogens. ERα is mainly expressed in the sex 
organs and ERβ is very important in the bone, urogenital tract, cardiovascular and 
central nervous systems and the developing brain [34-36]. 17β-estradiol (β-E2), es-
trone (E1) and estriol (E3) (see Figure 4) account for the most estrogenic activity in 
humans, mediated by the estrogen receptor [37]. 
   
  
 
Figure 4. Molecular structures of (A) 17β-estradiol (β-E2), (B) estrone (E1) and (C) estriol (E3).
However, the estrogen receptors can also bind exogenous hormones and EDCs 
having ER affinity. Table 1 shows the relative estrogenic potency (REP) values of 
A B C
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various endogenous and exogenous hormones demonstrating that next to endog-
enous estrogens many other exogenous compounds can be estrogenic.
Table 1. Reported relative estrogenic potency (REP) values in the RIKILT yeast estrogenic assay. Table 
used with permission [38].
Since natural estrogens are metabolized rapidly in the human body, oral adminis-
tration is only effective at very high concentrations. Estrogens can be used to treat 
menopausal and postmenopausal syndromes and prostate and breast cancers [39]. 
However, estrogens can also be used illegally as growth promoter in animal farming 
[40-42]. 
Androgens are C19 steroids which are important in differentiation and maturation of 
male reproductive organs and the development of male secondary sex characteris-
tics [43]. 17β-testosterone and 5α-dihydrotestosterone are the two most important 
steroid hormones of adult males (see Figure 5).
Compound REP
17β-estradiol 1
17α-ethinylestradiol 1.2
diethylstilbestrol 1.0
dienestrol 0.56
hexestrol 0.36
estrone 0.20
mestranol 0.11
17α-estradiol 0.093
2-hydroxyestradiol 0.011
17β-estradiol 3-benzoate 0.0086
estriol 0.005
nonylphenol 0.009
coumestrol 0.0057
zearalenone 0.0046
α-zearalenol 0.055
β-zearalenol 0.0026
bisphenol A 0.00005
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Figure 5. Molecular structures of (A) 17β-testosterone and (B) 5α-dihydrotestosterone.
17β-testosterone, which is made in the Leydig cells of the testes and in the adrenal 
cortex, has both androgenic and anabolic actions in humans and animals as shown 
in experimental studies [44-47]. The anabolic actions include the inhibition of protein 
catabolism and stimulation synthesis in the skeletal muscle. Many attempts have 
been made to make derivatives of 17β-testosterone, also called anabolic-androgenic 
steroids (AAS), to enhance the anabolic effect while the undesired androgenic effects 
are reduced [48, 49]. However, since both the AAS and 17β-testosterone bind to the 
same androgen receptor, the anabolic effects cannot be entirely separated from the 
androgenic effects [50]. AAS have also medical uses in certain types of anemia 
and they can help in stimulating sexual development in hypogonadal men [43, 51]. 
Following the publication of the results of muscle generating treatments, it became 
obvious that AAS could also be used illegally to enhance the performance of athletes 
[44, 50]. AAS are still available on the black market as growth promoting agent for 
animals because AAS cause weight increase and reduce feed conversion ratios, 
reduce nitrogen retention, increase water retention and fat content [34, 52, 53]. New 
AAS are being synthesized in order to be able to use the AAS in sports or animal 
farming while staying unnoticed during screening in the laboratories. For example, 
the designer steroids tetrahydrogestrinone (13,17-diethyl-17-hydroxy-18,19-dinor-
17-pregn-4,9,11-trien-3-one, THG) [54] and 17α-methyl-5α-androst-2-en-17β-ol 
(Madol) [55] were not detected in routine testing prior to finding the preparations of 
these designer steroids (these designer steroids were found in a syringe and an oily 
product respectively). 
Gestagens are C21 steroids like progesterone and they are excreted by the corpus 
luteum in the ovary of women, the testes, the adrenal glands and the placenta [34]. 
Gestagens are used for the treatment of endometriosis and in the management of 
certain kinds of breast and endometrial cancers [56]. They are also used in oral 
contraception [40] and have a growth promoting effect in man and animals [57-59]. 
This effect is caused by the improvement of weight gain and feed efficiency in meat-
producing animals [60, 61]. 
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Mycotoxins
Mycotoxins are secondary metabolites produced by a range of fungal species. Fungi 
of the genus Aspergillus, Penicillium, Fusarium and Alternaria are the predominant 
mycotoxin producers [62]. More than 300 different mycotoxins have been found to 
induce signs of toxicity in mammals [63]. It is estimated that 25% of the world’s crop 
production is contaminated with mycotoxins. High levels of mycotoxins, especially of 
aflatoxin (AF), fumonisin B (FB) or ochratoxin A (OTA), in food and feed commodities 
may have adverse effects on human and animal health, inducing different kinds 
of mycotoxicoses including carcinogenic effects [64]. OTA is a mycotoxin which 
has carcinogenic, nephrotoxic and teratogenic properties and is produced by 
Aspergillus and Penicillium fungi [65-68]. The Aspergillus fungus also produces OTA 
analogues such as the non-chlorinated ochratoxin B (OTB), ochratoxin α (OTα) and 
ochratoxin β (OTβ) (Figure 6). Most analogues are reported as less toxic than OTA 
but ochratoxin C (OTC) is considered as toxic as OTA since it is converted into OTA 
after metabolism [65, 66].
Figure 6. Molecular structures of (A) OTA, (B) OTB, (C) OTα, (D) OTβ and (E) OTC.
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All analogues are produced approximately 10 times less by the Aspergillus and 
Penicillium fungi [66, 69]. Regardless of the natural occurrence and toxicity of OTB, 
OTα, OTβ and OTC, the majority of existing methods are focused on OTA only. OTA 
is widely found in cereals, wine, coffee, beer, nuts, dried fruits and meat products 
[67, 70]. Table 2 shows the worldwide contamination of OTA in food commodities 
[71].
Table 2. Worldwide contamination of OTA in foods (used with permission [71]).
Country Food commodity Levels  (ppb) Reference
Argentina Peanut 5.6-130 [72]
Belgium Wheat 39E3-823E3 [73]
Bulgaria Wheat 1.5-18 [74]
Canada Oat-based cereals 0.12-0.4 [75]
Barley-based cereals 0.21-6.9
Soy-based cereals 0.15-0.9
Rice-based cereals 0.3-2.4
Croatia Wheat 0.02E9-160E9 [76]
Corn 0.02E9-40E9
Dry beans 0-0.21 [77]
Ethiopia Cereals 54.1-2106 [78]
Egypt Corn 9.3-15 [79]
India Maize 0-20 [80]
Spices 10-102 [81]
Spices 10-120 [82]
Japan Cereal products <39 [83]
Korea Rice 0.2-1 [84]
Kuwait Coffee 0.6-4.5 [85]
Morocco Rice 0.15-4.7 [86]
Nigeria Rice 24-1164 [87]
Qatar Cereals and cereal products 0.2-4.91 [88]
Tunisia Cereal 55-117 [89]
Turkey Wheat flour 0.025-10.5 [90]
Vietnam Rice 0.75-2.78 [91]
Cereal and cereal products are the main sources of EU consumer exposure to OTA 
[92]. The maximum levels (ML) established by the EU for OTA in food vary between 
0.5 and 10 ng g-1 [93]. The ML in cereal and cereal products is 5 ng g-1 and if the 
cereal is meant for direct human consumption, the ML is 3 ng g-1. The lowest OTA 
ML of 0.5 ng g-1 is established for baby food. Guidance values in feed vary between 
50 and 250 ng g-1 and for OTA in cereal or cereal products used as feed material 250 
ng g-1 is applied [94]. 
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EU legislation related to screening and confirmation methods
To ensure consumer’s health and fair trade, EU countries have to monitor all kinds 
of contaminants which may occur in food. To control and monitor food contaminants 
such as steroid hormones or mycotoxins, the EU has introduced regulations which 
describe at what levels contaminants are not considered a risk and which methods 
are considered suitable for monitoring various food samples. These regulations are 
mainly focused on existing known contaminants. 
Screening methods
Screening methods are used to detect the absence or presence of a substance 
or class of substances at the level of interest. Typically, these methods have high-
throughput capability and are used to screen large numbers of samples for potential 
non-compliant results. According to Commission Decision 2002/657/EC, screening 
methods are specifically designed to avoid false compliant results [95]: screening 
methods must be validated and have a false compliant rate of < 5 % (β-error) at the 
level of interest and in the case of suspect non-compliant findings, the result must 
be confirmed by a confirmatory method. Screening methods can be performed using 
commercially available (field) test kits. These test kits are rapid and low-cost and mostly 
based on immunoassays. The results produced by these test kits, are qualitative or 
at best semi-quantitative and multiplexing (combining different assays) is still rare. 
Multiplex flow cytometric immunoassay (FCIA) screening methods are described for 
food contaminants using the flow cytometer of Luminex®. This instrument works with 
microbeads and biomolecules and it is possible to simultaneously measure up to 100 
different biomolecular interactions in a single well [96]. Other distinct advantages 
are high-throughput capability (<1h/96 tests), versatility, accuracy and reproducibility 
[97]. More details on the principle of the Luminex®-based screening are described in 
“Existing methods for the analysis of contaminants”. Multiplex FCIAs are described 
for the screening of plant proteins, which might be used as adulterants in milk powders 
[98], pathogens [99], mycotoxins in cereal, wheat and feed [100, 101], sulfonamides 
in milk [102] and polycyclic aromatic hydrocarbons in fish [103]. An alternative 
screening approach was developed in this research in which biomolecules such as 
antibodies, transport proteins or receptor were immobilized onto superparamagnetic 
beads and LC-MS/MS was used as readout system [27, 104, 105]. More details 
of such a BioMS screening is described in “Existing Methods for the analysis of 
contaminants”. Using the BioMS approach, high-throughput screening of EDCs in 
process water and urine and steroids in dietary supplements was achieved. Indeed, 
like other conventional screening methods, the non-compliant results had to be 
subjected to a confirmatory or identification method. 
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Confirmation 
In Commission Decision 2002/657/EC, confirmatory methods are described as 
methods that provide full or complementary information enabling the substance to 
be unequivocally identified and if necessary quantified at the level of interest [95]. 
Table 3 shows confirmatory methods which are considered suitable according to 
Commission Decision 2002/657/EC [95].
Table 3. Confirmatory techniques for Group A and B substances according to 2002/657/EC [95].
Measuring technique Substances Annex I  Limitations
LC or GC with 
mass-spectrometric 
detection
Group A and B
Only if following either an on-line or 
an off-line chromatographic sepa-
ration. Only if full scan techniques 
are used or using at least 3 (group 
A) or 4 (group B) identification 
points for techniques that do not 
record the full mass spectra.
LC or GC with IR 
spectrometric detection
Group A and B
Specific requirements for absorp-
tion in IR spectrometry have to be 
met.
LC full-scan DAD Group B
Specific requirements for absorp-
tion in UV spectrometry have to be 
met.
LC fluorescence Group B
Only for molecules that exhibit na-
tive fluorescence and to molecules 
that exhibit fluorescence after ei-
ther transformation or derivatiza-
tion.
2D TLC – full scan UV/VIS Group B
Two-dimensional HPTLC and co-
chromatography are mandatory.
GC-Electron capture
 detection
Group B
Only if two columns of different po-
larity are used. 
LC- immunogram Group B
Only if at least two different chro-
matographic systems or a second, 
independent method are used.
LC-UV/VIS (single 
wave-length)
Group B
Only if at least two different chro-
matographic systems or a second, 
independent method are used.
96/23/EC
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Table 4. The numbers of IPs gained by each MS-technique.
MS-technique Identification points
Low resolution (LR) MS 1
LRMSn precursor ion 1
LRMSn product ion 1.5
High resolution (HR) MS 2
HRMSn precursor ion 2
HRMSn product ion 2.5
Confirmatory analysis of for instance veterinary drugs, steroids and mycotoxins are 
based on the collection of identification points (IPs), see Table 4. For confirmation, 
three (group B substances, see Table 5) or four IPs (group A substances, see Table 
5) are required which could be obtained by using low resolution mass spectrometers 
such as triple-quadrupole mass spectrometer (QqQ-MS) and ion trap-MS (IT-MS) in 
combination with a chromatographic separation prior to MS detection. In this way, 
1 IP is obtained for the precursor ion and 3 IPs for two product ions, yielding four 
IPs in total for “unequivocal conformation”. There are more ways to obtain three or 
four IPs, by using e.g. high resolution MS (HRMS) (≥ 20 000 at FWHM). For high 
resolution MS (HRMS), 2 IPs are earned for the precursor and 2.5 IPs for each 
product ion. Mass spectrometers with a resolution of 20,000 and higher can be used 
for confirmatory analysis when one precursor and one product ion can be recorded. 
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Table 5. Overview of substances in group A and B of 96/23/EC.
Group A:                                                          
Substances having anabolic effect and 
unauthorized substances
1)  Stilbenes, stilbene derivatives, and their 
salts and esters
1)  Antibacterial substances, including  
suphonomides, quinolones
2) Antithyroid agents 2) Other veterinary drugs
3) Steroids a) Anthermintics
4) Resorcylic acid lactones including zeranol b) Anticoccidial, including nitroimidazoles
5) Beta-agonists c) Carbamates and pyrethroids
6)  Compounds included in Annex IV to 
Council Regulation (EEC) No 2377/90 of 
26 June 1990
d) Sedatives 
e) Non-steroidal anti-inflammatory drugs (NSAIDs) 
f)  Other pharmacologically active substances
 3)  Other substances and environmental 
contaminants
a) Organochlorinc compounds including PcBs
b) Organophosphorus compounds
c) Chemical elements
d) Mycotoxins
e) Dyes
f) Others
In EU Commission Regulation 37/2010, all substances which should be subjected 
to monitoring are divided into two groups [106]. In this document, all allowed 
pharmacologically active type B substances with maximum residue levels (MRLs) 
are described. According to Council Regulation 2377/90, MRL means “the maximum 
concentration of a residue resulting from the use of a veterinary medicinal product 
which may be accepted by the Community to be legally permitted or recognized as 
acceptable in or on a food” [107]. For mycotoxins “maximum levels” (MLs) are used 
which describe at what level they are allowed to occur. For example, the ML values of 
mycotoxins (group B substances) in foodstuffs are described in the reference [108]. 
OTA has ML values between 0.5-10 µg kg-1 depending on the matrix. The ML values 
of other mycotoxins vary between 0.5-2000 µg kg-1. However, since steroids are 
categorized as group A substances (i.e. the use is prohibited), no ML or MRL values 
have been established [109]. This means that in animal farming, the administration 
of growth-promoting agents, such steroids, through supplements is also prohibited. 
For the purpose of control of residues of certain substances whose use is prohibited 
or not authorized in the EU community, the minimum required performance limits 
(MRPLs) are determined. This means that the monitoring labs should have methods 
which can detect substances of interest at MRPL levels. If results of analytical tests 
Group B:
Veterinary drugs and contaminants
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are at or above the MRPLs described in Decision 2002/657/EC, the samples are 
considered non-compliant. In order to achieve fair play, the use of hormones and 
anabolic steroids in sports are also forbidden by the World Anti-Doping Agency 
(WADA) [110]. In contrast to Council directive 96/22/EC [109], the WADA published 
a list of prohibited substances which include all anabolic steroids as well as their 
precursors. This list not only includes the compounds that control laboratories should 
screen for, such as exogenous and endogenous steroids, but also  “compounds 
having similar biological activity” must be screened to avoid missing new designer 
steroids. In the EU, food supplements (certain vitamins and minerals) are covered 
by Directive 2002/46, and to be able to use these ingredients in dietary supplements, 
they must be listed in the annex to this legislation. In this list no anabolic compounds 
are described and therefore their presence in supplements is prohibited [111]. 
Although TBBPA is registered in the Registration, Evaluation, Authorization and 
Restriction of Chemicals (REACH), TBBPA and its derivatives are not regulated 
for food so far by the European Commission [16]. In general, no EU legislation is 
defined yet concerning EDCs in food or environment [16].
Identification
Although Commission Decision 2002/657/EC contains specific criteria for screening 
and confirmation, no clear definition is described for the identification of know or 
unknown substances. Only in the case of a suspect-screened sample, identification 
criteria by means of confirmation are described. In the literature the terms 
“identification” and “confirmation” are used interchangeably while the meaning of 
these are not the same [112]: identification is a qualitative result from a method 
which provides structural information (e.g. using MS detection or nuclear magnetic 
resonance (NMR)). In contrast, confirmation is achieved when a combination of two 
or more analyses that are in agreement and at least one method should meet the 
confirmation criteria described in “Confirmation” paragraph of 2002/657/EC. For 
identification purposes, multiple instruments and methods could be used to identify 
the compound of interest while the confirmatory criteria are not met necessarily. For 
example, Toorians et al. applied a yeast estrogen bioassay and LC-MS and NMR 
to identify a compound in a herbal supplement which was marketed to help against 
prostate cancer [113]. Following a strong response in the yeast estrogen bioassay, 
indicating the presence of an estrogen, a gradient liquid chromatographic time-of-
flight mass spectrometry (LC-ToF-MS) method was used to obtain retention times 
and accurate mass data in full scan mode. This, together with NMR results, helped 
to identify the “unknown” compound which turned out to be diethylstilbestrol (DES). 
Similarly, Rijk et al. used an androgen yeast assay for screening and LC-Q-ToF-
MS to identify 1-testosterone which was not acquired during routine LC-QqQ-MS 
measurement in pre-selected mass mode called multiple reaction mode (MRM) [114]. 
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In this thesis, identifying known and unknown substances was achieved, following 
screening, by their chemical physical properties. This was done using e.g. LC-ion 
mobility (IM)-Q-ToF-MS to obtain retention time, accurate mass measurement in full 
scan mode, product ions and in one example also specific drift times. Drift times, 
acquired from ion mobility data from which collision-cross section (CCS) values can 
be derived, offer an additional orthogonal identification point next to retention time, 
accurate mass and MS/MS product ion data. All these points of identification were 
used for unequivocal identification of known and unknown compounds. Still, full 
structure analysis by 2D-NMR would be desirable but, unfortunately, that technique 
lacks sensitivity for trace analysis.  
Biorecognition elements
A large number of affinity pairs, such as lectin-sugar, antigen-antibody, ligand-
receptor and biotin-avidin, are known. In this thesis, different types of interactions 
are used by immobilizing the protein onto a solid surface (see “Immobilizations of 
biomolecules” for immobilization approaches) followed by protein-ligand interactions. 
This was done to achieve rapid bio-isolations of hazardous food and environmental 
contaminants having affinity towards the selected proteins for screening and 
identification purposes. In the following paragraph the proteins used in thesis are 
introduced.
Antibodies
Antibodies belong to the family of proteins called immunoglobulins (Igs) which are 
present at 12-15 mg mL-1 in blood serum comprising about 20% of its total protein 
content. There are five Ig classes known in mammals, IgG, IgM, IgA, IgD and IgE 
with molecular masses ranging from 150,000 to 970,000 Da. IgG represents 70% 
of the serum immunoglobulins and is responsible for the majority of the secondary 
immunological response to most antigens. IgG molecules consist of three domains 
(two Fab domains and one Fc domain) (see Figure 7). The Fab (fragment antigen 
binding site) domains form two arms of the Y shape and are identical which makes 
IgG molecules bivalent. The part that is involved in immune regulation is called 
Fc fragment (this fragment crystallizes) and is the base of the Y structure. The 
heterogeneity in the Fab regions of antibodies contributes to the capability to respond 
to a large number of antigens. This means that mammalians are able to generate an 
immune response with a diversity of up to 105-106 different antibodies. The specific 
binding between an antibody and an antigen or ligand is based on structural and 
chemical interactions that occur within the antigen-binding site.
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Figure 7. Typical immunoglobulin molecule in which Fab and Fc domains are displayed. 
The antigen-antibody interaction is a reversible interaction and involves the formation 
of non-covalent bonds. The binding between antigen and antibody is the result of a 
variety of interactions including hydrophobic, ionic, hydrogen bonds, π-π electron 
interaction and van der Waals forces. These interactions also play a role in the 
binding of a ligand to other biomolecules such as transport proteins and receptors. 
Typically, the affinity of antigen towards an antibody increases with the larger number 
of specific chemical interactions that occur in the antigen binding site. Therefore, 
the specificity and efficiency of biorecognition of ligands in a sample are heavily 
influenced by the precise nature of the antigen(ligand)-(biomolecule)antibody binding 
process. Any small change in antigen structure will affect the affinity of the antibody-
antigen interaction and with that the efficiency of any biorecognition procedure. The 
most applied antibodies for biorecognition isolation procedures are monoclonal 
antibodies (Mabs), polyclonal antibodies (Pabs) and recombinant antibodies (Rabs). 
The main difference between these types of antibodies is related to the specificity 
of the antigen-antibody binding. Mabs allow the isolation of antigens with very high 
specificity, whereas Pabs could show interactions with multiple epitopes or antigens. 
Rabs can possess both specific and generic specificity towards antigens, depending 
on how they were developed (e.g. generic sulfonamides Rabs [115]). Mabs, Pabs and 
Rabs have been shown to be sensitive, robust and selective biorecognition elements 
in binding assays. Another main difference is the way of production of Pabs, Mabs 
and Rabs. Pabs are derived from an immunized animal which produces generally a 
random number of clonotypes and its antiserum becomes polyclonal. Therefore, it is 
almost impossible to make reproducible Pabs against any epitope due to batch-to-
batch variations. Even antisera from the same animal taken at different times differ in 
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their properties. Pabs are typically produced by immunization of a suitable mammal, 
such as a mouse, rat, guinea pig, hamster, rabbit, goat, sheep, donkey or horse. 
The concentration of specific antibody in polyclonal sera is typically 50 to 200 μg 
mL-1, and the range of total IgG concentration in sera is between 5 and 20 mg mL-1 
[116]. The preparation of a homogeneous population of Mabs was achieved with the 
development of the technology for hybridoma production. Köhler et al., developed a 
technique that allows the growth of clonal populations of cells secreting antibodies 
with a defined specificity [117]. In this technique an antibody-secreting cell, isolated 
from an accumulating organ of an immunized animal (e.g. from the spleen), is mixed 
with a myeloma cell, a type of B-cell tumor. These hybridomas can be prepared by 
fusing myelomas and antibody-producing cells isolated from different species. The 
hybridomas can be maintained in vitro and will continue to secrete antibodies with a 
defined specificity. The antibody concentration in the medium is about 2-50 μg mL-1 
[118]. Standard procedures for the preparation, purification and characterization of 
Mabs are described in literature [119, 120]. The usefulness of Mabs is highlighted 
in three characteristics: their specificity of binding, their homogeneity and their 
production in unlimited quantities. The limitations of hybridoma technology include 
the extensive commitment of time, labor and expense, the requirement for animal 
use and specialized cell culture facilities and the expertise needed to prepare and 
screen large number of hybridomas to select the best ones [116]. Rabs are produced 
by the development of molecular methods for the expression of recombinant antibody 
fragments in bacteria. The techniques for production and screening of combinatorial 
libraries make a wide range of opportunities possible for the selection of Rabs and their 
engineering [121]. The most commonly used technology is phage display [122] which 
refers to the display of functional foreign peptides, proteins or antibody fragments on 
the surface of a bacteriophage. This is done by fusion of the DNA coding sequences 
of the protein to be displayed into the phage genome to the gene encoding one of 
the phage surface proteins. Surface display of the antibodies allows affinity selection 
of antibodies by exposing the phage library to immobilized antigen molecules. The 
captured phage particles can be eluted from the antigen, amplified by infecting 
Escherichia coli (E. coli) host cells and used in a next round of affinity selection. In 
the literature, various applications of antibodies are described for screening food 
and environmental contaminants [123-129]. Antibodies are used in immunoaffinity 
chromatography (IAC) for the specific isolation from sample materials prior to HPLC 
or LC-MS analysis [130-132]. However, such IAC columns are voluminous, use high 
amounts of carrier material with a high risk of non-specific binding. In an alternative 
approach, Chapter 2 describes the use of Mabs on magnetic beads for the specific 
isolation of the mycotoxin OTA followed by the identification by LC-MS [100]. Various 
immunoassays are described for rapid screening of contaminants using Mabs, Pabs 
or Rabs [123-129]. As rather novel approaches, surface plasmon resonance (SPR)-
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biosensor and flow cytometric immunoassays are described for the screening of e.g. 
sulphonamides (with Rabs) [115] and mycotoxins (with Mabs) [133], respectively. In 
this thesis, a Mab against the mycotoxin OTA was used to screen for its presence 
in wheat and cereal with a flow cytometry-based immunoassay and to confirm and 
identify an OTA analogue with mass spectrometry after immunoaffinity isolation. 
However, antibodies do not perform well when a group of structurally varied chemicals 
like steroids or endocrine disrupting chemicals (EDCs) have to be targeted in a single 
assay or if an effect-based isolation is required. In this case, other biorecognition 
elements, such receptors or transport proteins, are preferred for generic or effect-
based bioaffinity isolation procedures. 
Sex hormone-binding globulin (SHBG) 
SHBG is a glycoprotein in blood plasma that is produced primarily by the liver (See 
Figure 8).
Figure 8. The crystal structure of human sex hormone-binding globulin [134].
Expression of the SHBG gene in the testis of several mammals also gives rise to a 
protein commonly known as the testicular androgen binding protein (ABP), which 
is thought to play a key role in sperm maturation [135, 136]. Plasma SHBG and 
testicular ABP bind biologically active androgens and estrogens and play a critical 
role in regulating the access of these sex steroids to their target cells [137]. Next to 
sex steroids, SHBG also binds many pharmaceutically important synthetic steroids, 
flavonoids and xenobiotics which makes this transport protein a very interesting 
biorecognition element to screen and identify a broad range of compounds [138-
142]. Studies of SHBG in blood samples, or after its purification, indicated that its 
stability (in particular, stability of its dimer) is influenced by the presence of steroid 
ligands and metal ions [143]. Therefore, during production or purification, it is vital to 
	  
General introduction 
31
avoid any metal chelating agent (e.g. ethylenediaminetetraacetic acid) and a steroid 
ligand (e.g. cortisol) must be present to preserve the stability of the protein. In the 
literature, SHBG has been used in binding assays for screening of its ligands and for 
determining binding affinities. Typically, no coupling with MS is done and therefore 
the identity of the binders remains undetermined.  Mooney et al. developed an SPR-
based biosensor screening assay in which SHBG was used as a bioreagent to indicate 
the illicitly used growth-promoting agents estradiol benzoate and nortestosterone 
decanoate during rearing of calves [144]. Plasma from control animals and treated 
animals were measured and significant reductions of SHBG binding capacity were 
observed in treated animals only. Jury et al. developed an SHBG-based radioassay 
which demonstrated binding affinities of numerous compounds [141]. In this thesis, 
purified recombinant human SHBG (rhSHBG) was used to develop screening and 
identification approaches for androgens and estrogens with MS. The rhSHBG, 
produced in Chinese hamster ovary (CHO) cells, contained a polyhistidine-tag (His-
tag). This tag, which has affinity towards the metal ion Ni2+, was used to purify the 
protein and the steroid cortisol was used for stabilization purposes.     
Transthyretin (TTR)
TTR is a transport protein which is responsible for transporting thyroids hormones. 
TTR is a 55 KDa tetramer of identical subunits, each containing 127 amino acids. 
The four subunits form a symmetrical ß-barrel structure with a double trumpeted 
hydrophobic channel that traverses the molecule forming the two allosteric 
iodothyronine binding sites (Figure 9) [145, 146]. Although TTR is bivalent, only 
one L-thyroxin (T4) molecule is usually bound because the binding affinity of the 
second site is greatly reduced through a negative cooperative effect [147]. TTR from 
fish, amphibians, reptiles and birds binds triiodothyronine (T3) with higher affinity, 
whereas TTR from mammals binds T4 with higher affinity [18, 19]. The TTR used 
in this thesis, was recombinantly produced by cloning the coding DNA into a vector 
and transforming the most suitable organism (E. coli) for overexpressing the protein 
[148]. By using this approach, the supply of the biorecognition element is almost 
unlimited. Bioaffinity screening assays have been developed for EDCs based on 
binding with TTR in competition with radiolabeled T4 and yielded IC50 values for 
specific flame retardants in the range of 60-90 nM [19, 149-151]. However, the use of 
a radiolabel is a serious disadvantage in binding assays and the methods described 
did not focus on screening of real samples but just on the determination of binding 
affinities of EDCs towards TTR. 
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Figure 9. The crystal structure of human transthyretin [152]. 
A label-free SPR-based method was published by Marchesini et al. using T4 and 
TTR to determine binding affinities of EDCs (IC50 10 nM for T4) [17]. Although this 
method is sensitive and label-free, complex sample materials were not tested so the 
robustness of that method is yet unknown and no coupling with MS for confirmation 
and identification was described. In this thesis, rTTR was used to develop new 
bioaffinity-based procedures for the MS screening and identification of a broad range 
of compounds such as pharmaceuticals, flame retardants and triclosan.
Estrogens, such as 17β-estradiol, influence the growth, differentiation and functions 
of many target organs, such as the mammary gland, uterus, vagina, central nervous 
system and in the cardiovascular system [153]. Estrogens are produced in specialized 
tissues and are subsequently transported via the blood stream to their effector sites. 
Steroid hormones, such as estrogens, represent a subgroup mediating their action 
via a large group of related proteins, the super family of nuclear receptors (NRs) 
[154, 155]. Estrogen receptor (ER), an intranuclear binding protein, is one of these 
NRs which is mainly expressed in the sex organs like the mammary gland and the 
uterus (See Figure 10). 
Figure 10. The crystal structure of estrogen receptor [152].
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Once bound by estrogens, the ER undergoes a conformational change, allowing the 
receptor to bind with high affinity to chromatin and to modulate transcription of target 
genes. The two ER subtypes, α and β, have slightly different affinity to a range of 
compounds such as estrogens, some androgens, phytoestrogens, anti-estrogens 
and environmental estrogens. This makes both subtypes interesting biorecognition 
elements to develop screening and identification approaches for a broad range of 
compounds. Jonker et al. developed an online protein-affinity LC-MS method in which 
ERα was used for screening [156]. However, measurements had to be corrected for 
activity loss per hour caused by degradation of the ER. Non-immobilized ER tends 
to be very sensitive to slight changes in e.g. temperature, salt concentration and pH. 
Usami et al. developed an SPR-based biosensor assay in which 17β-estradiol (β-E2) 
was used as a ligand, human recombinant ERα for biorecognition and test chemicals 
as competitors [157]. By means of this biosensor assay, dissociation constants for 
the binding of estrone (E1), β-E2, estriol (E3), tamoxifen (Tamo), DES, bisphenol 
A (BPA) and 4-nonylphenol were determined. Blair et al. determined the relative 
binding affinity (RBA) for a large group of chemicals by using an ERα competitive 
binding assay [158]. In this radio receptor assay, ER was obtained from rats and 
[3H]-β-E2 was used as the competing label. The obvious disadvantages of this assay 
include the use of a radiolabel and the long assay time of 24h. Plotan et al. presented 
the development of an estrogen responsive reporter gene assay coupled with a 
solid phase sample preparation enabling the detection of estrogenic constituents 
in sport supplements [159]. Reporter gene assays are slow (analysis time >2 days) 
and require a specific lab qualification. The ERα used in this thesis, is a construct 
corresponding to the receptor binding domain of the ERα which was expressed in E. 
coli. Due to the His-tag, the ERα was successfully purified by its Ni-affinity followed 
by size exclusion chromatography, after scouting of several buffer conditions for the 
various purification steps. The resulting protein had a high degree of purity (>90%) 
and was immobilized onto paramagnetic beads using two different surface chemistry 
approaches. Following immobilization, a screening and identification method was 
developed for estrogens in dietary supplements using MS.
Immobilizations of biomolecules
Both in chemical screening assays based on biorecognition and in bioaffinity MS, 
biomolecules such as antibodies, transport proteins or receptors, can be immobilized 
to solid supports in various ways [27, 104, 160-171]. This includes physical adsorption, 
affinity adsorption and covalent binding onto a solid phase. Physical adsorption of 
e.g. antibodies onto solid supports is widely employed for coating microtiter plates to 
be used in immunosorbent assays [165-167]. This approach is based on hydrophobic 
interaction and ligand or protein leakage may occur if organic modifiers are used. 
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Therefore, this immobilization approach is considered simple and fast, however, only 
mild conditions are recommended. Affinity adsorption of antibodies can be done with 
a solid support containing protein A or protein G which bind to antibodies with high 
affinity [168-171]. This approach yields oriented immobilization which promotes the 
binding of the ligand to the binding site. The disadvantages of this approach include 
steric hindrance caused by protein A or protein G and undesired release of ligand 
can occur due to the reversible nature of this immobilization approach. Similarly, 
streptavidin-biotin interactions, one of the strongest non-covalent interaction 
known in biology, can be used for oriented and non-oriented immobilization 
manner of proteins [172]. In immunoassays, a 2 to 3 times higher binding signal 
for site-specifically biotinylated antibody species is reported [172]. Another oriented 
immobilization approach is to use histidine (His)-tagged biomolecules which show 
high affinity towards metal ions such as Ni2+ [156, 173]. In this way, the biomolecule 
is also immobilized in an oriented manner making the binding site better available for 
the ligand. This approach is simple, fast and can tolerate organic modifiers to some 
extend, however, the immobilized biomolecule tends to stay stable for a shorter 
time compared to a covalently immobilized biomolecule. In this thesis, several His-
tagged biomolecules, such as transport proteins and a receptor, are immobilized 
using paramagnetic microbeads containing the Ni2+ metal complex in Chapters 3, 4 
and 5. The mechanism of this approach is displayed in Figure 11. 
Figure 11. Illustration of non-covalent oriented immobilization of His-tagged (black bars) proteins onto 
Ni2+-containing superparamagnetic microbeads.
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Covalent immobilization onto solid surfaces can be achieved through amine groups 
on the biomolecule [100, 169, 174]. Usually, first a chemical group e.g. N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide (EDC) is attached to the solid support 
for activation purposes. The EDC reacts with the terminal carboxylate groups 
from the magnetic bead to highly reactive O-acylisourea derivatives. This is done 
to form, in a next step, a covalent bond with amine groups on the biomolecule in 
a non-oriented manner. Following immobilization, the remaining active groups 
on the solid support are blocked to prevent any non-specific binding during the 
subsequent assay. Mostly, free amine groups present in the biomolecule are used 
for immobilization. Other functional groups which could be used for covalent non-
oriented immobilization include carboxyl, hydroxyl, thiol and oligosaccharide groups 
present in the biomolecule of interest [160-164]. Figure 8 shows a typical covalent 
immobilization using the amine groups in the biomolecule and carboxyl groups 
present on the solid surface of a paramagnetic microbead. The advantages of 
such an approach include prolonged stability of the immobilized biomolecule and 
the increased chance to reuse the biomolecules [27, 175]. Disadvantages include 
a relatively long immobilization time compared to affinity oriented immobilization 
approaches (3 h vs <1) and, due to the non-oriented nature of this immobilization 
approach, the binding sites of the biomolecule will be less available. In this thesis, 
the amine groups of an antibody, two transport proteins and a receptor were used 
for covalent immobilization onto paramagnetic microbeads containing carboxyl 
groups (see Figure 12). By applying both oriented and non-oriented immobilization 
approaches, the influence of immobilizing proteins on the performance of the assay 
could be investigated. 
Chapter 1
36
Figure 12. Illustration of covalent non-oriented immobilization of a protein onto a superparamagnetic 
microbead containing carboxylic acid moieties. 
Biorecognition-based isolation of contaminants
Bioaffinity isolations are based on specific reversible interactions of proteins 
with ligands in which the proteins are either in solution  (using cut-off filters) or 
immobilized to a solid support (e.g. magnetic microparticles, as used in this thesis). 
Ligands binding to a protein, regardless whether the protein is immobilized or not, 
can be disrupted by a change in pH, salt, organic liquids, etc which weakens the 
interactions in protein-ligand complexes [176-179]. In the case that the protein is 
used in solution, the ligands are dissociated on basis of their size since only the 
free ligands pass through a cut-off filter. If the protein is immobilized, eluted ligands 
can be separated from the protein by using a magnet. Typical incubation, wash and 
elution volumes are 50-200 µL and 100-1500 µL using magnetic beads and cut-
off filters respectively. Due to the combination of low-volumes and the specificity of 
the interaction, bioaffinity isolations can result in a very high enrichment in a single 
step (10-1000 fold). Apart from the enrichment, biopurified extracts are cleaner 
compared to chemical sample treatment procedures such as solid-phase extraction 
(SPE) or liquid-liquid extraction (LLE). This phenomenon is even observed when 
both types of extracts are measured on a rather specific LC-QqQ-MS system. Figure 
13 illustrates the measurement of 17β-testosterone in a biopurified urine extract and 
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non-biopurified urine extracts in highly selective single reaction monitoring mode 
(SRM). Despite the selective detection and the sample pretreatment procedure, co-
eluting peaks are still observed in chromatogram B whereas no co-eluting peaks 
were measured in the biopurified extract depicted in chromatogram A.
Figure 13. Reconstructed chromatograms of 17β-testosterone in biopurified (A) and non-biopurified (B) 
urine extract by LC-QqQ-MS in SRM mode. The ion transition m/z 289 à m/z 97 was measured.
Existing methods for the analysis of contaminants
Screening methods can be performed by using commercially available (field) test 
kits. These test kits are rapid and low cost and mostly based on immunoassays. The 
results produced by these test kits, are qualitative and multiplexing is in most cases 
not possible. In another immunoassay format, multiplex flow cytometric immunoassay 
(FCIA) screening methods have been described for food contaminants using the flow 
cytometer Luminex® [98, 99, 102, 133]. This instrument uses superparamagnetic 
or non-magnetic carboxylated polystyrene microbeads (6.5 μm diameter beads). 
Superparamagnetic means that the beads can easily be magnetized when an 
external magnetic field is applied and redispersed immediately when the magnet is 
removed, which enhances both ease-of-use and automation capabilities [180]. The 
microbeads are internally dyed with a red and an infrared fluorophore and by varying 
the ratio of the two fluorophores, up to 100 different color-coded bead sets can be 
distinguished (MultiAnalyte Profiling (xMAP®) technology). Each bead set can be 
covalently coupled, via its carboxylated surface, to a different biological probe such 
as antibodies or other (bio)molecules. Therefore, it is possible to simultaneously 
measure up to 100 different biomolecular interactions in a single well [96, 181]. 
Other distinct advantages are high-throughput capability (<1h/96 tests), versatility, 
accuracy and reproducibility [182]. Following screening, all non-complaint results 
have to be re-measured with a confirmatory method such GC-MS or LC-MS. 
Although FICAs can perform high-throughput screening on basis of biorecognition, 
they are unable to determine the identity of the screened compounds. For various 
contaminants, such as EDCs, a screening method was developed based on 
competition between EDCs and radiolabeled T4 for the binding sites of the transport 
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protein TTR [149-151]. However, the use of a radiolabel is a serious disadvantage 
in binding assays. A label-free SPR-based method was published by Marchesini 
et al. using T4 and TTR to determine binding affinities of EDCs (IC50 10 nM for T4) 
[183]. Although this method is sensitive and label-free, complex sample materials 
were not tested so the robustness of that method is yet unknown and no coupling 
with MS for confirmation and identification was described. For the analysis of food 
and environmental contaminants existing methods generally are considered either 
screening methods or confirmatory/identification methods. In modern laboratories, 
gas chromatography (GC)-MS and LC-MS are used for the sensitive and specific 
detection of steroids, veterinary drugs, mycotoxins and pharmaceuticals in food and 
environmental samples [184-187]. In the literature, the screening of >100 compounds 
in one chromatographic run by ToF-MS or Orbitrap in full scan mode is reported [188, 
189]. However, for quantification and confirmation in accordance with EU legislation 
and to achieve the highest sensitivity, most labs still use LC-MS and GC-MS in pre-
selected ion or ion transition acquisition modes [190]. Figure 14 demonstrates the 
principle and set-up of such a pre-selected ion transition acquisition. 
Figure 14. Principle of highly selective and sensitive electropray ionization (ESI)-QqQ-MS in MRM mode: 
following ionization, precursor ions are selected in Q1, Q2 is the collision-induced-dissociation cell in 
which selected precursor ions are fragmented and finally Q3 filters the pre-selected product ions. 
The throughput of these methods is affected by long data processing times (each 
compound yields two ion transition peaks) and time-consuming sample pretreatment 
procedures such as pressurized liquid extraction, liquid-liquid extraction, solid 
phase extraction (SPE) and Soxhlet extraction and, more important, they do not 
provide information about bioactivity. For the screening of (designer) steroids, 
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a yeast androgen bioassay (YAB) was developed by Bovee et al. [191]. This 
assay expresses yeast enhanced green fluorescent protein (yEGFP) of which the 
fluorescent emission is measured in response to androgens. The identification of 
androgens was performed by LC-fractionation of the suspect found sample into two 
96-well plates after which one 96-well plate was screened again to indicate in which 
well androgens are present for identification with MS. The YAB demonstrated the 
presence of the designer steroid THG in spiked urine sample [192] and also the 
anabolic steroid 1-testosterone (1,(5α)-androsten-17α-ol-3-one), which is chemically 
closely related to the natural testosterone, but often escapes routine testing, was 
found in dietary supplements [193]. This work demonstrated the power of using a 
biorecognition element for screening and MS in full scan mode for identification as a 
designer steroid was detected and moreover, 1-testoterone was found in a sample 
which was reported as negative by van Poucke et al. previously [194]. They applied 
a conventional chemical analysis and used an LC-QqQ-MS in highly selective pre-
selected mass mode (i.e. MRM) in which the product ions of 1-testosterone were not 
acquired. Also the absence of any biorecognition element in their approach, which 
could help the MS analysis, contributed to report this sample as compliant. Although 
Bovee et al. were able to provide a more correct picture of the content of the sample, 
extracts were not biopurified causing more signal suppression in their MS which 
could influence the detection of any new compound negatively. Moreover, these 
whole cell bioassays are inherently slow and require at least 2 days. In a similar 
approach, Nielen et al. identified an unknown β-agonist in feed by LC-bioassay 
followed by LC-Q-ToF-MS [195]. Bioaffinity-based extraction procedures using e.g. 
antibodies, transport proteins or receptors in combination with MS are of particular 
interest since high-throughput screening (HTS) is possible while identification of 
contaminants remain feasible and these methods might pinpoint the occurrence of 
emerging yet unidentified but highly relevant contaminants. In next paragraph, the 
two different approaches, in particular post-column and pre-column bioaffinity MS, 
and accompanying challenges are described. In the two approaches, a biorecognition 
element in both screening and identification of contaminants is present. 
Post-column bioaffinity mass spectrometry
Several post-column on-line bioaffinity MS methods were described for protein-
affinity selection, drug discovery or screening of combinatorial libraries [196-198]. 
In post-column bioaffinity MS format, the LC effluent is either directly connected 
to a bioassay which is followed by MS detection or the LC effluent is connected to 
a bioassay and MS detection setup in parallel. An example of the  latter setup is 
illustrated in Figure 15. Typically, the bioassay is followed by UV or fluorescence 
detection, however, nowadays MS is the preferred readout system. By using 
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fluorescent detection, fluorescent labels, if available, are required. In contrast, by 
using MS, all ligands can be used.  
Figure 15. Schematic view of a post-column bioaffinity MS format. Superloop-A (SL-A) and superloop-B 
(SL-B) are used to deliver enzyme and substrate to the reaction coil, respectively. Ligands are introduced 
into the system by a gradient reversed phase HPLC system. Any ligands temporarily inhibit the fluorescent 
product formation, which is monitored by a fluorescence detector (FLD). After HPLC, the make-up pumps 
produce a counteracting gradient, resulting in a biomolecule compatible constant and relatively low 
organic modifier concentration. Via a splitter a part is connected to the bioassay and a part flows to an 
MS [197]. 
When in post-column bioaffinity MS format the LC effluent is directly connected 
to a bioassay and MS detection, there are specific issues which make the online 
post-column bioaffinity MS format challenging to use. Generally, the challenges are 
related to the ESI-MS detection in which, at least in positive ESI high organic modifier 
content together with low pH is desirable while these conditions are not compatible 
with bioassays. Since the effluent of an LC is directly coupled online to a bioassay, 
the effluent should not contain more than 5-10% organic modifier in order to keep 
the effluent compatible with most biomolecules such as enzymes or receptors. 
Therefore, the effluent needs to be diluted by a factor of 10-20, especially when 
reversed-phase gradients are used which typically end in very high organic modifier 
composition. Next to the organic modifier content, the use of acids in LC separations 
needs attention as the pH should be compatible with the bioassay. Usually, this issue 
is tackled by diluting the LC effluent with bioassay buffer. This buffer should have 
sufficient capacity, however the MS performance is seriously hampered by the use 
of high concentration buffers. In some cases, MS-compatible volatile buffers like 
ammonium formate or acetate can be used, but, these buffers could compromise the 
performance of the bioassay. The on-line incubation is commonly done in tubing in a 
continuous flow and, as a result of this, peak broadening takes place and relatively 
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long incubation times are not feasible. As an example of post-column bioaffinity 
MS in which the LC effluent is connected to a bioassay and MS detection setup in 
parallel, De Vlieger et al. developed an on-line dual post-column receptor affinity 
assay based on parallel detection by MS (LoD 40 nM) and fluorescence (LoD 4.7 
nM) for quantification and identification purposes of estrogenic compounds [196]. 
The effluent was split to ERα and ERβ fluorescent bioassays and to the MS. In this 
way, only in the screening a biorecognition element was used. Another disadvantage 
of the post-column bioaffinity MS format is the wasting of expensive biorecognition 
elements. This is mainly caused due to the continuous addition of the biorecognition 
elements throughout the whole chromatographic separation while no binders are 
present in the beginning of the chromatographic run. Although the online post-
column bioaffinity MS format provides both biological and chemical information on 
the ligands of interest, there are several major drawbacks as neither in the bioassay 
nor in the MS detection optimal conditions are possible. Due to these challenges, the 
required limit of detection might not be met and the use of various target biomolecules 
is limited because only specific buffer conditions are feasible in this format.
 
Pre-column bioaffinity MS
Pre-column bioaffinity MS methods are being used mostly as a tool to determine 
affinities of compounds towards the chosen target protein [199-205]. This can be 
achieved in two ways: 1) the compound of interest is measured by LC-MS following 
incubation with target protein and wash and dissociation steps [203-205], or 2) a 
stable MS label is used in a competitive inhibition format with other compounds 
of interest and the label is measured by LC-MS [199-202]. High consumption of 
target protein and inability to detect multiple compounds having low affinity, are 
the disadvantages of approach 1). To overcome these issues, several pre-column 
bioaffinity MS methods in competitive inhibition format 2) are described in the literature. 
For example, Niessen et al. developed an off-line competitive MS binding assay 
for determining the binding affinity of dopamine receptor ligands using spiperone 
as a label (see Figure 16) [200]. That binding assay was presented as a possible 
alternative to radiolabeled assays; however, since only the unbound fraction of the 
marker was measured, at best, indirect information was obtained about the bound 
ligands. Moreover, because of the use of a nonvolatile buffer, an additional SPE step 
was required prior to LC-MS detection. Due to the SPE step and the absence of 
microtiter plates, HTS was not feasible. Zepperitz et al. described a competitive MS 
binding assay in which the γ-aminobutyric acid (GABA) transporter-bound fraction 
of the label was measured after elution with methanol [202]. Although this method 
had the potential for high-throughput characterization of new drug candidates, that 
format was used for kinetic measurements in buffer only and no screening in real 
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samples was performed. By the lengthy (30-60 min) filtration steps during wash and 
dissociation steps, the method became longer and less straightforward. In a similar 
approach Hess et al. determined binding affinities of human serotonin transporter 
(hSERT) inhibitors [199]. The main change in this method concerned the dissociation 
step which was performed by displacing the label (fluoxetine) by another ligand (i.e. 
imipramine) and no methanol was used. This method was able to determine affinities 
of inhibitors for hSERT. In general, these off-line pre-column bioaffinity MS methods 
are focused on determining affinities and no screening or identification is performed 
for food or environmental contaminants.  In this thesis, off-line pre-column bioaffinity 
MS (BioMS) is used for rapid screening and identification of various contaminants 
in food and environmental samples. Figure 17 displays a schematic overview of 
the BioMS approach. In this BioMS approach, biomolecules such as antibodies, 
transport proteins or receptors were immobilized onto paramagnetic beads. The 
principle of this method is demonstrated in Figure 18.
 
Figure 16. Binding curves for (+)-butaclamol, as generated by nonlinear regression for competitive 
MS binding assays. Three binding experiments were carried out for each ligand. The individual points 
describe nonbound spiperone quantified by LC-ESI-MS-MS from the supernatant of binding samples 
(figure is used with permission [200]). 
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Figure 17. A schematic overview of pre-column bioaffinity MS (BioMS) for rapid screening and identification. 
Figure 18. The principle of the competitive inhibition assay format applied in BioMS screening.
For screening, a stable isotope label can be used to screen indirectly for the presence 
of any displacing ligands. The competitive inhibition screening assay is based on 
competition between the stable isotope label and other active contaminants in the 
sample. Following incubation, wash and dissociation steps, only the isotope label is 
measured by means of an ultrafast, sensitive and selective UPLC-QqQ-MS system, 
operating in a dedicated SRM mode. The amount of measured label is reversibly 
indicative for the amount and affinity of active compounds in the sample. For 
identification of any known or unknown active contaminants, the same biorecognition 
element can be used in a bioaffinity isolation procedure in combination with high 
resolution full scan accurate mass mode. In BioMS, HTS can be achieved since in 
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screening paramagnetic beads in 96-well plates can be used allowing the use of an 
automatic magnetic wash station. In Figure 19, the wash station and the principle of 
the automated wash steps are depicted. 
Figure 19. The principle of the magnetic automatic wash station containing 96 small magnets to attract 
magnetic microbeads and an eight-channel multipipet. In (A) the 96-well plate is placed on the magnet 
and all microbeads are magnetized against the bottom of each well. In (B) the automatic wash station 
adds washing solution while the microbeads are on bottom and, in the same way, the added wash solution 
is discarded by the wash station.   
Note that in post-column bioaffinity MS, methods have been suggested to perform 
HTS, however, in this thesis, the generally accepted definition of HTS is when the 
assay time for 96 tests is <2 h while the LC-MS run time is less than a few minutes 
per sample. As the BioMS approach is off-line, in contrast to post-column formats, 
the most suitable LC conditions can be selected for the most sensitive MS detection. 
This applies also to the final biopurified extract which is injected onto the LC-MS 
system. Typically, the final extract in the BioMS contains organic modifier at low pH to 
ensure an effective elution of any ligand from the biomolecule while at the same time 
the extract would be fully MS-compatible. It is noteworthy, that any buffer needed for 
optimal performance of the bioassay can be used in the BioMS approach, because 
only the MS-compatible elution solution is injected onto the LC-MS system.
For identification of any known or unknown active 
contaminants, the same biorecognition element 
can be used in a bioaffinity isolation procedure 
in combination with high resolution MS in full 
scan accurate mass mode. In general, the same 
BioMS screening approach is used with slight 
changes, i.e. more coupled beads can be used 
and the label can be omitted. These changes will 
enhance the bio-isolation of contaminants. Since 
biomolecules are expensive, in this thesis, the bioassays are miniaturized by coupling 
the biomolecules onto paramagnetic microbeads. Due to this, highly enriched low-
volume (50 µL) final extracts can be obtained. These low volume extracts can be 
	  
	  
Figure 20. An image of the NanoTileTM 
containing the analytical column and 
an integrated ESI emitter (image from 
Waters website).
A B
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injected into a UPLC-QqQ-MS for screening and for the subsequent identification, 
the same extract can be injected into an LC-MS system which is able to inject low 
volumes and operated in full scan accurate mass mode. Therefore, an LC-MS system 
capable of injecting low volumes is required for identifying compounds. Regarding 
this system, several critical conditions were considered: the LC-MS identification 
system should be sensitive (low ng mL-1 levels), able to inject low volumes (0.1-4 
µL), provide reproducible retention times, accurate mass, product ions, and possibly 
provide ion mobility drift times for additional identification points. In this thesis, three 
different LC-Q-ToF-MS systems, which met these conditions, were used. The first 
system consisted of a nano-UPLC coupled to a Q-ToF-MS system. In this system, 
the combination of nano-column and nano flow rate permitted low volume injections 
of only 4 µL extract while obtaining adequate sensitivity. The advantages of this 
identification technique were its high sensitivity, small injection volumes, ultralow 
flow rates, resulting in the low consumption of hazardous chemicals, and the 
option to operate in full scan accurate mass mode for the identification of unknown 
compounds based on elemental composition calculated thereof. The disadvantages 
of nano-LC include undetectable clogging and dead volumes between connections 
which all contribute to the more difficult handling of the system and/or poor 
chromatographic performance. The second identification system used consisted of 
the same nano-UPLC pump coupled to the same Q-ToF-MS system. But in this 
case, the chromatography was performed on a Waters NanoTileTM containing a C18 
column (50 mm × 150 µm I.D., 1.7 µm particles) and having an integrated nano-ESI 
emitter (See Figure 20). The flow rate is 4 µL min-1 and injection volumes are 1-2 µL. 
The advantages of this identification system include the absence of dead volumes, 
superior chromatographic performance and the ease-of-use (“plug-and-play”) while 
providing adequate sensitivity. The third identification system consisted of a UPLC-
pump, compatible with alkaline conditions, which was coupled to an ion mobility (IM)-
Q-ToF-MS system equipped with a novel atmospheric pressure ionization source 
operated in negative ionization mode. With this system reproducible retention times, 
accurate mass, product ions and ion mobility drift times as additional identification 
points were obtained while low ppb-level sensitivity was achieved. By using the drift 
times, experimental collision-cross section (CCS) values could be calculated which 
could contribute to the identification of contaminants. 
Aim and scope of this thesis
Looking at the history of monitoring programs, it is quite imaginable that in sports 
and animal farming new unknown compounds are being used which are at the 
moment undetectable in the existing screening or confirmatory methods. Also due to 
fraudulent use of compounds, unexpected contaminants might end up in food which 
are not monitored. This means that fair play in sports and the health of consumers 
Chapter 1
46
cannot be ensured using the existing methods. Therefore, in this thesis, new 
bioaffinity mass spectrometry concepts are presented which were used for screening 
and identification of both known and unknown food and environmental contaminants. 
Below, the most important objectives of this thesis are summarized.     
•   The development of bioaffinity isolation procedures using different biorecognition 
elements such as Mabs, transport proteins (TTR, SHBG) and an estrogen receptor.
•    To investigate the influence of immobilization on the performance of the 
biorecognition elements (i.e. stability, robustness, high-throughput capabilities) by 
using superparamagnetic microbeads versus cut-off filters. 
•    The influence of oriented non-covalent immobilization of the biorecognition element 
compared to non-oriented covalent immobilization in terms of capacity, stability and 
ease-of-use of the immobilization procedure.     
•    Set-up of competitive inhibition binding assay format(s) for the rapid screening of 
contaminants using a non-radioactive stable isotopic label and measuring the label 
with LC-QqQ-MS in a short run time (e.g. 2 min/sample) in SRM mode.  
•    Applying different stable isotopic labels with biorecognition elements to develop 
screening assays for ochratoxins, EDCs and steroids in various food and 
environmental samples such as wheat, cereal, process water, urine and dietary 
supplements. 
•    Use the same biorecognition element as used in screening to develop bioaffinity 
isolation procedures to obtain biopurified extracts for identification purposes. 
•    Identify known and unknown contaminants using LC-Q-ToF-MS full scan accurate 
mass mode.  
Outline 
This thesis presents novel concepts in bioaffinity mass spectrometry (BioMS) for 
the screening and identification of known and unknown contaminants in food and 
environment. In Chapter 1, general information is given about contaminants and 
their harmful effects on wildlife and humans. In this chapter, the existing conventional 
bioaffinity-based screening methods and targeted instrumental analysis for identifying 
contaminants are described including their lack of ability to identify unknown 
compounds. Due to the emergence of new unknown contaminants, novel BioMS 
methods are needed to identify these contaminants. In Chapter 2 such a concept 
is described by using superparamagnetic microbeads coated with anti-ochratoxin 
A (OTA) monoclonal antibodies (Mabs) in a novel direct inhibition flow cytometric 
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immunoassay (FCIA) for high-throughput screening (HTS) of ochratoxins in wheat and 
cereal samples. The same anti-OTA Mabs-coated beads were used for immunoaffinity 
isolation prior to identification by nano-ultra performance-liquid chromatography-
quadrupole-time-of-flight-mass spectrometry (nano-UPLC-Q-ToF-MS) in full scan 
accurate mass mode. Retention times, experimental accurate mass data were used 
as identification points. For the analysis of thyroid transporter ligands, a BioMS 
concept is described in Chapter 3 with three different analytical purposes: screening, 
confirmation and identification. In order to avoid the usage of any fluorescent reporter 
molecule and expensive Luminex®-compatible paramagnetic beads in screening, a 
stable isotopic thyroid hormone 13C6-L-thyroxine was used as label in competitive 
inhibition MS binding assay format and the recombinant transthyretin (rTTR) was 
immobilized onto inexpensive paramagnetic microbeads. For screening and 
confirmation of EDCs in process water and urine, a fast UPLC- triple quadrupole 
(QqQ)-MS was used as readout system and for identification nano-LC-Q-ToF-MS 
in full scan mass mode. All extracts were biopurified using the same biorecognition 
element in screening, confirmation and identification. Retention times, experimental 
accurate mass and MS/MS data were used for identification. In Chapter 4, a generic 
HTS BioMS approach was developed and applied for the screening and identification 
of known and unknown recombinant human sex hormone-binding globulin (rhSHBG)-
binding steroids in dietary supplements. For screening, 17β-testosterone-d3 was used 
as stable isotopic MS label and the previously described paramagnetic microbeads 
were used for immobilizing rhSHBG onto the bead surface. The same UPLC-QqQ-
MS system was used for screening while for identification chip-UPLC-Q-ToF-MS was 
used for superior chromatographic performances and sensitivity. Multiple dietary 
supplements, which were previously analyzed using a conventional LC-MS method 
in multiple reaction monitoring (MRM) mode, were screened and identified. This 
chapter demonstrates the limitations of using LC-MS in highly specific MRM mode for 
confirmation or identification of steroids and highlights the potential of the proposed 
BioMS methodology. In Chapter 5, another high-throughput bioaffinity LC-MS 
approach was developed for estrogens in dietary supplements but using the estrogen 
receptor α (ERα). The highly unstable ERα was stabilized by immobilizing it onto the 
surface of paramagnetic microbeads using two different surface chemistries. With 
this method, instead of the normally applied GC-MS, LC-QqQ-MS was used for the 
screening of estrogens by using a suitable LC-MS-compatible label. By using LC-MS 
instead of GC-MS, derivatization and long run times were avoided. The identification 
of estrogens in ERα-purified supplement extracts was achieved by using a UPLC-ion 
mobility-Q-ToF-MS which gave, next to retention times, experimental accurate mass, 
MS/MS data, also specific drift times. Finally, Chapter 6 presents general conclusions 
of the research chapters and future recommendations. 
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flow cytometry and identification with nano-liquid 
chromatography mass spectrometry of ochratoxins in 
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Abstract
Multi-analyte binding assays for rapid screening of food contaminants require 
mass spectrometric identification of compound(s) in suspect samples. An optimal 
combination is obtained when the same bioreagents are used in both methods; 
moreover miniaturization is important because of high costs of bioreagents. A concept 
is demonstrated using superparamagnetic microbeads coated with monoclonal 
antibodies (Mabs) in a novel direct inhibition flow cytometric immunoassay (FCIA) 
plus immunoaffinity isolation prior to identification by nano-liquid chromatography-
quadrupole-time-of-flight-mass spectrometry (nano-LC-Q-ToF-MS). As a model 
system, the mycotoxin ochratoxin A (OTA) and cross-reacting mycotoxin analogues 
were analyzed in wheat and cereal samples, after a simple extraction, using the FCIA 
with anti-OTA Mabs. The limit of detection for OTA was 0.15 ng g-1, which is far below 
the lowest maximum level (ML) of 3 ng g-1 established by the European Union. In the 
immunomagnetic isolation method, a 350 times higher amount of beads was used 
to trap ochratoxins from sample extracts. Following a wash step, bound ochratoxins 
were dissociated from the Mabs using a small volume of acidified acetonitrile/water 
(2/8 v/v) prior to separation plus identification with nano-LC-Q-ToF-MS. In screened 
suspect naturally contaminated samples, OTA and its non-chlorinated analogue 
ochratoxin B were successfully identified by full scan accurate mass spectrometry 
as a proof of concept for identification of unknown but cross-reacting emerging 
mycotoxins. Due to the miniaturization and bioaffinity isolation, this concept might 
be applicable for the use of other and more expensive bioreagents such as transport 
proteins and receptors for screening and identification of known and unknown (or 
masked) emerging food contaminants.
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Introduction
For the rapid detection of food contaminants, such as mycotoxins, many rapid 
immunoassays have been developed [1-7]. However, such immunoassays are 
considered as screening assays due to the risk of false non-compliant results and 
subsequent confirmation with instruments such as liquid chromatography (LC) 
combined with mass spectrometry (MS) is compulsory [8]. Screening assays with 
multi-analyte reagents (group-specific antibodies  [9], transport proteins [10] or 
receptors [11]) are of particular interest since they might pinpoint the occurrence of 
emerging yet unidentified food contaminants and the subsequent MS identification 
of the interacting compound(s) is essential. In an ideal situation, to avoid different 
sample preparations with different selectivities, the screening should be as close 
as possible to the MS confirmation or identification of unknowns, which could be 
achieved by using identical bioreagents in both methods. Moreover, miniaturization 
is important because of the high costs of bioreagents in general. Superparamagnetic 
carboxylated polystyrene microbeads (MagPlexTM (6.5 μm diameter beads)) might 
be used in a multiplex flow cytometric immunoassay (FCIA) for screening several 
mycotoxins including ochratoxin A (OTA). Superparamagnetic means that the 
beads can easily be magnetized when an external magnetic field is applied and 
redispersed immediately when the magnet is removed, which enhances both ease-
of-use and automation capabilities [12]. These beads are internally dyed with a red 
and an infrared fluorophore and by varying the ratio of the two fluorophores, up 
to 80 different color-coded bead sets can be distinguished (MultiAnalyte Profiling 
(xMAP®) technology). Each bead set can be covalently coupled, via its carboxylated 
surface modification, to a different biological probe such as antibodies or other (bio)
molecules. In combination with a special flow cytometer (Luminex®), it is possible to 
simultaneously measure up to 80 different biomolecular interactions in a single well 
[13]. Other distinct advantages are high throughput capability, versatility, accuracy 
and reproducibility [14]. Multiplex FCIAs were described for the screening of plant 
proteins, which might be used as adulterants in milk powders [15], pathogens [16], 
mycotoxins [17], sulfonamides in milk [9] and polycyclic aromatic hydrocarbons in 
fish [18]. However, all of these are indirect inhibition FCIAs and most of them use 
non-magnetic beads (MicroPlex®) coated with antigens and fluorescent labeled 
(secondary) antibodies for detection. OTA is a mycotoxin which has carcinogenic, 
nephrotoxic and teratogenic properties and is produced by Aspergillus and 
Penicillium fungi [19]. The Aspergillus fungus also produces OTA analogues such as 
the non-chlorinated ochratoxin B (OTB), ochratoxin α (OTα) , ochratoxin β (OTβ) and 
ochratoxin C (OTC) (Figure 1). Most analogues are reported less toxic than OTA but 
OTC is considered as toxic as OTA since it is converted into OTA after metabolism 
[19]. All analogues are produced approximately 10 times less by the Aspergillus 
fungus [20]. Regardless of the natural occurrence and toxicity of OTB, OTα, OTβ 
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and OTC, the majority of existing methods are focused on OTA only. OTA is widely 
found in cereals, wine, coffee, beer, nuts, dried fruits and meat products [21]. Cereal 
and cereal products are the main sources of EU consumer exposure to OTA [22]. 
The maximum levels (ML) established by the EU for OTA in food [23] vary between 
0.5 and 10 ng g-1. The ML in cereal and cereal products is 5 ng g-1 and if the cereal is 
meant for direct human consumption, the ML is 3 ng g-1. The lowest OTA ML of 0.5 ng 
g-1 is established for baby food. Guidance values in feed vary between 50 and 250 ng 
g-1 and for OTA in cereal or cereal products used as feed material 250 ng g-1 is applied 
[24]. For the detection of OTA and other mycotoxins, immunoaffinity chromatography 
(IAC) is a common tool for the specific isolation from sample materials prior to HPLC 
or LC-MS analysis [25-27]. However, such IAC columns are voluminous, use high 
amounts of carrier material with a high risk of non-specific binding. They consume 
lots of antibodies and require large volumes of chemicals for extraction and elution, 
with extra time for evaporation, and sometimes filtration of the sample extracts 
to remove matrix particles. Several of these disadvantages are overcome by the 
miniaturized immunoextraction method for OTA as described by Faure et al. [4] using 
in-situ polymerization of a monolithic stationary phase with highly reactive epoxy 
groups for protein coupling. However, the crucial polymerization step requires both 
time (>10 h) and expertise and the antibody immobilization is also time-consuming 
(>18 h).
Figure 1. Molecular structures, elemental compositions and theoretical exact masses of (A) OTA, (B) 
OTB, (C) OTC, (D) OTα and (E) OTβ.
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and OTC, the majority of existing methods are focused on OTA only. OTA is widely 
found in cereals, wine, coffee, beer, nuts, dried fruits and meat products [21]. Cereal 
and cereal products are the main sources of EU consumer exposure to OTA [22]. 
The maximum levels (ML) established by the EU for OTA in food [23] vary between 
0.5 and 10 ng g-1. The ML in cereal and cereal products is 5 ng g-1 and if the cereal is 
meant for direct human consumption, the ML is 3 ng g-1. The lowest OTA ML of 0.5 ng 
g-1 is established for baby food. Guidance values in feed vary between 50 and 250 ng 
g-1 and for OTA in cereal or cereal products used as feed material 250 ng g-1 is applied 
[24]. For the detection of OTA and other mycotoxins, immunoaffinity chromatography 
(IAC) is a common tool for the specific isolation from sample materials prior to HPLC 
or LC-MS analysis [25-27]. However, such IAC columns are voluminous, use high 
amounts of carrier material with a high risk of non-specific binding. They consume 
lots of antibodies and require large volumes of chemicals for extraction and elution, 
with extra time for evaporation, and sometimes filtration of the sample extracts 
to remove matrix particles. Several of these disadvantages are overcome by the 
miniaturized immunoextraction method for OTA as described by Faure et al. [4] using 
in-situ polymerization of a monolithic stationary phase with highly reactive epoxy 
groups for protein coupling. However, the crucial polymerization step requires both 
time (>10 h) and expertise and the antibody immobilization is also time-consuming 
(>18 h).
Figure 1. Molecular structures, elemental compositions and theoretical exact masses of (A) OTA, (B) 
OTB, (C) OTC, (D) OTα and (E) OTβ.
B
Applications of bioaffinity superparamagnetic beads are described for extracting 
and pre-concentrating proteins, lipopolysaccharides [28, 29], hormones and drugs 
[30] and in proteomic profiling [31]. They can operate in small volumes and simplify 
sample preparation procedures. MagPlexTM superparamagnetic microbeads coated 
with antibodies have the extra advantage that they can also be used in the flow 
cytometric screening assay. Covalent coupling of these beads with proteins (e.g. 
antibodies) is not laborious (<4 h). In the present research, the concept of using 
identical bioreagents in both screening and identification methods was investigated 
by using superparamagnetic microbeads (beads) in a direct inhibition FCIA for the 
screening of OTA, a relevant model food contaminant, and for the immunomagnetic 
isolation prior to identification by nano-LC-Q-ToF-MS. This identification technique 
was used because of its high sensitivity, small injection volumes, ultralow flow rates, 
resulting in the low consumption of hazardous chemicals, and the option to operate 
in full scan accurate mass mode for the identification of unknown compounds 
based on elemental composition calculated thereof. The optimization experiments 
were performed with high performance-liquid chromatography-triple quadrupole-
mass spectrometry (LC-QqQ-MS) due to its high sensitivity and availability. In this 
research, one set of the paramagnetic beads was coated with monoclonal antibodies 
(Mabs) against OTA and, for the detection, OTA was coupled to the fluorescent 
protein R-Phycoerythrin (R-PE) according to a procedure described by Kawamura 
et al. [32]. As a model, we focused on the development and application of a rapid 
screening assay for OTA in wheat and cereal for human consumption, which can 
easily be extended to other mycotoxins in the future. The same Mab-coated beads, 
but different amounts, were used for the specific miniaturized immunoaffinity isolation 
of OTA and cross-reacting analogues, prior to the identification with nano-LC-Q-ToF-
MS. 
Materials and Methods
Materials
Acetonitrile (ACN), methanol (MeOH) and ToF grade water were purchased 
from Biosolve (Valkenswaards, The Netherlands). Formic acid (HCOOH) and 
ethylene diamine were from Merck (Whitehouse Station, NJ, USA) and N-(3-
dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC), NaHCO3, Tween-20, 
OTA, OTB and NaN3 from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands). 
Beads (magnetic carboxylated microspheres (MagPlexTM no. 086)) and the sheath 
fluid were supplied by Luminex Corporation (Austin, TX, USA). Mabs (purified 
mouse anti-OTA IgG (201051-5G9)) were purchased from Soft Flow Biotechnology 
(Pécs, Hungary) and water was purified using a Milli-Q system (Millipore, Bedford, 
MA, USA). Protein LoBind Tubes (1.5 mL) were supplied by Eppendorf (Hamburg, 
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Germany) and the LoBind 96-wells microplates by Greiner Bio-One B.V. (Alphen 
a/d Rijn, The Netherlands). The N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) 
was provided by Fluka Analytical (Steiham, Switzerland). Amicon Ultra Ultracel 50K 
centrifugal filter units were purchased from Millipore (Bedford, MA, USA) and all 
BCA reagents were from Thermo Scientific (Rockford, Il, USA). R-PE was from 
Moss (Pasadena, Maryland, USA). Surface Plasmon Resonance (SPR) biosensor 
chips (CM5), the amine coupling kit (containing 0.1 M NHS, 0.4 M EDC, and 1 M 
ethanolamine hydrochloride (pH 8.5)) were from GE Healthcare (Uppsala, Sweden). 
Instrumentation
High performance-liquid chromatography-triple quadrupole-mass spectrometry 
A Waters (Milford, MA, USA) Acquity Ultra Performance LC (UPLC) system, consisting 
of a degasser, a binary gradient pump, an autosampler (at 10 °C) and a column oven 
(at 40 °C), was used. The sample injection volume was 50 µL and the analytical 
column was an Xbridge 3.5 µm C18, 2.1 mm I.D. × 100 mm from Waters. The UPLC 
system was coupled to a Micromass (Manchester, UK) Quattro Ultima tandem mass 
spectrometry (QqQ) system equipped with an electrospray interface (ESI). The two 
mobile phases used consisted of (A) H2O/HCOOH (99.9/0.1% v/v) and (B) MeOH/
HCOOH (99.9/0.1% v/v) and the flow rate was 0.3 mL min-1. The gradient started at 
100% A and was kept at this composition for 1 min and decreased linearly to 50% A 
in 2 min. The mobile composition decrease to 0% A was done in 3 min and kept at 
0% A for 7 min and returned to 100% A in 0.5 min with a final hold of 1.5 min. The LC 
was interfaced with the MS/MS system without a flow split. The mass spectrometer 
was operated in the positive ESI mode, which was found to be more sensitive than 
negative ESI in preliminary experiments, at a capillary voltage of 2.5 kV, cone voltage 
of 30 V, a desolvation gas temperature of 350 °C and source temperature of 120 °C. 
The desolvation gas was nitrogen (600 L h-1) and the collision-induced dissociation 
(CID) gas was argon at a pressure of 2.5 x 10-3 mbar. The run time was 15 min and 
data acquisition for OTA was performed in multiple reaction monitoring mode (MRM) 
at transitions m/z 404.2 → m/z 221.0 and m/z 404.2 → m/z 238.8 using collision 
energy 35 eV and 30 eV respectively. The absolute limit of detection (LoD) of OTA 
was determined at 10 pg on-column (S/N > 6). 
Nano-liquid chromatography-quadrupole-time-of-flight-mass spectrometry (nano-
LC-Q-ToF-MS)
The nanoAcquity UPLC System of Waters consisted of a degasser, a binary 
gradient pump, a nano-autosampler (at 20 °C) and a column oven (at 60 °C). Lower 
autosampler temperature induced precipitation of particles in real sample extract 
causing system overpressure. The trapping column was a nanoAcquity UPLC HSS 
Screening and identification of ochratoxins
73
T3 5 µm C8, 180 µm I.D. x 20 mm, and the analytical column was a nanoAcquity 
UPLC BEH 1.7 µm C18 column, pore size 130 Å, 75 µm I.D. x 100 mm, all from 
Waters. The nanoAcquity UPLC System was coupled to a Xevo quadrupole-time-of-
flight (Q-ToF) (from Waters) mass spectrometry system equipped with a nano-ESI 
interface without a flow split. The two mobile phases consisted of (A) H2O/HCOOH 
(99.9/0.1 % v/v) and (B) MeOH/HCOOH (99.9/0.1% v/v) and the flow was 500 nL 
min-1. After injection (4 µL), the sample was preconcentrated on the trapping column 
at a flow rate of 10 µL min-1 (100% A). After 3 min trapping time, the gradient started 
at 99% A and was kept at this composition for 5 min and decreased linearly to 5% 
A in 5 min. This mobile phase composition was kept for 12 min and returned to 
100% A in 1 min with a final hold of 7 min. The total run time was 33 min. The 
mass spectrometer was operated in the positive ESI mode (again found to be more 
sensitive than negative ESI in preliminary experiments) at a capillary voltage of 
2.8 kV, cone was at 40 V and source temperature was 80 °C. The purge gas was 
nitrogen (50 L h-1) and cone gas 10 L h-1 and data acquisition was performed in full 
scan centroid mode. The detector, containing a 4 GHz TDC, was set to accumulate 
spectra during 0.3 s in full scan mode at a resolution of 10,000 FWHM. The dynamic 
range enhancement option was applied to achieve accurate mass measurements 
over a wide concentration range. A 2 ng µL-1 standard solution of leucine-enkephalin 
was introduced as a lock-mass via the lock-spray needle (capillary voltage 2.8 kV 
and cone voltage 40 V) at a flow rate of 500 nL min-1.
Other instruments
The Luminex FM-3D flow cytometer with Xponent System 2.0 control software was 
purchased from Luminex Corporation (Austin, TX, USA). The NanoDrop ND-1000 
spectrophotometer was from Thermo Scientific (Rockford, Il, USA) and the Biacore 
3000 SPR biosensor from GE Healthcare (Uppsala, Sweden). The automated 
magnetic wash station BioPlexTM Pro II, with a magnetic carrier, was from BioRad 
Laboratories B.V. (Veenendaal, The Netherlands) and the magnetic separator rack 
DynaMag-2TM from Invitrogen Dynal (Oslo, Norway). The microtiter plate vari-shaker 
was from Dynatech (Alexandria, VI, USA) and the REAX2 head-over-head shaker 
from Heidolph (Schwabach, Germany). The Eppendorf 5810 R centrifuge, using the 
A-4-62 rotor, was purchased from VWR International (Amsterdam, The Netherlands) 
and the test tube rotator from Snijders (Tilburg, The Netherlands).
Methods
SPR biosensor immunoassay
For testing several dissociation conditions of OTA from the Mabs, OTA was 
immobilized onto the carboxymethylated dextran surface of a CM5 biosensor chip. 
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For this, the CM5 sensor chip surface was activated with 50 µL of a mixture of 0.4 
M EDC and 0.1 M NHS (1:1, v/v) during 15 min at room temperature (RT). The chip 
surface was washed with water and dried under a stream of nitrogen gas. To the 
chip, 50 µL of 1 M ethylene diamine (pH 8.5) was added and after 15 min incubation 
at RT, the chip was washed with water and dried under a stream of nitrogen gas. 
OTA was immobilized on the activated sensor surface using the following procedure. 
OTA (1 mg) was dissolved in 0.2 mL ACN/water (80:20, v/v) and 0.2 mL sodium 
carbonate buffer (pH 9.6) and 50 μL was mixed with 50 μL 0.4 mL EDC and 50 μL 
NHS and after incubation at RT for 45 min, this mixture (50 μL) was added to the 
activated chip. After incubation of 45 min at RT, the chip was washed with water, 
dried under a stream of nitrogen and docked into the Biacore 3000. Mab dilutions 
in HBS-EP buffer were injected (20 μL at 20 μL min-1) over the chip surface which 
resulted in OTA-Mab complexes. Several solutions (10 mM HCl, ACN/H2O/HCOOH 
(20/79/1 % v/v/v), HCOOH/H2O (1/99 % v/v), ACN and MeOH) were injected (10 
μL) for testing the dissociation of the Mabs from the sensor chip. The most suitable 
dissociation solution was used later on during immunoaffinity extraction of OTA from 
wheat and cereal to dissociate OTA from the immunomagnetic microbeads.
Preparation of the anti-OTA Mab-coated superparamagnetic beads 
Superparamagnetic bead set no. 86 was coated with anti-OTA Mabs using the 
slightly modified two-step carbodiimide coupling protocol provided by Luminex®. This 
covalent coupling was based on conjugating the amino groups of the anti-OTA Mab 
to the carboxylic groups on the surface of the beads. In short, the stock of beads 
(suspension containing 1.25 × 107 beads mL-1) was resuspended by vortexing for 5 
min. From this stock, 400 µL (containing 5 × 106 beads) was transferred to a protein 
LoBind tube in which the beads were concentrated in the magnetic separator rack in 1 
min. After gently removing of the supernatant, the pellet was washed by resuspending 
in 100 µL activation buffer (0.1 M NaH2PO4, pH 6.2). The beads were concentrated 
in the magnetic separator rack and the supernatant was removed. The pellet was 
resuspended in 80 µL of activation buffer (0.1 M NaH2PO4, pH 6.2). Solutions of 
sulfo-NHS and EDC (both at 50 mg mL-1) were prepared just before adding 10 µL of 
each to the 80 µL bead suspension. The concentrations of both these solutions were 
50 mg mL-1 made in H2O. The beads were incubated in the dark at room temperature 
for 20 min. The activated beads were concentrated by the magnet and washed by 
adding 250 µL of 100 mM MES (2-N-morpholino ethanesulfonic acid) buffer at pH 5. 
This wash step was performed twice. To the activated and precipitated beads, first, 
100 µL of 100 mM MES buffer was added to prevent the beads from becoming dry 
then a solution containing 100 µg of the anti-OTA Mab in 400 µL of 100 mM MES 
buffer was added. The suspension was vortexed shortly and incubated for 2 h under 
mixing by rotation in a test tube rotator at room temperature in the dark. Following 
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the incubation, the supernatant containing unbound anti-OTA Mabs was removed 
and the beads were washed three times with storage buffer (the first wash with 500 
µL, the remaining two steps with 1 mL) consisting of PBS (5.4 mM Na2HPO4, 1.3 mM 
KH2PO4, 150 mM NaCl, 3 mM KCl, pH 7.4) to which, 0.02% Tween-20 and 0.05% 
NaN3 were added. Finally, the beads were suspended in 500 µL of the storage buffer 
and stored at 4 °C in dark until used (counted 3.5 x 106 beads per 500 µL). Usually, 
after incubation, bovine serum albumin (BSA) is used to block the free activated 
sites of the bead surface. In this study, no blocking procedure was used because 
BSA might contribute to non-specific binding of OTA [33]. The possible non-specific 
binding of OTA to the unblocked bead surface was tested.
OTA-PE conjugation
The OTA-PE conjugate was prepared according to a minor modified protocol of 
Kawamura et al. [32] and was based on conjugating the carboxylic group of OTA 
to the amino groups of R-PE. In short, 3.5 mg of R-PE was dissolved in 4 mL of 0.1 
M NaCl. To this solution, 50 µL ethanol which contained 1 mg of OTA was added 
dropwise. To this mixture, 3 mL of 0.1 M phosphate buffer (pH 7) containing 10 mg of 
EDC was added to initiate the coupling. This reaction was incubated for 24 h at room 
temperature while stirring in the dark. Following the incubation, the mixture was added 
to a 50 kD microcon filter to remove uncoupled free OTA from the OTA-PE conjugate 
by centrifuging at 12.000 g for 10 min after which the OTA-PE was reconstituted in 
1 mL PBS buffer. In total, five subsequent wash steps were performed to remove all 
unbound OTA. Finally, after the last wash step, OTA-PE was reconstituted in 2 mL of 
PBS buffer containing 0.05% NaN3 and stored in the dark at 4 °C. 
Protein analysis
BCA. The BCA protocol consisted of the following steps; 10 µL sample solution 
was added to a microtiter plate (n=2). Then, 200 µL of a mixture, consisting of an 
alkaline agent, bicinchoninic acid (BCA) and CuSO4 (reduced to Cu1+ by proteins), 
was added to the samples and the calibration curve. The reagent is responsible for 
color change by chelating 2 BCA molecules to Cu1+ ions. The calibration curve was 
made by diluting an immunoglobulin G (IgG) with PBS buffer. Following the addition 
of reagents, the microtiter plate was incubated at 37 °C during 30 min after which 
the microtiter plate was cooled for 5 min at RT and the concentration of proteins was 
measured using an UV microtiter plate reader at 562 nm.
NanoDrop. First, one blank UV-absorbance measurement with 0.5 µL H2O was 
performed at 280 nm after which 0.5 µL of sample solution was measured at 280 
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nm. The samples (antibody solutions), before and after coupling, were measured in 
the Nanodrop spectrophotometer in duplicate to determine coupling efficiency.
OTA extraction from wheat and cereal samples
One gram of sample (either wheat or cereal) was weighed into a 50 mL tube and 10 mL 
of a 1% aqueous solution of NaHCO3 (pH 8.1) was added to extract ochratoxins from 
wheat or cereal samples. The tubes were vortexed for 10 s and placed into the head-
over-head shaker (rotating slowly) for 30 min. After shaking, the tubes were centrifuged 
for 5 min at 3500 rpm. For the FCIA, 40 µL of the supernatant was used (either diluted 
to fit in the calibration curve or undiluted). For nano-LC-Q-ToF-MS-based identification, 
instead of 40 µL, 1 mL of extract was used which corresponded to 100 pg OTA from a 
sample containing 1 ng g-1 OTA.
Flow cytometry immunoassay (FCIA) protocol
First, 40 µL of either sample or standard solution was pre-incubated for 15 min in 
a well of a LB 96-well microtiter plate to which approximately 2000 beads coated 
with anti-OTA Mab were added. After the pre-incubation, 10 μL of diluted OTA-
PE (125 times diluted in NaHCO3 buffer (pH 8.1)) was added to each well. This 
mixture was incubated for 30 min on a plate shaker at RT in the dark. After these 
incubations, a washing step with PBS-Tween 20 (PBST) was applied to remove the 
excess unbound bioreagents and matrix compounds. The wash step was carried 
out with the magnetic washing plate carrier of the automated wash station. After 
washing, the beads were resuspended in 100 µL of PBST and the measurement in 
the Luminex® was done in <60 s using 75 µL per well. To prepare a dose-response 
calibration curve in buffer (NaHCO3, pH 8.1) or in blank wheat extract, a dilution 
series of OTA (0.0001-1000 ng mL-1) was prepared in buffer or in blank wheat extract 
and the results were fitted using the 5 parameter curve fitting in the GraphPad Prism 
software of GraphPad Software Inc. (La Jolla, CA, USA).
Immunoaffinity isolations of OTA for LC-MS detection
Of the anti-OTA Mab-coated bead stock suspension (containing 3.5 x 106 beads per 
500 µL), 100 µL beads was transferred into a 1.5 mL Eppendorf tube (7.0 x 105). The 
coated beads were trapped by applying the magnetic separator rack for 60 s and 
the supernatant was removed. One hundred to 1500 µL of either buffer containing 
100-300 pg OTA or sample supernatant was added to the beads after which the 
incubation (tested 1-60 min) was done under gently vortexing. After the incubation, 
the magnetic separator rack was applied for 60 s and the supernatant was removed 
gently. To remove matrix compounds, the trapped beads were washed with 100 µL 
NaHCO3 buffer (pH 8.1) by vortexing for 5 min. The magnetic separator rack was 
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applied for 60 s to concentrate beads followed by removal of supernatant. This wash 
step was repeated once and after the final wash step, 100 µL of the dissociation 
solvent (ACN/H2O/HCOOH (20/79/1 % v/v/v)) was added to the trapped beads to 
dissociate OTA from the beads. This was achieved by gentle vortexing for 5 min 
after which the magnetic separator rack was applied for 60 s and the supernatant 
(OTA-containing eluate) was transferred into an LC-QqQ-MS vial. For nano-LC-Q-
ToF experiments, 25 µL of dissociation solvent was used.
Results and discussion
Coupling efficiency of anti-OTA Mabs to the beads
For the FCIA and the immunoaffinity isolation, the same beads were coated with 
the same anti-OTA Mabs ensuring a uniform bioaffinity during the screening and 
the isolation prior to MS confirmation or identification. Several Mabs were tested 
in the FCIA (data not shown) and the anti-OTA Mab from Soft Flow was selected 
because of its highest sensitivity and its cross-reactivity towards OTB. The amount 
of antibodies immobilized determines the amount of beads needed for isolation 
purposes. Following the Luminex® coupling protocol for proteins to the MagPlexTM 
beads, 0.4 mL of 0.25 mg mL-1 anti-OTA Mab was added to 5 x 106 activated beads. 
To determine the coupling efficiency, antibody concentrations were measured in the 
solutions before and after six immobilizations by two different protein determination 
techniques; BCA [34, 35] and NanoDrop [36]. With the BCA method, average 
protein concentrations of 0.28 ± 0.01 mg mL-1 and 0.17 ± 0.01 mg mL-1 were found 
in the solutions before and after coupling, respectively (BCA usually overestimates 
glycoprotein concentration [37]). Therefore, the average coupling efficiency was 
calculated to be 39%. With the NanoDrop, the coupling efficiency was determined 
to be 44%. Based on these two different techniques for protein analysis, from the 
absolute amount of Mab (100 µg) added to 5 x 106 beads, between 39 and 44 µg 
was coupled.
Flow cytometric screening
For the rapid screening of OTA in wheat and cereal samples, a direct inhibition FCIA 
with Mab-coated superparamagnetic beads and OTA-PE, as the label for detection, 
was developed. This direct assay format is less laborious and faster, compared 
to the indirect assay format developed recently [17], because only two (instead of 
three) incubation steps and one (instead of two) washing step are required. During 
the development of the direct inhibition method, various steps and parameters 
were optimized using an OTA concentration range of 0.0001-1000 ng mL-1. The 
pre-incubation step was performed at different times (15, 30, 60 min) and 15 min 
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was found to be sufficient. Omitting the pre-incubation step influenced the precision 
negatively at low OTA levels. The effect of the amount of beads (1000 or 2000/well) 
was tested and the latter was optimal. Following this, different dilutions of OTA-PE 
(250, 125, 62.5 times) were tested and the 125 times dilution was optimal with regard 
to the sensitivity of the assay and aiming for an average final response of 2000 mean 
fluorescent intensity (MFI). The optimum OTA-PE incubation time was 30 min (15, 
30, 60 min tested). After the incubation, a washing step with PBST in the magnetic 
washer was performed. Two wash buffers (PBS and PBST) were tested to remove 
matrix compounds and PBST was found most suitable as wash buffer and the same 
buffer was used to resuspend the beads. Finally, the measurement in the Luminex 
was optimized by testing the injection volumes (50 and 75 µL, latter was optimum), 
injection times (30 and 60 s, latter was optimum) and detector settings (low and 
high detector voltage, latter was used). For the extraction of ochratoxins from wheat 
and cereal samples, various ratios of acetonitrile/water and methanol/water with and 
without formic acid were tested. Further, NaHCO3 buffer (pH 8.1) was tested and was 
found to be most suitable extraction solution because in contrast to other extraction 
solutions, no false suspect results were produced with this FCIA. The final protocol 
with selected optimal conditions is described in the material and methods section. 
This protocol resulted in a dose-response curve for OTA in buffer with a sensitivity at 
50% inhibition (IC50) of 0.3 ng mL-1 (Figure 2a), which is comparable to the sensitivity 
obtained in the indirect format [17], but more sensitive than ELISAs (IC50 0.45-400 
ng mL-1) [38, 39], the used SPR biosensor immunoassay (IC50 around 5 ng mL-1) and 
the non-instrumental dipstick OTA assay [40] (cut-off level of 3.2 ng mL-1). 
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Figure 2a. Average dose-response curves (n=2) of OTA in buffer (■) (IC50 = 0.30 ng mL-1) and in wheat 
extract (●) (IC50 = 0.09 ng mL
-1) obtained in FCIA screening assay.
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The dose-response curve in wheat extract (Figure 2a) showed a slightly better 
sensitivity with an IC50 of 0.09 ng mL-1 or 0.9 ng g-1 in the wheat sample. Due to 
this matrix effect, (semi-)quantification of OTA in wheat was performed with a dose-
response curve in a blank wheat extract which showed good precision and a wide 
measurement range (0.01 to 1 ng mL-1 or 0.1 to 10 ng g-1) which is adequate for the 
detection at even the lowest ML levels of 3 or 5 ng g-1. The assay was also tested for 
cross-reactivity with OTB and Figure 2b presents the dose-response curves in buffer 
and blank wheat extract. According to the IC50 values for OTB in buffer and wheat 
extract of 2.1 and 0.13 ng mL-1, respectively, the cross-reactivities compared to OTA 
were calculated as 14 and 69 %, respectively, which are higher compared to the 
supplier’s data obtained with ELISA (9.2 % in buffer). Under current buffer condition, 
the OTB dose-response curve showed a wide measurement range, in which (semi-)
quantification is allowed with good precision.
Figure 2b. Average dose-response curves (n=2) of OTB in buffer (■) (IC50 = 2.1 ng mL-1) and wheat extract 
(●) (IC50 = 0.13 ng mL-1).
Assigned blank wheat samples (n=11) without and with the addition of OTA (1 
and 5 ng g-1) were analyzed with the FCIA screening assay. These blank samples 
were also analyzed by an in-house validated LC-QqQ-MS method and 10 of them 
were found negative (<0.6 ng g-1). Figure 3 shows that there are clear differences 
in responses MFI between those 10 blank wheat samples and the spiked wheat 
samples at different levels. 
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Figure 3. Average FICA responses (n=2) obtained with the 10 blank wheat samples (0 ng g-1) and blank 
wheat spiked with OTA at 1 and 5 ng g-1.   
The results obtained with these 10 blank wheat samples, in combination with 
calibration curves in a blank wheat extract, were used to calculate the limit of 
detection (LoD) of the screening method (the concentration at the average maximum 
response minus 3 x SD) which was calculated as 0.15 ng g-1. The concentrations 
found in the wheat samples spiked at 1 ng g-1 varied between 0.3 and 0.6 ng g-1 with 
an average of 0.5 ± 0.08 ng g-1 and in the wheat sample spiked at 5 ng g-1 between 
2.5 and 4 ng g-1 with an average of 3.0 ± 0.37 ng g-1. These results show that this 
screening assay is semi-quantitative and suitable to identify suspect wheat samples 
at the required ML’s of 3 or 5 ng g-1. The eleventh wheat sample was found suspect 
in the FCIA screening (5.6 ± 0.9 ng g-1) and the OTA concentration found with the LC-
QqQ-MS-based chemical method in MRM mode was 15 ng g-1. Primary extraction 
recovery of OTA  (50-60%) from wheat and cereal remained uncorrected in FCIA 
procedure. Three naturally OTA contaminated cereal samples from a collaborative 
study were kindly provided by the IRMM (Geel, Belgium); sample 1 (35 ng g-1), 
sample 2 (190 ng g-1, from proficiency test) and sample 3 (290 ng g-1). In the semi-
quantitative screening method, all incurred cereal samples were found suspect and 
after analyzing diluted extracts, the concentrations found were 35 ng g-1 (sample 1), 
60 ng g-1 (sample 2) and 110 ng g-1 (sample 3). The samples were also re-analyzed 
with the in-house validated LC-QqQ-MS method and OTA concentrations found were 
45 ng g-1 (sample 1), 171 ng g-1 (sample 2) and 397 ng g-1 (sample 3).
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Immunoaffinity microbead isolation method
For future identification purposes of OTA and cross-reacting analogues in wheat 
and cereal sample extracts by means of nano-LC-Q-ToF, a microbead-based 
immunoaffinity isolation method was developed. For this isolation the same, but 
different amounts, Mab-coated beads were used as applied in the screening method. 
Most of the optimization experiments were performed with an LC-QqQ-MS system 
operated in the MRM mode, because of its high sensitivity (absolute 10 pg of OTA) 
and wide availability. 
Dissociation conditions
In order to find suitable dissociation condition of the immunomagnetic isolated OTA, 
an SPR-based biosensor (Biacore 3000) was used in combination with a biosensor 
chip coated with OTA. Note that this SPR set-up is in reversed assay format compared 
to the applied immunoaffinity isolation method, however, in both methods identical 
immunochemistry is involved to dissociate the Mab-OTA complex. Injections of anti-
OTA Mabs (10 μl of 0.1 mg mL-1) onto this chip resulted in high responses (9400 
response units (RU)) of bound antibodies which could be dissociated under mild 
acidic conditions (e.g. a few injections (10 μL) of 10 mM HCl). Due to this pH shift, 
protein charge and conformation changed causing the dissociation of the OTA-Mab 
complex. Alternative solvents, HCOOH/H2O, MeOH (0-100%) and ACN (0-100%) 
were tested as well (see Method section of SPR biosensor) and the mixture of ACN/
H2O/HCOOH (20/79/1 % v/v/v) worked out well and was preferred because of better 
compatibility with LC-MS. Either 25 µL or 100 µL of this dissociation solution was 
used in the immunomagnetic microbead isolation method. 
Immunoaffinity capture efficiency and capacity
To determine the minimum amounts of immunoaffinity beads necessary to capture 
a reasonable amount of OTA (100 pg), the capture efficiency had to be determined. 
This 100 pg of OTA was chosen because it can easily be detected by the MS (LoD 
of 10 pg) and it corresponds with the amount of OTA in 1 mL of extract of a positive 
sample incurred at 1 ng g-1 level. For this experiment, 100 pg of OTA was added to 
different amounts of beads (1.4 x 106, 7.0 x 105, 3.5 x 105, 1.75 x 105, 8.8 x 104 and 
0 beads). The 0 beads were used as blank control to prove that OTA was not bound 
to the test tubes. The 100 pg were offered to the beads in a fixed final volume of 100 
μL and incubated for 60 min at RT under mild mixing. After capturing and washing, 
the captured OTA was dissociated from the beads by the addition of 100 µL ACN/
H2O/HCOOH (20/79/1 % v/v/v) dissociation solution of which 50 μL were injected in 
the LC-QqQ-MS. Figure 4 shows the amounts of OTA dissociated from the various 
amounts of beads. 
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Figure 4. Average amounts of OTA (n=3) recovered from different amounts of beads after incubation with 
100 pg OTA.   
OTA was not found in the control, which proves that the Mab-coated beads are 
responsible for capturing OTA. To capture most of the 100 pg OTA added, at least 
1.75 x 105 beads were necessary. The dissociated amount of OTA decreased with 
lower amounts of beads (to 64 pg using 8.8 x 104 beads), and the precision decreased 
significantly. Further, plain beads (3.8 x 105), which were activated but no Mab was 
added, and plain beads (3.8 x 105) which did not contain Mab but were blocked with 
BSA were tested with 100 pg OTA and no OTA was found in the dissociated fraction. 
This indicates that the affinity capture of OTA was Mab-specific and OTA was not 
captured by BSA when used as blocking agent, probably because a lower amount 
of BSA (0.1 mg) was used compared to Hong et al [33] who used several milligrams 
of BSA to capture OTA. The bead capacity was determined with a fixed amount of 
beads (7.0 x 105) and various amounts of OTA (100, 300, 900 and 2000 pg). Figure 
5 shows that the overall capturing plus dissociation efficiency was >75% when 100, 
300 and 600 pg was incubated with 7.0 x 105 beads. This recovery decreased to 
about 65% and <40% with 900 and 2000 pg of OTA, respectively. The maximum 
amount of OTA which could be bound to and recovered from this amount of beads 
under the conditions mentioned was estimated to be around 750 pg. 
Incubation times and volumes
So far, an incubation time of 60 min was used (also used in the FCIA previously) and 
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the influence of the applied incubation time (1, 5, 30 and 60 min) on the efficiency 
of 7.0 x 105 beads to capture 100 pg of OTA was determined in duplicate. Minor 
differences were observed in recovered OTA quantities (92-105 pg), which proves 
the possible use of a very short incubation time (1 min) for immunoaffinity isolation 
of OTA from samples. The influence of incubation volumes on the capture efficiency 
of 7.0 x 105 beads was also tested, because in a real-life situation it is possible that 
more sample volume is required (> 100 µL) to capture the minimum amount of OTA 
which is detectable by the LC-MS.
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Figure 5. Average amounts of OTA (n=3) dissociated after the addition of different amounts of OTA to a 
fixed number of beads (7.0 x 105).
In this experiment, 100 µL incubation volumes containing 100 pg OTA was used 
as reference and 50 µL, 500 µL and 1500 µL incubation volumes were tested with 
an incubation time of 60 min: incubation volumes of 500 and 1500 µL gave similar 
results as the 100 µL incubation volume. By reducing the incubation volume to 50 µL, 
the overall recoveries decreased (<40%) and the precision decreased significantly. 
Possibly, the beads and OTA were not mixed well in 50 µL when vortexed during the 
incubation step. Therefore, incubation volumes of 100 µL, 500 µL and 1500 µL were 
considered applicable.
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Nano-LC-Q-ToF-MS-based identification of ochratoxins
The three suspect cereal samples and one positive and one blank wheat sample 
were subjected to the immunoaffinity isolation after which the obtained extracts were 
injected into the nano-LC-Q-ToF-MS system. Figures 6 shows the chromatogram 
and mass spectra of cereal 3 sample. Figure 6 demonstrates that OTA was found 
and identified in cereal 3. This means that the positive response found in the FCIA 
was indeed caused by OTA, as expected. 
Figure 6. Chromatograms and mass spectra of cereal 3 containing OTA (A) and OTB (B).
Moreover, due to the full scan ability of the nano-LC-Q-ToF-MS system, another 
ochratoxin (OTB) was detected in the extract of cereal 3. The remaining cereal samples 
(cereal 1 and 2) were also measured. Like the cereal 3 sample, these samples contained 
both OTA and OTB (results not shown). The wheat sample found suspect in the FCIA 
screening, was measured with nano-LC-Q-ToF-MS. In agreement with the screening 
results and LC-QqQ-MS results, OTA was found in this sample. Furthermore, a blank 
wheat extract which underwent the immunomagnetic isolation method was injected 
onto the nano-LC-Q-ToF-MS system. In this extract no ochratoxins were found. The 
chemical identifications of OTA and OTB were achieved by means of accurate mass, 
retention time and isotopic pattern (see appendix 2.1 and 2.2). 
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Conclusions
In this study, a rapid Luminex®-based immunoaffinity flow cytometric screening assay 
with Mab-coated superparamagnetic microbeads was developed. The screening 
assay proved to be suitable for screening OTA in wheat and cereal samples far 
below the low ML levels (3 and 5 ng g-1) and at high levels after additional dilutions 
(e.g. 300 ng g-1) and no false suspect or false-compliant results were obtained as 
confirmed by means of an in-house validated reference method based on LC-QqQ-
MS. After running the screening assay, all suspect samples were subjected to the 
newly developed immunoaffinity isolation method for confirmation and identification 
purposes with nano-LC-Q-ToF-MS using the full scan accurate mass abilities and 
both OTA and the mycotoxin analogue OTB were identified. The ratio OTA and OTB 
found in the cereals (10:1) was in agreement with the literature [20]. OTB was not 
detected routinely by the LC-QqQ-MS reference method due to the preselected 
specific MRM data acquisition used. This concept demonstrates the advantages of a 
miniaturized biospecific-based isolation of mycotoxins to isolate known and unknown 
or masked analogues which may be overlooked during conventional chemical sample 
preparation and instrumental analysis. The results presented show the convenience 
of using the same bioreagents in both the screening and immunoaffinity isolation 
for MS confirmation and/or identification. For screening food contaminants, MS in 
MRM mode is widely applied [41-43]. In this concept, nano-LC-Q-ToF in full scan 
accurate mass mode was used for identification instead. By using nano-LC-Q-ToF, 
not only the consumption of costly bioreagents decreased significantly, it was also 
made plausible that unlike targeted MS MRM mode, full scan accurate mass MS is 
able to detect known and unknown contaminants in affinity purified extracts. Since 
the extraction procedure is bioactivity-based both known and unknown emerging 
food contaminants can be detected which is especially important when more generic 
or mixtures of antibodies are applied in future experiments.
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Appendix 2.1
Measured retention time and mass error of OTA in 1 ng mL-1 standard and cereal 
sample. 
Theoretical Measurement tR Experimental Mass error Elemental composition*
[M+H]+  (min) [M+H]+ (ppm) [M+H]+ 
404.0901 standard 15.98 404.0966 -16 C20H19ClNO6
406.0881 (37Cl) 406.0937 -16
sample 15.98 404.0958 -14 C20H19ClNO6
   406.0924 -11  
* OTA was identified on the basis of measured accurate mass and isotopic patterns using the following 
elemental composition limits: C 1-22, H 1-22, N 1-5, O 1-9 and Cl 1. OTA was the first realistic option 
within calculated results with reasonable double bond equivalents. 
Appendix 2.2
Measured retention time and mass error of OTB in 1 ng mL-1 standard and cereal 
sample. 
Theoretical Measurement tR Experimental Mass error Elemental composition*
[M+H]+  (min) [M+H]+ (ppm) [M+H]+ 
370.1291 Standard 15.60 370.1350 -16 C20H20NO6
Sample 15.60 370.1351 -16 C20H20NO6
* OTB was identified on the basis of measured accurate mass and isotopic patterns using the following 
elemental composition limits: C 1-22, H 1-22, N 1-5, O 1-9. OTB was the first realistic option within 
calculated results with reasonable double bond equivalents. 
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Abstract
For the analysis of thyroid transporter ligands, a triple bioaffinity mass spectrometry 
(BioMS) concept was developed aiming at three different analytical objectives: rapid 
screening of any ligand, confirmation of known ligands in accordance with legislative 
requirements and identification of emerging yet unknown ligands. These three 
purposes share the same bio-recognition element, recombinant thyroid transport 
protein transthyretin (rTTR), and dedicated modes of liquid chromatography-mass 
spectrometry (LC-MS). For screening, a rapid and radiolabel-free competitive 
inhibition MS binding assay was developed with fast ultra-high-performance-LC-
electrospray ionization-triple-quadrupole-MS (UPLC-QqQ-MS) as readout system. It 
uses the non-radioactive stable isotopic thyroid hormone 13C6-L-thyroxine as label of 
which the binding to rTTR is inhibited by any ligand such as thyroid drugs and thyroid 
endocrine disrupting chemicals (EDCs). To this end, rTTR is either used in solution or 
immobilized on paramagnetic microbeads. The concentration-dependent inhibition 
of the label by the natural thyroid hormone L-thyroxine (T4), as a model analyte, is 
demonstrated in water at part-per-trillion and in urine at part-per-billion level. For 
confirmation of identity of known ligands, rTTR was used for bioaffinity purification for 
confirmation of naturally present free T4 in urine. As a demonstrator for identification 
of unknown ligands, the same rTTR was used again, but in combination with nano-
UPLC–quadrupole time-of-flight–MS (nano-UPLC-Q-ToF-MS) and urine samples 
spiked with the model ‘unknown’ EDCs triclosan and tetrabromobisphenol-A. This 
study highlights the potential of BioMS using one affinity system, both for rapid 
screening as well as for confirmation and identification of known and unknown 
emerging thyroid EDCs.
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Introduction
L-thyroxine (T4) is a hormone produced by the thyroid gland. In the bloodstream, 
99% of T4 is bound to carrier proteins such as thyroxine binding globulin (TBG), 
transthyretin (TTR) and human serum albumin. T4 plays an important role in many 
physiological processes, such as embryonic development, cell differentiation, 
metabolism and the regulation of cell proliferation [1, 2]. Patients who suffer from 
lack of T4 are recommended to use T4 to obtain normal plasma concentrations. 
Although the measured environmental concentration of T4 is only 19 ng L-1 in waste 
water, it has been classified as a potential waste water contaminant with remarkably 
high biological activity [3]. Endocrine disrupting chemicals (EDCs) are exogenous 
substances that alter functions of the endocrine system and consequently cause 
adverse health effects in an organism. It has been proven that EDCs have the capacity 
to compete and inhibit natural thyroid hormones such as T4 in thyroid transport 
protein-hormone complexes [4]. For example, the abundantly produced flame 
retardant tetrabromobisphenol-A (TBBPA) is reported to have a binding affinity equal 
to or higher than T4 to TTR [5-7]. Triclosan is a broad spectrum antimicrobial used 
widely in e.g. disinfectants, soap, toothpaste and shampoo [8], but also reported to 
be an EDC that competes with thyroid hormones for TTR [5]. Calafat et al. described 
triclosan levels between 2.4 and 3800 µg L-1 in nearly 75% of urine samples collected 
from US National Health and Nutrition Examination Survey who were subjects ≥ 6 
years old [9]. For the detection of hazardous compounds in the environment, such as 
EDCs, many analytical methods have been developed [10-18]. In general analysis 
techniques for EDCs in environmental samples are based on gas chromatography-
mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS). 
The LoDs of these methods are typically at the low nM levels [18-20]. These methods 
are low-throughput due to long run-time, data processing time and time-consuming 
sample treatment procedures such as pressurized liquid extraction, liquid-liquid 
extraction, solid phase extraction (SPE) and soxhlet extraction and more important, 
they do not provide information about bioactivity. In contrast, for the monitoring of T4 
in environmental samples, such as water, only a few analytical methods have been 
described. Svanvelt et al. developed a sensitive LC-electrospray ionization-triple-
quadrupole-MS (LC-ESI-QqQ-MS) method having an LoD of 1-10 ng L-1 [21]. Next 
to chemical analysis, in vitro bioaffinity screening assays have been developed for 
EDCs based on binding with TTR in competition with radiolabeled T4  and yielding 
IC50 values for specific flame retardants in the range of 60-90 nM. However, the use 
of a radiolabel is a serious disadvantage in binding assays, besides the methods 
described did not focus on screening of real samples but just on the determination 
of binding affinities of EDCs towards TTR [7, 22-24]. A label-free surface plasmon 
resonance (SPR)-based method was published by Marchesini et al. using T4 and 
TTR to determine binding affinities of EDCs (IC50 10 nM for T4) [25]. Although this 
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method is sensitive and label-free, complex sample materials were not tested so the 
robustness of that method is yet unknown and no coupling with MS for confirmation 
and identification was described. Bioaffinity-based extraction procedures using e.g. 
antibodies [26] or receptors [27] in combination with MS are of particular interest 
since they might pinpoint the occurrence of emerging yet unidentified but highly 
relevant EDCs. Previously, several on-line bioaffinity MS methods were described 
for protein-affinity selection [28], drug discovery [29] or screening combinatorial 
libraries [30] using either filter units or beads. However, in continuous flow formats, 
binding assay buffer salts and surfactants can cause serious ion suppression and/
or must be removed  prior to MS detection. De Vlieger et al. developed an on-line 
dual post-column receptor affinity assay based on parallel detection by MS (LoD 40 
nM) and fluorescence (LoD 4.7 nM) for quantification and identification purposes of 
estrogenic compounds [31]. However, in order not to decrease receptor activity by 
the LC mobile phase gradient, a make-up gradient had to be added in order to dilute 
the organic solvent content. Niessen et al. developed an off-line competitive MS 
binding assay for determining the binding affinity of dopamine receptor ligands by 
using spiperone as a marker [32]. That binding assay was presented as a possible 
alternative to radiolabeled assays, however, since only the unbound fraction of 
the marker was measured, at best indirect information was obtained about the 
bound ligands. Moreover, because of the use of a non-volatile buffer an additional 
SPE step was required prior to LC-MS. Zepperitz et al. described a competitive 
MS binding assay in which the γ-aminobutyric acid (GABA) transporter-bound 
fraction of the marker was measured after elution with methanol, but that format 
was used for kinetic measurements in buffer only and no screening in real samples 
was performed [33]. In the present work, a triple bioaffinity MS (BioMS) concept is 
presented in which recombinant TTR (rTTR) and MS are used for different analytical 
objectives, i.e. rapid screening, confirmation and identification. First, a rapid and 
easy to use radiolabel-free competitive MS binding assay has been developed (in 
two different formats) in which a stable isotope of a model analyte (13C6-T4) was used 
as label to screen indirectly for the presence of any EDC having an affinity towards 
rTTR. Following incubation, wash and dissociation steps, only the isotope-labeled 
competitor was measured by means of an ultrafast, sensitive and selective ultra-high 
performance-liquid chromatography-electrospray ionization-triple-quadrupole-MS 
(UPLC-QqQ-MS) system, operating in a dedicated single reaction monitoring mode 
(SRM). The amount of measured label is indicative for the amount and affinity of 
rTTR-active compounds in the sample. Second, for legislative confirmatory analysis 
requirements of  known ligands, the same rTTR biorecognition element was used in 
a bioaffinity isolation procedure in combination with UPLC-QqQ-MS but operating in 
a multiple reaction monitoring mode (MRM). Third, for identification of any unknown 
ligands having rTTR bioaffinity, the same rTTR biorecognition element was used in a 
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bioaffinity isolation procedure in combination with UPLC-Q-TOF-MS operating in the 
high resolution full-scan accurate mass mode, and having the EDCs triclosan and 
TBBPA as model unknown substances. See Figure 1 for a schematic overview of the 
three different BioMS applications.
Figure 1. Schematic presentation of the steps involved in the three different BioMS applications in which 
X is (are) the active compound(s) in the sample, ? is (are) the unknown active compound(s), 13C6-T4 is 
the label used in the screening only and rTTR is the applied biomolecule. The main differences between 
the three applications are the analytes, the MS detection in either SRM, MRM and using time-of-flight-MS 
in full scan mode. The screening approach will result in the identification of negative samples or samples 
containing compounds with bioaffinity towards rTTR. The confirmation approach is used only to legislative 
confirmatory analysis of known bioactive compounds and the identification approach is used to identify 
known and unknown rTTR ligands.
Materials and Methods 
Materials
T4, triiodo-L-thyronine (T3), TBBPA and triclosan were purchased from Sigma 
Aldrich Chemie (Zwijndrecht, The Netherlands) and had purities above 95%. 13C6-T4 
of 90% purity (no T4 present) was supplied by Cambridge Isotope Laboratories Inc. 
(Andover, MA, USA) while the His-tagged rTTR was produced and kindly offered by 
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the Toyama Medical and Pharmaceutical University (Toyama, Japan) [34]. Formic 
acid (HCOOH), sodium dihydrogen phosphate (NaH2PO4), tri-sodium phosphate 
(Na3PO4), ethanol (EtOH), sodium chloride (NaCl), acetyl chloride (CH3COCl), 
sodium azide (NaN3), imidazole and ethylenediaminotetra acetic acid (EDTA) were 
all purchased from Merck (Darmstadt, Germany). HPLC grade methanol (MeOH) 
was provided by Biosolve (Valkenswaards, The Netherlands) and water purification 
was performed using a Milli-Q system (Milipore, Bedford, MA, USA). Microcon 
Ultracel YM-30 UF units were also from Milipore. Nanosep 30K Omega UF units 
were from Pall Corporation (Port Washington, NY, USA) and VectaSpin Micro 20K 
UF units from Whatman International (Maidstone, England). Protein LoBind tubes 
(0.5 and 1.5 mL) were purchased from Eppendorf AG (Hamburg, Germany). SiMAG-
Carboxyl (product number 1402-1, 1 µm diameter) beads were supplied by Chemicell 
GmbH (Berlin, Germany). The N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) 
was purchased from Fluka Analytical (Buchs, Germany) while, the 2-(N-Morpholino)
ethanesulfonic acid (MES) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
hydrochloride (EDC) were from Sigma Aldrich Chemie. The BCA reagents were 
provided with the BCATM Protein Assay Kit from Pierce (Rockford, IL, USA). OASIS® 
HLB 6 mL cartridges with 200 mg sorbent were purchased from Waters (Milford, 
MA, USA) and 1 mL Empore C18-SD cartridges were from 3M (Zoeterwoude, The 
Netherlands).  The instruments used in this study are described in appendix 3.1.
Methods
BioMS binding assay using 13C6-T4 as competing label and UPLC-QqQ-MS as a 
readout system
The competitive inhibition BioMS screening assay was performed both with dissolved 
rTTR, using UF units, and with immobilized rTTR, using superparamagnetic beads. 
UF method. The competitive inhibition BioMS assay consisted of the following steps. 
First, 0.25 µg of rTTR in 100 µL of assay buffer (10 mM phosphate buffer pH 8.5) 
was added to the UF unit and a centrifugation step was performed at 11,000 g for 
10 min at room temperature (RT). Subsequently, the label (13C6-T4) was mixed with 
the standard or sample and this mixture was added to the UF unit. To construct 
0-1000 ng dose-response curves, 750 pg of the label in 90 µL assay buffer was 
mixed with 10 µL of T4 solutions in 100% MeOH with concentrations from 0 to 100 
ng µL-1. Dose-response curves were fitted using the five parameter curve fitting in the 
GraphPad Prism software of GraphPad Software Inc. (La Jolla, CA, USA). To screen 
urine sample, 750 pg of the label in 100 µL assay buffer/MeOH (9:1, v/v) was mixed 
with 50 µL 2 times diluted urine (in assay buffer). To screen water samples, 750 pg of 
13C6-T4 in 10 µL assay buffer/MeOH (9:1, v/v) was mixed with 250 µL of 2000 times 
concentrated water extract. The incubation with rTTR was 15 min at RT under gentle 
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vortexing. A centrifuge step of 10 min was performed in order to remove the unbound 
13C6-T4 and T4 by discarding the filtrate. To wash the retentate, 100 μL of washing 
buffer (assay buffer/MeOH, 9:1, v/v) was added. After two subsequent washing steps, 
the rTTR complex was resuspended in the UF unit by 100 µL dissociation solution 
(H2O/MeOH/HCOOH, 49/50/1 %, v/v/v). This dissociation step was performed by 
vortexing the UF unit for 15 min and a centrifuge step of 10 min was performed to 
collect the dissociated label plus competing analytes in the filtrate. This filtrate was 
then transferred to an autosampler vial and injected into the UPLC-QqQ-MS system 
for screening purposes. The total duration of this bioaffinity purification procedure 
was 80 min; note that in routine settings, many samples can be handled in parallel 
within the same time frame.
Superparamagnetic beads method. The same protocol as used for the UF units was 
followed with minor modifications. Instead of using rTTR in solution, 1 µL of rTTR-
coated beads were used and the centrifuge step was replaced by a 1 min magnetizing 
step (the protocols for preparation of rTTR-coated microbeads and determining its 
immobilization efficiency are described in appendix 3.2). The total length of this 
procedure was 35 min (approximately twice as fast as with the UF units).  
T4 extraction from process water
T4 was extracted and concentrated from process water by applying two consecutive 
SPE procedures.  The first SPE procedure used was based on the protocol described 
by Svanfelt et al. [21] with minor modifications. In short, first, the pH of 1 L of process 
water sample was adjusted to pH 2.5 using a few drops of 5 M HCl. The OASIS® HLB 
SPE cartridges were preconditioned with 6 mL of MeOH followed by 6 mL of acidified 
distilled water (pH 2.5). The extraction of T4 from 1 L process water was carried out 
at an approximate flow rate of 5–10 mL min-1. After drying the cartridges by applying 
vacuum, the analyte was eluted with 4×1 mL of MeOH. This SPE step proved to have 
>90% T4 recovery. Evaporating the eluate decreased the T4 recovery (<25%). In 
order to omit this evaporation step, a second SPE procedure was performed in order 
to concentrate T4 without evaporation using 1 mL Empore C18-SD SPE cartridges. 
These cartridges were preconditioned with 1 mL of MeOH followed by 1 mL of 
acidified distilled water (pH 2.5). To the 4 mL eluate from the OASIS® cartridge, 16 
mL of acidified distilled water (pH 2.5) was added (in order to reduce the solvent 
strength) and then this mixture was loaded onto a Empore C18-SD SPE cartridge. 
After drying the cartridge by applying vacuum, the analytes were eluted with 150 
µL of MeOH. Finally, 350 µL of assay buffer was added to the eluate and mixed by 
vortexing. The second SPE step proved to have 60% T4 recovery. Most likely, this 
was caused by the relatively high volume (20 mL) which was loaded onto this 1 mL 
cartridge. 
Chapter 3
98
BioMS confirmatory analysis of known rTTR ligands following bioaffinity purification 
of urine samples
Urine samples from a male hypothyroid patient and a healthy male volunteer were 
analyzed for T4. First, 100 µg of rTTR was pipetted into a UF unit and concentrated 
by centrifuging at 11,000 g for 10 min at RT for extraction purposes of T4 from 
the healthy male volunteer’s urine. A volume of 250 µL of urine was diluted in 250 
µL assay buffer and this mixture (500 µL) was added to the rTTR-containing UF 
unit. The subsequent incubation, wash and dissociation steps were performed as 
described in the “BioMS binding assay” protocol and the final extract was injected 
into the UPLC-QqQ-MS system. For quantitative reference analysis of T4 in urine, 
the described SPE procedure for process water was used with slight modifications; 
instead of one liter of water, 6 mL of urine (pH 2.5) was applied to preconditioned 
SPE cartridge and the second SPE procedure was omitted.
BioMS identification of unknown EDCs following bioaffinity purification and nano-
UPLC-Q-ToF-MS
Urine samples (500 µL) were spiked with either TBBPA at 1.2 ng mL-1 or with 
triclosan at 1000 ng mL-1. The spiked urines were added to UF units each containing 
10 µg of rTTR. Note that for identification, ten times less rTTR was needed than in 
confirmatory analysis due to the high spike level of triclosan and the high affinity of 
TBBPA towards rTTR. The subsequent incubation and wash steps were performed 
as described in the “BioMS binding assay” protocol. The dissociation step, however, 
was modified because the acidic dissociation step proved not to be sufficient to 
dissociate and dissolve triclosan and TBBPA. Two subsequent dissociation steps 
were performed with 50 µL MeOH/NH4OH (1:1) and 50 µL H2O/MeOH/HCOOH 
(49/50/1 %, v/v/v). Both dissociation filtrates were collected after two subsequent 
centrifuge steps (11,000 g for 10 min at RT) and mixed. Finally, 100 µL of H2O/
HCOOH (1:1) was added to the eluate mixture to lower the pH to acidic and the MeOH 
content to 25%. The final extract was injected into the nano-UPLC–quadrupole time-
of-flight–MS (nano-UPLC-Q-ToF-MS) for identification purposes.
Results and discussion
BioMS binding assay
During the development of this screening assay, various parameters were optimized. 
At first, as it influenced the sensitivity of the BioMS screening, the minimum amount 
of added label necessary for a robust UPLC-QqQ-MS quantification in the SRM 
mode (m/z 783.7 à m/z 737.7) was determined as 750 pg. In assay buffer and in 
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dissociation solution this and less recovered amounts of the label could easily be 
detected having a LoD of 25 pg. For the dissociation of the bound label in a small 
volume of 100 µL of an LC-MS compatible acidified MeOH/H2O mixture (H2O/MeOH/
HCOOH, 49/50/1 % v/v/v) was chosen (see appendix 3.3 for optimization details). 
Typical UPLC-QqQ-MS reconstructed chromatograms of the 13C6-T4 label recovered 
from rTTR-coated beads are displayed in Figure 2 and illustrate the fast analysis 
with a total run time of 2 min. In this study, two assay formats ultrafiltration (UF) units 
and superparamagnetic microbeads were critically compared. Because of observed 
non-specific binding of the label, several UF units and 96-well filter plates (for high-
throughput screening purposes) from different manufacturers (see “Materials” 
section) were tested for non-specific binding. The filter plates displayed the highest 
amount of non-specific binding (nearly 100%) and therefore, high-throughput well 
plate screening with rTTR in solution was not feasible. The Microcon Ultracel YM-30 
UF units were selected for this study, because they showed the lowest amount of 
non-specific binding. Next, the influence of the amount of rTTR on the UPLC-QqQ-
MS measured recovery of the added label was determined (see Figure 3). 
Figure 2. Reconstructed UPLC-QqQ-MS single reaction monitoring (SRM) chromatograms showing the 
peak areas and retention times of the label (13C6-T4) recovered from rTTR-coated beads in the absence 
(A) and in the presence of 1 ng of the competing model ligand T4 (B). 
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For this experiment, 750 pg of the label in absence of any competitor was added 
to different amounts of rTTR in UF units. The 0 µg rTTR was used as blank control 
to prove that the label did not bind to the test tubes. Only a very low amount of 
the label (<LoD) was found in the control, which proved that rTTR was responsible 
for capturing the label. The absolute recovered amount of label decreased with 
decreasing amounts of rTTR (from 532 pg using 10 µg rTTR to 230 pg using 0.25 µg 
rTTR). Similar results were observed when T4 in the absence of the label was added 
to rTTR, showing the expected similar affinity of rTTR for the label (13C6-T4) and for 
T4. The influence of the amount of rTTR on the label recovery was also tested using 
rTTR-coated beads. In this experiment 0-0.1-1-5-10 µL of beads (corresponding with 
0-0.01-0.1-0.5-1 µg of rTTR, respectively) were used to capture 750 pg of the label 
and similar increasing label recoveries were obtained with increasing amounts of 
beads (data not shown).
Figure 3. Average amounts (n=2) of with UPLC-QqQ-MS measured 13C6-T4 label recovered from different 
amounts of rTTR in the UF unit after incubation with 750 pg of label.
The detailed optimization experiments of the BioMS screening are described in 
appendix 3.3. It is important to note that by using beads, high-throughput screening in 
conventional 96-well plate format in combination with an automated magnetic wash 
device will be feasible. With the BioMS screening assay in UF units, dose-response 
curves were constructed for T4 in buffer, urine and concentrated process water with 
sensitivities at 50% inhibiting concentration (IC50) of 0.8 ng (8 ng mL-1 buffer), 7 ng 
(280 ng mL-1 urine) and 7 ng (14 pg mL-1 process water) respectively, and all curves 
illustrate good precision of the method (see Figure 4A). Although similar IC50s were 
obtained in the dose-response curves prepared in urine and process water, both 
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curves display clearly the influence of matrix when compared to the curves in buffer. 
Figure 4B demonstrates the results when beads are used and a similar sensitivity 
was obtained in buffer (IC50 of 1 ng or 10 ng mL-1 buffer) but in urine (IC50 of 1 ng or 
40 ng mL-1 urine) and concentrated process water extract (IC50 of 4 ng or 8 pg mL-1 
process water) slightly higher sensitivities were achieved. Note that in all displayed 
dose-response curves, the maximum absolute recovery of the label varied between 
100-230 pg depending on the matrix. The IC50 values under buffer conditions indicate 
that indeed a concentration step is required in order to be able to screen EDCs at 
the part-per-trillion level in the aquatic environment. The BioMS screening in the 
two formats showed  similar sensitivities versus the label-free SPR-based method 
(10 nM) [25], but is more sensitive than the post-column bioaffinity MS (40 nM) [31] 
and radiolabeled assay (61-88 nM) [7, 22, 23]. Note that the targeted LC-ESI-QqQ-
MS method of Svanfelt et al. is more sensitive, but no information on the biological 
relevance of the measured compounds was obtained in that method [21]. 
BioMS screening of model ligand T4 in process water at ng L-1 level
For screening purposes at the ppt level, one liter of process water was spiked with 
50 ng L-1 of T4, which is close to the concentration of T4 found in surface water of 
19 ng L-1 [3, 21]. This sample was subjected to the SPE procedures as described in 
the “Methods” section. Two thousand times concentrated extract was screened in 
the BioMS assay with UF units and beads and the results showed in both formats 
(31% and 45% respectively) a higher inhibition with the spiked sample compared to 
the blank water extract. 
BioMS screening of endogenous ligand T4 in urine at ng mL-1 level
In order to broaden the scope of the study and to test the robustness of the developed 
competitive inhibition BioMS assay, two different urine samples were subjected to 
the two screening assay formats. The urine of two male volunteers was collected 
and screened after diluting the urine sample twice. In both formats, the label was 
inhibited more (recovery 134±15 pg, n=2) by the urine from the healthy subject 
compared to the urine from the hypothyroid patient (recovery 205±10 pg, n=2). To 
support these results, both urines were measured with a classical chemical method 
using an SPE step and UPLC-QqQ-MS method for T4. In the urine extract of the 
hypothyroid patient, no T4 was detected while T4 was indeed detected in the urine 
extract of the euthyroid subject. This suggests that the difference in recovery of the 
label was caused by T4 and probably not by matrix compounds. Additionally, both 
urine extracts were spiked with 25 ng of T4 and screened again with the competitive 
BioMS assay. The recovery of label decreased to 50 pg in both urine samples again 
indicating that the difference in label levels in both urine samples was T4-related.
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Figure 4A. Normalized average dose-response curves (n=2) of T4 in buffer (x), in urine matrix (♦) and in 
concentrated process water extract (●) obtained by the BioMS screening assay using UF units. 
Figure 4B. Normalized average dose-response curves (n=2) of T4 in buffer (x), in urine matrix (♦) and in 
concentrated process water extract (●) obtained by the BioMS screening assay using superparamagnetic 
beads. 
BioMS confirmatory analysis of known rTTR ligands
For confirmatory analysis of known rTTR ligands the endogenous agonist T4 in 
urine was chosen as a demonstrator and Commission Decision 2002/657/EC [35] 
as regulatory requirements. A urine sample of an euthyroid volunteer was subjected 
to the rTTR bioaffinity isolation procedure as described in the “Methods” section. The 
extract was injected into UPLC-QqQ-MS operated in the MRM mode for confirmatory 
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analysis of T4 on the basis of the identification point concept from 2002/657/EC. By 
means of two measured MRM transitions (m/z 777 à m/z 731 and m/z 777  m/z 
633), the ion ratios obtained for T4 in the urine extract and in standard solutions were 
calculated as 13.9±0.1% and 13.2±0.1%, respectively, and well within the permitted 
range (±30%) as described in the regulation. All retention times were 1.23 min and 
within the tolerances set by the regulation; as a result the identity of the compound 
in urine was successfully confirmed. The level of naturally present T4 in urine was 
estimated at 1.1 ng mL-1 which is very close to the expected value of 0.9 ng mL-1 
(based on 1.41 µg/day, and assuming 1.5 L urinary excretion/day) [21]. Compared 
to the BioMS screening method presented above, simply 400 times more rTTR was 
used to isolate the T4 from the complex urine matrix.  
BioMS identification of unknown EDCs having bioaffinity for rTTR by nano-UPLC-
Q-ToF-MS
Urine samples were spiked separately with two model EDCs, triclosan (1000 ng mL-
1) and TBBPA (1.2 ng mL-1). Schauer et al. demonstrated that when 0.1 mg/kg/bw 
TBBPA is administrated orally to humans, around 0.9 ng mL-1 TBBPA-glucuronide 
can be found in urine [36]. The TBBPA spike level in the present experiment is in 
the same range and therefore considered realistic. The samples were subjected 
to rTTR bioaffinity isolation and the obtained extracts were injected into the nano-
UPLC-Q-ToF-MS for identification purposes. On basis of accurate mass, retention 
time and elemental composition both triclosan and TBBPA were found and identified 
in the urine sample at these relevant levels (see appendix 3.5). The chromatograms 
and spectra of triclosan and TBBPA urine samples are given in appendix 3.6. See 
appendix 3.4 also for the identification of T4 in process water.
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Conclusions
In this study, a triple BioMS concept is presented in which rapid bioaffinity-based 
MS screening  of thyroid transporter ligands and confirmation and identification 
with MS are performed following the same rTTR biorecognition. The influence of 
immobilization of rTTR on binding assay performance was tested by applying UF 
units and superparamagnetic beads and it was demonstrated that in both formats 
similar results could be obtained. However, beads are more amenable to high-
throughput screening. For screening purposes, a radiolabel-free BioMS binding 
assay was developed and focused on T4 screening as a model ligand in water. The 
assay is capable of screening T4 at the part-per-trillion level in water and at the part-
per-billion levels in urine samples. In this BioMS binding assay, a stable isotope is 
used as a marker, therefore this improved method using MS as a readout system 
can serve as a safe alternative to radiolabel assays. For confirmatory analysis 
of endogenously present T4 in urine, the developed BioMS method was slightly 
modified (just 400 times more rTTR and no 13C6-T4 label) and the identification of T4 
was successfully confirmed on the basis of ion ratios and retention time. By adjusting 
the dissociation conditions of the developed assay and using 40 times more rTTR, 
two EDCs (triclosan and TBBPA) were identified at relevant levels with full scan 
accurate mass nano-UPLC-Q-ToF-MS. Finally, the developed triple BioMS concept 
can be used as a screening, confirmatory and identification tool for early warning of 
known and unknown emerging bioactive EDCs in the environment. 
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Appendix 3.1
Instrumentation
UPLC-QqQ-MS
The applied Acquity Ultra Performance Liquid Chromatography (UPLC) system 
(Waters, Milford, MA, USA) consisted of a degasser, a binary gradient pump, an 
autosampler at 10 °C and a column oven which was set at 50 °C. The analytical 
column was an Acquity UPLCTM BEH 1.7 μm C18, 50 mm x 2.1 I.D. from Waters and 
the injection volume was 10 μL. The UPLC system was coupled to the electrospray 
(ESI) interface of a Micromass (Manchester, UK), Quattro Ultima Platinum tandem 
mass spectrometer (QqQ). The two mobile phases consisted of (A) H2O/CH3COOH 
(99.8/0.2%, v/v) and (B) MeOH/CH3COOH (99.8/0.2%, v/v) and the flow rate was 0.3 
mL min-1. By using acetic acid in the mobile phase instead of formic acid, better peak 
shapes were obtained. The gradient started at 30% B and this composition remained 
constant for 0.30 min and increased sharply to 95% B in 0.10 min and remained 
stable at this composition for another 1.10 min. After 0.05 min, the composition 
of the mobile phase returned to the initial state (70% A and 30% B) with a final 
hold of 0.45 min. The LC was interfaced with the ESI MS/MS instrument without a 
flow split. ESI in the positive mode (ESI+) proved to be the most sensitive for the 
measurements. The total run time was 2 min and data acquisition for 13C6-T4 was 
performed in single reaction monitoring mode (SRM) at transition m/z 783.7→737.7 
using collision energy 20eV. Data acquisition for non-labeled T4 was performed in 
MRM data acquisition mode, at transitions m/z 777.7 → m/z 731.7 and m/z 777.7 → 
m/z 633.7 using collision energy 20 eV and 35 eV respectively. The capillary voltage 
was set at 2.70 kV and the cone voltage was 35 V. The desolvation gas temperature 
was 350 °C and the source temperature 120 °C. Nitrogen was the desolvation gas 
(600 L h-1); the collision-induced dissociation gas was argon at a pressure of 2.5×10-
3 mbar. The absolute LoD of 13C6-T4 was determined as 25 pg on-column (S/N>6).
Nano-UPLC–quadrupole time-of-flight–MS (nano-UPLC-Q-ToF-MS)
The nanoAcquity UPLC System of Waters consisted of a degasser, a binary gradient 
pump, an autosampler (at 10 °C) and a column oven (at 50 °C). The trapping column 
was a nanoAcquity UPLC HSS T3 5 μm C8, 20 mm x 180 μm I.D. and the analytical 
column was a nanoAcquity UPLC BEH 1.7 μm C18 column, pore size 130 Å, 100 
mm x 75 μm I.D., all from Waters. The nanoAcquity UPLC system was coupled to a 
Waters Xevo quadrupole time-of-flight (Q-ToF) mass spectrometry system equipped 
with a nano-ESI interface without a flow split. The two mobile phases consisted of (A) 
H2O/CH3COOH (99.8/0.2%, v/v) and (B) MeOH/CH3COOH (99.8/0.2%, v/v) and the 
flow was 1000 nL min-1. After injection (4 μL), the sample was preconcentrated on the 
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trapping column at a flow rate of 10 µL min-1 (0% B). After a 3 min trapping time, the 
gradient started at 1% B and was kept at this composition for 1 min and increased 
linearly to 40% B in 4 min. After 1 min the composition of mobile phase increased to 
80% B and in another 1 min to 95% B. This mobile phase composition was kept for 
13 min and returned to 1% B in 1 min with a final hold of 5 min. The total run time 
was 28 min. The MS was operated in the positive ESI mode for identification of T4 
and in negative ESI mode for triclosan and TBBPA at a capillary voltage of 3 kV, 
cone was at 40 V and source temperature was 80 °C. The purge gas was nitrogen 
(50 L h-1) and cone gas (10 L h-1) and data acquisition was performed in full scan 
continuum mode. The detector, containing a 4 GHz TDC, was set to accumulate 
spectra during 0.3 s in full scan mode at a resolution of 10,000 FWHM. A 2 ng μL-1 
standard solution of leucine–enkephalin was introduced as a lockmass via the lock-
spray needle (capillary voltage 2.8 kV and cone voltage 40 V) at a flow rate of 500 
nL min-1.
Other instrumentation
The magnetic separation of the paramagnetic beads was performed with a DynaMagTM 
Pro 2 separator rack from Invitrogen Dynal (Oslo, Norway). The centrifugal steps were 
performed in the Eppendorf 5810 R centrifuge purchased from VWR International 
(Amsterdam, The Netherlands) and in the Model 16K Microcentrifuge supplied by 
BioRad Laboratories BV (Veenendaal, The Netherlands). 
Appendix 3.2 
Methods
Preparation of the rTTR-coated superparamagnetic beads
The rTTR was immobilized onto the superparamagnetic SiMAG-carboxyl bead 
surface by the formation of covalent bonds between amino-groups of the protein and 
the activated carboxyl groups on the bead surface. This immobilization was performed 
according to the slightly modified protocol provided by the manufacturer. In short, 
the stock of beads (containing 50 mg of beads mL-1) was resuspended by vortexing 
for 15 min. From this stock, 200 µL (containing 10 mg beads) was transferred to a 
protein LoBind tube in which the beads were concentrated in the magnetic separator 
rack in 1 min. After gently removing of the supernatant, the pellet was washed by 
resuspending in 1 mL 0.1 M MES buffer (pH 5). The beads were concentrated in 
the magnetic separator rack and the supernatant was removed. This wash step was 
done twice. To activate the bead surface, the pellet was resuspended in 0.25 mL 
MES buffer containing 10 mg of EDC and mixed for 10 min at room temperature 
(RT). Subsequently, the activated beads were washed twice with 1 mL MES buffer 
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and resuspended in 0.25 mL MES buffer. A solution containing 50 μg of rTTR in 0.25 
mL MES buffer was added to the activated beads. The suspension was vortexed 
shortly and incubated for 2 h under mixing by rotation in a test tube rotator at RT. 
Following the incubation, the supernatant containing unbound rTTR was removed 
and the beads were washed three times with 1 mL of PBS (5.4 mM Na2HPO4, 1.3 
mM KH2PO4, 150 mM NaCl, 3 mM KCl, pH 7.4) buffer. Finally, the rTTR-coated beads 
were resuspended in 0.5 mL of PBS containing 0.05% sodium azide and stored 
at 4 °C. Usually, after incubation, bovine serum albumin (BSA) should be used to 
block the free activated sites of the bead surface. In this study, the blocking was 
omitted because T4 might bind to BSA. The possible non-specific binding of T4 to the 
unblocked bead surface was tested.
Immobilization efficiency
In this study, the influence of immobilization of rTTR was investigated. The rTTR 
was used in immobilized state (using SiMAG-Carboxyl superparamagnetic beads) 
and in solution (using UF units). The amount of rTTR immobilized on beads (or in 
solution) determines what amount of beads are needed for efficient binding and 
competition in the binding assay. Therefore, the immobilization efficiency of rTTR to 
the bead surface was determined using the BCA method. To determine the average 
immobilization efficiency, rTTR concentrations were measured in the solutions before 
and after five immobilizations. The BCA analysis showed that 90 ± 10% (n=5) of the 
50 µg rTTR added to the beads was immobilized indicating a high coupling efficiency. 
The rTTR-immobilized beads were stored in 500 µL storage buffer. Consequently, 
1 µL of coupled bead stock corresponds approximately to 0.1 µg rTTR. Alternative 
superparamagnetic beads (6.5 µm MagPlex®-C Magnetic Carboxylated beads from 
Luminex Corporation, SiMAG-IDA/Nickel particles (1 µm), SiMAG-Carboxyl particles 
(1 µm) and 200 nm fluid MAG-CMX all from Chemicell GmbH), having different 
surface chemistry or diameter, were tested. On the basis of immobilization efficiency, 
ease-of-use and cost, the SiMAG-Carboxyl were found to be the most suitable for 
this study.
Protein analysis
The BCA protocol consisted of the following steps; 10 μL of sample solution was 
added in duplicate to a microtiter plate. Then, 200 μL of a mixture, consisting of an 
alkaline agent, bicinchoninic acid (BCA) and CuSO4 (reduced to Cu1+ by proteins), 
was added to the samples and the calibration curve. The reagent is responsible 
for color change by chelating 2 BCA molecules to Cu1+ ions. The calibration curve 
was made by diluting a BSA stock solution of 1 mg mL-1 with PBS buffer. Following 
the addition of reagents, the microtiter plate was incubated at 65 °C during 30 min 
after which the microtiter plate was cooled for 5 min at RT and the concentration of 
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proteins was measured using an UV/Vis ELx808 absorbance microplate reader at 
562 nm from BioTek (Winooski,VT, USA).
Appendix 3.3
Optimizing BioMS binding assay protocol
The optimal sequence of competing 13C6-T4 (label) and model ligand T4 (analyte) 
addition to the rTTR was determined and showed a great influence on the efficiency 
of competition. The addition of a mixture of label and ligand was found to be the most 
optimal: only a low amount of model ligand T4 was needed (± 1 ng) to decrease the 
recovery of 236 pg competing 13C6-T4 label by 50%. This particular experiment was 
performed with the same rTTR concentrations as displayed in Figure 3. According 
to our results, the highest amount of label inhibition with the lowest amount of 
analyte (1 ng) was observed using 0.25 µg rTTR. The same phenomenon was also 
observed when beads were used. The optimal amount of beads was found to be 1 µL 
corresponding to ± 0.1 µg rTTR. Following this experiment, different incubation times 
(0, 15, 30, 60 min) were tested and 15 min was found optimal. It is important to note 
that when the incubation volume is larger than 300 µL, the label recovery decreases 
even in absence of any analyte. Probably, this relatively low amount of rTTR (0.25 µg) 
cannot capture any ligand efficiently in a relatively high volume of >300 µL. The two 
wash steps were performed with 100 µL of assay buffer/MeOH (9:1, v/v) to remove all 
unbound ligands together with hydrophilic matrix compounds. It was found that only 
a low amount of label (± 10%) was lost in these steps. In order to fully dissociate the 
label after the wash steps, a solution was selected which could alter the rTTR charge 
and conformation causing the dissociation of the label-rTTR affinity complex. For this 
purpose, 100 µL of acidified MeOH was chosen (H2O/MeOH/HCOOH, 49/50/1 % 
v/v/v) which is also compatible with LC-MS. This solution, dissociated 80% of ligands 
in one dissociation step and the remaining 20% was dissociated in a second step. 
When acetic acid was used to dissociate ligands, the dissociation efficiency dropped 
dramatically.  Also different dissociation times (0-15-30-60 min) were tested and 
again 15 min was found to be optimal. The optimized BioMS binding assay protocol is 
described in the section “Methods”. Next, the optimized assay was repeatedly applied 
(40 times with UF units and 10 times with beads) under buffer conditions to determine 
an average 13C6-T4 recovery in absence of analyte. Similar results were obtained with 
beads (23% recovery, i.e. 172 ±19 pg) and UF units (31% recovery, i.e. 236 ±15 pg) 
and both formats showed good precision. In order to demonstrate that the developed 
competitive inhibition MS binding assay is rTTR-related, two competitors were tested 
using UF units. The first competitor TBBPA is reported to have a binding affinity equal 
or higher than T4 to TTR and the second tested competitor T3 is reported to have a 
binding affinity lower than T4 to TTR. By adding only 1 ng of the strong binder TBBPA, 
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75% of 236 pg bound label was inhibited and by adding eight time more T3 (8 ng) 
only 20% of the 236 pg bound label was inhibited. In comparison, as shown in Figure 
4A, 1 ng of T4 was needed for a 50% inhibition of 236 pg bound label, indicating the 
high binding affinity of TBBPA and low binding affinity of T3 to TTR. The results are 
in agreement with the affinities reported in literature and strongly suggest that the 
developed competitive inhibition BioMS binding assay is rTTR-related.
Appendix 3.4
BioMS identification of model ligand T4 in process water by nano-UPLC-Q-ToF-
MS
Following the screening of the model ligand T4 in a two thousand times concentrated 
process water extract, the same extract was injected into the nano-UPLC-Q-ToF-MS 
and T4 was identified on the basis of retention time and accurate mass (∆5.9 ppm) 
and retention time (∆0.01 min). 
Appendix 3.5
Theoretical and experimental exact masses, mass errors, retention times and 
elemental composition of triclosan and TBBPA in standard solutions and in bioaffinity 
purified and nano-UPLC-ToF-MS analyzed urine extract.
Theoretical Measurement tR Experimental Mass error Elemental composition*
[M-H]- (min) [M-H]- (ppm) [M-H]-
Triclosan
286.943 standard 10.60 286.940 -10 C12H6Cl3O2-
287.947 (13C) 287.945 -7
288.940 (37Cl) 288.937 -10
290.938 (37Cl2) 290.936 -7
sample 10.63 286.940 -10 C12H6Cl3O2-
287.945 -7
288.943 10
290.949 38
TBBPA
538.749 standard 10.60 538.751 4 C15H11Br4O2-
540.447 (81Br) 540.749 4
542.745 (81Br2) 542.746 2
544.743 (81Br3) 544.745 4
546.742 (81Br4) 546.754 22
sample 10.60 538.749 0 C15H11Br4O2-
540.751 7
542.748 6
544.745 4
   546.736 -11  
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* Triclosan and TBBPA were identified on the basis of measured accurate mass and isotopic patterns 
using the following elemental composition limits for triclosan C 10–22, H 5–22, N 0-4, O 1–9 and Cl 1-3. 
C 10–22, H 8–22, N 0-4, O 1–9 and Br 1-5 for TBBPA. Both EDCs were the first realistic option within 
calculated results with reasonable double bond equivalents and correct halogen number when halogens 
were recognized in the isotope cluster.
Appendix 3.6
Nano-UPLC-Q-ToF-MS chromatograms and accurate mass spectra of two bioaffinity 
purified urine extracts containing 1000 ng mL-1 triclosan (A, the [M-H]- peak 
corresponds to 286.940 Da) and 1.2 ng mL-1 TBBPA (B, [M-H]- peak of the 81Br2 
isotope corresponds to 542.748 Da). 
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calculated results with reasonable double bond equivalents and correct halogen number when halogens 
were recognized in the isotope cluster.
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Abstract
A generic high-throughput bioaffinity liquid chromatography-mass spectrometry 
(BioMS) approach was developed and applied for the screening and identification 
of known and unknown recombinant human sex hormone-binding globulin 
(rhSHBG)-binding designer steroids in dietary supplements. For screening, a semi-
automated competitive inhibition binding assay was combined with fast ultra-high-
performance-LC-electrospray ionization-triple-quadrupole-MS (UPLC-QqQ-MS). 
17β-testosterone-d3 was used as the stable isotope label of which the binding to 
rhSHBG-coated paramagnetic microbeads was inhibited by any other binding 
(designer) steroid. The assay was performed in a 96-well plate and combined with 
the fast LC-MS, 96 measurements could be performed in 4 h. The concentration-
dependent inhibition of the label by steroids in buffer and dietary supplements was 
demonstrated. Following an adjusted bioaffinity isolation procedure, suspect extracts 
were injected into a chip-UPLC(NanoTileTM)-Q-time-of-flight-MS system for full scan 
accurate mass identification. Next to known steroids, 1-testosterone was identified in 
three of the supplements studied and the designer steroid tetrahydrogestrinone was 
identified in a spiked supplement. The generic steroid-binding assay can be used 
for high-throughput screening of androgens, estrogens and gestagens in dietary 
supplements to fight doping. When combined with chip-UPLC-MS, it is a powerful 
tool for early warning of unknown emerging rhSHBG bioactive designer steroids in 
dietary supplements. 
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Introduction
Dietary supplements are preparations to supplement the diet and provide nutrients, 
such as vitamins, minerals, fibers, fatty acids or amino acids, that may be missing 
or may not be consumed in sufficient quantities in a diet. However, several 
investigations have shown the deliberate and unintentional addition of (pro)hormones 
to supplements [1-4]. Although, this is banned in the EU and USA, anabolic steroid-
containing supplements are still widely available on the internet and easy to order 
for professional athletes to enhance their performance and for people with certain 
life styles. In order to achieve fair play, the use of hormones and anabolic steroids 
in sports are forbidden by the World Anti-Doping Agency (WADA) [5]. Therefore, 
athletes and their entourage have been searching for new anabolic steroids to evade 
the doping controls [6]. In modern doping control laboratories, gas chromatography-
mass spectrometry (GC-MS) and liquid chromatography (LC)-tandem mass 
spectrometry (MS/MS) are used for fast, robust, sensitive and specific detection in 
sport drug testing [7]. In order to achieve the highest sensitivity and selectivity, both 
GC-MS and LC-MS are set up in pre-selected mass data acquisition modes in which 
only known steroids can be measured [8-12]. In this way, new designer steroids could 
escape from routine testing and stay undetected. For example, the designer steroids 
tetrahydrogestrinone (13,17-diethyl-17-hydroxy-18,19-dinor-17-pregn-4,9,11-trien-
3-one, THG) [13] and 17α-methyl-5α-androst-2-en-17β-ol (Madol) [14] were not 
detected in routine testing prior to finding the preparations of these designer steroids 
(these designer steroids were found in a syringe and an oily product respectively). 
Another approach to screen unknown anabolic steroids, is the use of precursor ion 
scans in triple quadrupole mass spectrometers (QqQ-MS). Since steroids may have 
similar MS/MS fragmentations, characteristic product ions were used as markers 
for the identification of unknown steroids [15]. Next to these classical instrumental 
analysis concepts, biorecognition-based assays are used for rapid screening of 
anabolic steroids. These assays use antibodies or transport proteins such as sex 
hormone-binding globulin (SHBG), are rapid and can provide information about the 
biological relevance; however identification is not possible [16-19]. For example, 
Mooney et al. developed a surface plasmon resonance (SPR)-based biosensor 
screening assay in which SHBG was used as a bioreagent to indicate the illicitly 
used growth-promoting agents estradiol benzoate and nortestosterone decanoate 
during rearing of calves [16]. Plasma from control animals and treated animals (25 
mg estradiol benzoate and 150 mg nortestosterone decanoate) were measured and 
significant reduction of SHBG binding capacity was observed in treated animals only. 
In order to determine binding affinity of various SHBG ligands under physiological 
conditions, Jury et al. developed a radiolabeled-based assay [20]. This assay 
demonstrated binding affinities of numerous compounds, however, the use of a 
Chapter 4
118
radiolabel is a disadvantage and moreover MS-based identification of SHBG ligands 
was not possible [20]. By applying simply a binding assay or a classical instrumental 
method, new designer steroids can escape from routine testing and therefore any 
abuse will stay unnoticed. The combination of bioaffinity extraction with MS detection 
could serve as a powerful tool for the identification of designer steroids. For the 
screening of (designer) steroids a yeast androgen bioassay (YAB) was developed 
by Bovee et al. [21]. This assay expresses yeast enhanced green fluorescent 
protein (yEGFP) of which the fluorescent emission is measured in response to 
androgens. The identification of androgens was performed by LC-fractionation of 
the suspect found sample into two 96-well plates after which one 96-well plate was 
screened again to indicate in which androgens are present for identification with 
MS [2, 22]. The YAB demonstrated the presence of designer steroid THG in spiked 
urine sample [23] and also the anabolic steroid 1-testosterone (1,(5α)-androsten-
17α-ol-3-one) which is chemically closely related to the natural testosterone, but 
often escapes routine testing was found in dietary supplements [2]. The YAB is not 
generic as for the screening of estrogens a yeast estrogen bioassay is required. 
Moreover, these whole cell bioassays are inherently slow and require 2 days. 
In this work, a generic semi-automated high-throughput bioaffinity MS (BioMS) 
method is presented in which for the first time recombinant human sex hormone-
binding globulin (rhSHBG) and dedicated modes of LC-MS are used for screening 
and identification of androgenic and estrogenic (designer) steroids in dietary 
supplements. RhSHBG covalently immobilized onto paramagnetic beads was used 
in a competitive inhibition format for screening and in a slightly adapted bioaffinity 
isolation format for identification of rhSHBG binders ensuring uniform biorecognition 
in both screening and identification approaches. For identifying rhSHBG binders, a 
chip-ultra-performance-LC(NanoTileTM)-quadrupole-time-of-flight mass spectrometry 
(chip-UPLC-Q-ToF-MS) system with sub 2 µm particles and operating in the high 
resolution full-scan accurate mass mode was used. The screening and identification 
results of steroids in dietary supplements obtained with the newly developed MS-
binding assay are critically compared with data from LC-QqQ-MS and YAB.
Materials and methods 
Materials
All chemicals and their abbreviations are described in appendix 4.1. The LoBind 
Tubes were provided by Eppendorf (Hamburg, Germany) and the LoBind 96-well 
micro flat bottom plate (655161) and 96-well micro V-shaped bottom plate (651201) 
by Greiner Bio-One B.V. (Alphen a/d Rijn, The Netherlands). Water purification was 
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performed using a Milli-Q system (Milipore, Bedford, MA, USA). SiMAG-Carboxyl 
(product number 1402-1, 1 µm diameter) microbeads were supplied by Chemicell 
GmbH (Berlin, Germany). The Milliplex magnet Handheld Magnetic Separator 
Block for 96-Well Flat Bottom Plates was purchased from Milipore (Bedford, MA, 
USA). The microtiter plate vari-shaker was from Dynatech (Alexandria, VI, USA) 
and the REAX2 head-over-head shaker from Heidolph (Schwabach, Germany). The 
automatic magnetic wash station BioPlexTM pro II was from BioRad Laboratories 
B.V. (Veenendaal, The Netherlands). 
Instrumentation
High-performance liquid chromatography–triple-quadrupole mass spectrometry
 A Waters (Milford, MA, USA) Acquity Ultra-Performance LC (UPLC) system, 
consisting of a degasser, a binary gradient pump, an auto sampler (at 10 °C) and a 
column (at 50 °C), was used. The injection volume of the sample was 10 μL and the 
analytical column was an Acquity UPLCTM BEH 1.7 μm C18, 50 mm x 2.1 mm I.D. from 
Waters. The UPLC system was coupled to a Micromass (Manchester, UK) Quattro 
Ultima tandem mass spectrometry (QqQ) system equipped with an electrospray 
interface (ESI) used in positive mode. The two mobile phases consisted of (A) H2O/
HCOOH (99.9/0.1%, v/v) and (B) ACN/HCOOH (99.9/0.1%, v/v) and the flow rate 
was 0.3 mL min-1. The gradient started at 30% B and this composition remained 
constant for 0.30 min, increased sharply to 95% B in 0.10 min and remained stable 
at this composition for another 1.10 min. After 0.05 min, the composition of the 
mobile phase returned to the initial state (70% A and 30% B) with a final hold of 0.45 
min. The total run time was 2 min only. The UPLC was interfaced with the ESI MS/
MS instrument without a flow split. The ESI capillary voltage was +2.7 kV and the 
cone voltage was 30 V. The desolvation gas had a temperature of 350 °C and the 
source temperature was 120 °C. The desolvation gas was nitrogen (700 L h-1) and 
the collision-induced dissociation gas was argon at a pressure of 2.5 × 10−3 mbar. 
Data acquisition for 17β-testosterone-d3 (T-D3), used throughout the study as label, 
was performed in single reaction monitoring (SRM) mode at transition m/z 292 → 
m/z 97 using collision energy 20eV. The absolute limit of detection (LoD) of T-D3 was 
determined at 5 pg on-column (S/N > 6). 
Chip-ultra-performance liquid chromatography (NanoTileTM) quadrupole-time-of-
flight mass spectrometry
Chromatography was performed on a Waters NanoTileTM containing a BEH C18 
column (50 mm × 150 µm I.D., 1.7 µm particles) and having an integrated nano 
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electrospray ionization (ESI) emitter. Solvent was delivered by a nanoAcquity 
UPLC system from Waters. The NanoTileTM was kept at a temperature 45°C. The 
autosampler was at 10°C and a volume of 0.5 µL was injected from the 96-well 
plate. The mobile phase consisted of (A) H2O/HCOOH (99.9/0.1%, v/v) and (B) ACN/
HCOOH (99.9/0.1%, v/v). After injection, separation was done using gradient elution 
at a constant flow rate of 4 µL min-1. The gradient started at 10% B for 0.5 min 
followed by a linear increase to 20% B in 1.5 min, and from 20 to 50% B in 6 min and 
from 60 to 95% B in 1 min. The gradient remained for 3 min at 95% B, returned in 0.5 
min to 10% B and remained at this level for 3.5 min prior to the next injection. The 
NanoTileTM was directly interfaced with a Xevo Q-ToF mass spectrometer (Waters) 
using the Waters TrizaicTM source equipped with a lock mass probe. The system 
was operated in positive ESI mode. The source temperature was set at 110 °C and 
a capillary voltage of 3.1 kV and cone voltage of 40 V was applied. In order to get 
extra structural information MSe was applied, which means simultaneously a scan 
at low (6 eV) and at high collision energy (ramped from 15 to 35 eV) in separated 
data acquisition functions. Additionally, in order to measure specific product ions with 
highest sensitivity, the MS was also operated in accurate product ion scanning mode. 
As lock mass, a solution of 500 pg mL-1 of leucine-enkephalin was continuously 
introduced by the lock mass probe at a flow rate of 0.4 μL min-1. For accurate mass 
calibration of the mass axis, the following lock masses were used m/z 556.2771, 
425.1825, 397.1876, 278.1141 (the latter three masses are fragment ions of leucine-
enkephalin produced at a collision energy of 21eV in ESI+). 
Methods
Covalent immobilization of rhSHBG
SiMAG-carboxyl paramagnetic microbeads of 1 µm (having a maghemite core and 
a non-porous silica surface containing propyl linkers on which carboxyl groups 
are immobilized) were used in this study because of their proven high coupling 
efficiency for proteins [24]. The rhSHBG protein was immobilized randomly by 
covalent bond formation between its amino groups and the carboxyl groups on 
the super paramagnetic SiMAG-carboxyl bead surface. For this immobilization, 
the carbodiimide coupling protocol of Chemicell (“Covalent Coupling Procedure in 
SiMAG-Carboxyl by Carbodiimide Method”) was used. In short, the beads suspended 
in storage solution were vortexed for 15 min. Then 200 µL of the bead stock was 
transferred to a LoBind tube and the tube was placed in the magnetic rack for 1 min. 
The supernatant was removed and the pellet was washed twice with 1 mL 0.1 M 
MES buffer (pH 5) using the magnetic rack. For activation of the bead surface, the 
pellet was resuspended in 0.25 mL MES containing 10 mg EDC (prepared freshly). 
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This mixture was mixed for 10 minutes at room temperature (RT). After the activation 
of the beads, the mixture was washed twice with 1 mL MES buffer and resuspended 
again in 0.25 mL MES buffer. Subsequently, 50 µg rhSHBG protein was added to the 
activated beads and this mixture was incubated for 2 h by mixing with the rotator at 
RT. After incubation, the unbound rhSHBG in the supernatant was removed by using 
the magnetic rack and the beads with covalently coupled rhSHBG were washed 
three times with 1 mL PBS (5.4 mM Na2HPO4, 1.3 mM KH2PO4, 150 mM NaCl, 3 mM 
KCl, pH 7.4). Finally, the rhSHBG-coated beads were resuspended in 0.5 mL of PBS 
containing 0.05% sodium azide and stored at 4 °C. 
Non-covalent immobilization of rhSHBG
SiMAG-IDA/Nickel paramagnetic microbeads of 1 µm (having a maghemite core 
and a non-porous silica surface on which Ni2+-metal complex is formed with 
iminodiacetic acid) were used for oriented non-covalent immobilization of rhSHBG. 
The immobilization is based on the His-tag sequence of rhSHBG which binds to 
the Ni2+ cations on the beads and the protocol of Chemicell (“Purification of 6xHis-
tagged proteins with magnetic SiMAG-IDA/Nickel particles”) was used. In short, the 
beads were vortexed for 15 min. and then 100 µL of SiMAG-IDA/Nickel bead stock is 
transferred to a LoBind tube. The tube was placed in the magnetic rack for 1 min. The 
supernatant was removed and the pellet was washed three times with 0.5 mL Wash 
& Binding buffer (500 mM NaCl, 100 mM HEPES, 20 mM imidazole, pH 8.0). After 
the last wash step, the beads were resuspended in 0.5 mL Wash & Binding buffer. 
Subsequently, 25 µg of rhSHBG was added to the beads and mixed gently for 30 
min. at RT. After incubation, the unbound rhSHBG in the supernatant was removed 
and the beads with non-covalently bound rhSHBG were washed three times with 
Wash & Binding buffer. Finally, the rhSHBG-coated beads were resuspended in 0.5 
mL of PBS containing 0.05% sodium azide and stored at 4 °C.
Sample preparation
The primary extraction procedure of steroids from dietary supplements was based 
on the procedure described by Rijk et al. [2], which was simplified by omitting the 
solid phase extraction (SPE) and evaporation steps. The dietary supplements were 
ground and 0.05 gram was weighed into a 10 mL plastic tube. To this tube, 2 mL 
MeOH and 2 mL 12.5 mM sodium acetate (pH 4.8) were added for extraction of 
steroids. First, the tubes were placed in an ultra-sonic bath for 10 min., followed 
by 15 min. head-over-head mixing. The samples were centrifuged at 3000 x g for 
10 min. The supernatant was transferred into glass vials and diluted five times with 
HBS-EP buffer (2.38 g HEPES, 8.77 g NaCl, 1.12 g EDTA, 50 µL P20 in 1 L H2O) 
from which 100 µL was used in the BioMS assay. 
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BioMS screening
As mentioned in literature, the binding sites of SHBG are highly unstable when 
they are not occupied by any binder [25]. Therefore, the two purchased batches 
of rhSHBG were either stabilized with the strong binder 17β-testosterone (β-T) or 
with cortisol (weak binder). During preliminary experiments, the batch of rhSHBG 
containing β-T was used to determine the optimal conditions to displace the β-T 
by T-D3 during a pre-incubation. This was determined by measuring displaced β-T 
in extracts with and without the addition of T-D3 and UPLC-MS/MS in multiple-
reaction monitoring (MRM) mode as analysis system. The same optimal displacing 
conditions were used for the rhSHBG batch containing cortisol. To prevent any 
chance to obtain false-suspect results for β-T during bioaffinity isolation, the cortisol-
stabilized rhSHBG batch was finally used in this study. The first step in the assay 
was a pre-incubation with an excess of T-D3 (5 ng) label to displace all cortisol from 
the rhSHBG binding sites. For this pre-incubation step, the stock of T-D3 label was 
diluted to 50 ng mL-1 using HBS-EP/MeOH (9:1) and 100 µL of this solution was 
added to a 96-well flat bottom plate, followed by 10 µL of 10 times in assay buffer 
(HSB-EP) diluted rhSHBG-coated beads. This mixture was pre-incubated for 15 min 
on the shaker at 550 rpm (Dynatech Alexandria, VI, USA). To remove the unbound 
T-D3 label and replaced original stabilizers, the automatic magnet wash station was 
used to wash the 96-well plate three times with HBS-EP buffer. The binding assay 
incubation of 15 min. was done after addition of 100 µL of competitor solution (either 
standard for dose-response curves or supplement extracts in HBS-EP/MeOH (9/1)). 
The second wash cycle (3x) was done by the automatic magnetic wash station 
to remove unbound T-D3 label and unbound competitor. After the second wash 
cycle, 70 µL HBS-EP buffer were added to the wells and all bead solutions were 
mixed and the content of each well was transferred into a new 96-well plate by an 
eight channel pipette. This was done prior to the dissociation step because at high 
concentrations, the competitors might bind non-specifically to the wells of the plate. 
The well-plate was placed on the Milliplex magnetic plate (Milipore, Bedford, MA, 
USA) and the beads were magnetized against the well wall in one min after which 
the supernatant was removed. To dissociate all the bound label and competitors, 100 
µL of dissociation solution (H2O/MeOH/HCOOH, 49/50/1 %, v/v/v) was added to the 
plate and the plate was shaken for two min on the shaker (550 rpm). With the help 
of the Milliplex magnetic plate, the supernatants with all the dissociated compounds 
were transferred to a V-shape 96-well plate for UPLC-QqQ-MS rapid screening. The 
total duration of this BioMS assay procedure was 60 min. for 96 samples. Dose-
response curves were fitted using the five parameter curve fitting in the GraphPad 
Prism software of GraphPad Software Inc. (La Jolla, CA, USA).
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Bioaffinity isolation for identification
The bioaffinity isolation procedure is similar to the BioMS screening of supplements, 
except that ten times more rhSHBG-coated beads are used and no label is added. 
First, 10 µL of undiluted rhSHBG-coated beads was added to the plate. After diluting 
the primary supplement extract in HBS-EP/MeOH (9/1), 100 µL were added to the 
plate, incubated for 15 min and the same procedure was followed as described for 
the screening, except that the chip-UPLC-Q-ToF-MS was used for identification. The 
total duration of this bioaffinity purification procedure was <30 min for 96 samples.  
Results and discussion 
BioMS screening assay
During the development of the semi-automated BioMS screening assay for dietary 
supplements, various parameters were optimized, such as influence of buffer 
composition, incubation times and incubation volumes. At first, the limit of detection 
(LoD) of the label (T-D3) in the UPLC-QqQ-MS was determined at the fastest LC 
conditions (2 min run time) and found to be 5 pg on-column (S/N > 6). Then, the 
optimal amount of rhSHBG-coated beads needed for the isolation of a reproducible 
and detectable quantity of the label was investigated. Also the amount of the label 
needed to displace all steroidal stabilizers from the binding sites of the rhSHBG was 
investigated and found to be 5 ng. By displacing all these stabilizers, false suspect 
results were prevented. The influence of oriented non-covalent immobilization of 
the His-tagged rhSHBG onto Ni2+-coated paramagnetic beads and non-oriented 
covalent coupling of rhSHBG onto carboxyl-coated paramagnetic beads was also 
investigated. As the binding capacity of equivalent amounts of Ni2+-beads was higher 
than COOH-beads the oriented immobilization of rhSHBG on Ni2+-beads gave 
slightly higher eluted amounts of T-D3 (20%). However, the non-oriented covalently 
immobilized rhSHBG on COOH-beads proved to be stable for a longer time (3 weeks 
vs 1 week) and was chosen for this study. Typical reconstructed UPLC-QqQ-MS 
chromatograms of the eluted label from non-oriented covalently coupled rhSHBG-
coated beads are shown in Figure 1A. This figure illustrates the fast analysis with a 
total run time of 2 min and the principle of the developed BioMS screening assay: 
the eluted amount of label decreases if a competing rhSHBG binder, e.g. β-T, is 
present in a sample. Next, the influence of the amount of rhSHBG on the UPLC-
QqQ-MS measured recovery of the isotopic label was determined (see appendix 
4.2). For this experiment, 5 ng of the T-D3 label in absence of any competitor was 
added to different volumes of rhSHBG-coated beads. A well with no rhSHBG-coated 
beads was used as blank control to prove that the label did not bind to the 96 well-
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plate. The amount of the label found in this control was <LoD, which proved that 
rhSHBG was responsible for capturing the label. The absolute amount of eluted label 
increased with increasing amounts of rhSHBG-coated beads (from 20 pg using 0.5 
µL of rhSHBG-coated beads to 1900 pg using 10 µL of rhSHBG-coated beads) (see 
appendix 4.2). Further experiments proved that as little as 1 µL of rhSHBG-coupled 
beads (or 10 µL of 10 times diluted beads) both yielded reproducible results and, 
in the presence of steroid competitors , good competition (see Figure 1B). With the 
BioMS screening assay, dose-response curves were constructed for β-bol, β-T, DHT, 
β-1-T and β-E2 in buffer (Figure 1B). Sensitivities at 50% inhibiting concentration 
(IC50) were found to range from 1.8 ng mL-1 (0.18 ng absolute) for the strong binder 
DHT to 55 ng mL-1 (5.5 ng absolute) for the weaker binder β-bol and all curves 
illustrate good precision of the method. Steroids occurring in dietary supplements 
and when added intentionally, are typically present at high levels (0.02-2 mg g-1) [11] 
which would correspond to a final concentration in the BioMS screening assay of 
0.04-4 µg mL-1; the IC50 values of the developed BioMS screening are below these 
levels. The developed BioMS assay showed better sensitivities compared with the 
receptor-based YAB (10-2000 ng mL-1) [2]. The LoDs of targeted GC-MS and LC-
MS-based [11, 26] methods are even better (0.01-20 ng mL-1).
Figure 1. Reconstructed UPLC-QqQ-MS SRM chromatograms showing the peak areas and retention 
time of the label (T-D3) eluted from 1 µL rhSHBG-coated beads in the absence (•) and in the presence of 
1 ng (▼) and 10 ng (▲) of the competing β-T binder (A) and normalized average dose-response curves 
(n=2) of β-bol (♦), β-T (▼), DHT (▲), β-1-T (○), β-E2 (■) in HBS-EP buffer obtained by the BioMS assay 
using 1 µL of rhSHBG-coated beads (B).
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Next to IC50 values, the BioMS assay was used to determine relative rhSHBG binding 
(RB) values for various competitors (see Table 1). The RB values were calculated by 
comparing the degree of inhibition caused by a competitor with β-T (both at a level of 
10 ng), the latter was given a reference value of 1. RB values <1 represent binders 
having a lower affinity towards rhSHBG than β-T at the 10 ng level. In literature, 
affinities of SHBG binders were investigated by in silico approaches or by tritium-
label displacement methods using SHBG and [3H]-E2 as label [20, 27-29]. The RB 
values in Table 1 and the values obtained from literature compare generally very 
well: similar weak and strong binders are found in the BioMS assay (DHT>β-T=β-
E2>β-bol>proges.). When the RB values of Table 1 are compared to the Relative 
Androgenic Potencies (RAP) of various compounds in the YAB [2] larger differences 
are observed. This is not unexpected since the YAB is not a binding assay but a 
receptor-based transcription activation assay. 
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Table 1. Relative binding (RB) and IC50 values of various anabolic steroids in the BioMS assay 
compared to tritium-label displacement [29] and in silico [27, 28] methods and (RAP) in YAB [2]. 
Compound BioMS 
RB 
value
IC50 (ng mL-1) IC50 (µM) [29] In silico [27, 28] YAB [2]
   BioMS assay Protein-Ligand Dis-
sociation* 
RAP**
      
β-T 1 20 5.9E-3 9.20 1
α-T 0.1 - - - 0.0063
β-T-glu 0.4  -  -  -  -
T-Ac 0  -  -  -  -
T-cyp 0  -  -  -  -
Cl-T 1  -  -  -  -
CLAD 0.4  -  -  -  -
β-1-T 1.1 3.5  -  - 1.9
α-1-T 0.7  -  -  -  -
β-norT 0.3  -  - 6.30 1.6
α-norT 0.1  -  -  -  -
β-E2 0.9 18 5.4E-3 8.83 0.019
α-E2 0.7  -  -  -  -
E1 0.9  -  - 8.18  -
β-E2-glu 0  - 3.2E-2  -  -
β-E2-sul 0  -  -  -  -
DHT 1.3 1.8  - 9.74  -
4α-androstane-3β-
17β-dione 
0  -  -  -  -
THG 0.4  -  -  -  -
Zea 0  - 0.32  -  -
α-zear 0.2  -  -  -  -
β-zear 0  -  -  -  -
equol 0.6  -  -  -  -
naringenin 0 - 200*** - -
proges. 0.3  - 2.5 6.94 0.038
β-bol 0.6 55  -  - 0.18
α-bol 0  -  -  -  -
DHEA 0.3  -  -  -  -
androst-4-ene-3β-
17β-diol 
1  -  - 9 0.049
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 BioMS assay Protein-Ligand Dis-
sociation* 
RAP**
5α-androstane-3β-
17α-diol
0.6  -  -  -  -
5α-androstane-3β-
17β-diol
1.1  -  - 9.17  -
5α-androstane-3α-
17β-diol
1.1  -  -  -  -
5α-androstane-3α-
17α-diol
0  -  -  -  -
5β-androstane-3β-
17α-diol
0  -  -  -  -
5β-androstane-3β-
17β-diol
0.7  - -  -  -
5β-androstane-3α-
17β-diol 0  - -  -  -
5β-androstane-3α-
17α-diol 0  - -  -  -
* Corresponding protein–ligand dissociation parameters produced by QSAR and virtual screening 
approaches.  
** RAP is defined as the ratio between the 50% effective concentration (EC50) of 17β-T and the EC50 of 
the compound.
*** 200 µM naringenin displaced 34% of [3H]-E2 [20].
BioMS screening of steroids in dietary supplements
To investigate the performance of our new BioMS screening, 21 dietary supplements, 
previously analyzed for the presence of anabolic steroids by YAB [2] and by LC-
MS/MS in MRM mode [11] were screened again and the outcome was critically 
compared. Figure 2 shows the screening results using the newly developed BioMS. 
Samples 1-14 were previously screened as blanks and samples 15-21 as suspect 
by YAB [2] and LC-MS [11]. The BioMS assay results show that the blanks gave an 
average eluted amount of T-D3 of 32±7 SD pg. A decision level calculated from these 
data (average minus 3 times SD) indicate that T-D3 levels below 11 pg pinpoint to 
suspect samples. The known suspect samples gave T-D3 eluted amounts of 1±1 pg. 
These T-D3 data clearly demonstrate that there is a significant difference between 
blank and suspect samples. 
Compound BioMS 
RB 
value
IC50 (ng mL-1) IC50 (µM) [29] In silico [27, 28] YAB [2]
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Figure 2. BioMS screening results of dietary supplements measured with UPLC-QqQ-MS (grey bars) 
and with chip-UPLC-Q-ToF-MS (black bars) earlier screened by the YAB as <LoD (sample nr 1-14) and 
suspect for the presence of anabolics according to YAB [2] and/or LC-MS/MS [11] (sample nr 15-22). Data 
are the mean of duplicate analysis. 
Since phytosterols may occur in sports supplements, the potential binding of 
phytosterols to rhSHBG was investigated by re-examining the screening results. The 
labels of supplements 8 and 13 described the presence of 10 mg of phytosterols 
β-sitosterol, campesterol and stigmaterol. As these supplements were screened as 
blanks, no false-suspect results are obtained in the BioMS screening by the presence 
of 10 mg/pill phytosterol in dietary supplements. Another indication that phytosterols 
do not bind to rhSHBG or have a low RB in the BioMS, is the comparison of the 
binding affinity of β-sitosterol and naringenin. In the radiolabel displacement method 
by Jury et al. [20] both compounds displaced similar amount of the label (i.e. 40%). 
In the BioMS approach an RB value of 0 was obtained for naringenin. 
BioMS identification of known and designer steroids by chip-UPLC-Q-ToF-MS
In this study, a chip-based NanoTileTM UPLC was used because, compared to 
conventional (UP)LC, chromatographic performance is superior and low volume 
injections (0.1-2 µL) are feasible. The latter is important in order to be able to inject 
extracts which were previously injected onto the LC-QqQ-MS for screening. As rather 
exciting example, Figure 3 shows typical NanoTileTM-UPLC-Q-ToF-MS reconstructed 
ion chromatograms on a 5 cm chip-column in which excellent efficiency (effective 
plate numbers 20,000-60,000), peak shape (asymmetry factor at 10% peak height; 
0.8-1.3) and separation is displayed, even for isobaric steroid isomers at very low 
levels (1-10 pg on-column). The same sample extracts used for screening purposes 
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were injected onto the chip-UPLC-Q-ToF-MS system. Re-injecting the same bio-
purified sample extracts previously used for the BioMS screening assay on this 
second LC-MS system was possible because the chip-UPLC-Q-ToF-MS system 
is capable of injecting low sample volume samples (0.1-2 µL) while still providing 
adequate full scan accurate mass sensitivity. In each sample screened suspect in 
Figure 2, the strongest rhSHBG-binding steroid was identified on basis of retention 
time, accurate mass and MS/MS spectra (in accurate product ion scanning mode). In 
Table 2 the identification results observed by chip-UPLC-Q-ToF-MS are summarized 
and compared with previous LC-MS/MS [11] and YAB data [2] from literature. In order 
to identify also additional weaker rhSHBG binders in the sample extracts, all suspect 
samples were also subjected to a slightly adapted BioMS identification procedure in 
which ten times more rhSHBG-coated beads was used and without pre-incubation 
with T-D3 (Table 2).  
Figure 3. Reconstructed chip-UPLC-Q-ToF-MS ion chromatograms of (A) the isomers α-bol and β-bol, 
α-norT and β-norT, α-T and β-T, α-1-T, β-1-T and of THG (all 1 pg on-column) and androst-4-ene-3β-17β-
diol (10 pg on-column), and of (B) β-1-T in suspect sample nr 22. 
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Table 2 demonstrates that if a weak rhSHBG binder is present (at low levels) among 
other strong binders in the same sample extract, then only the strong binder is 
identified in the sample extract previously used for the BioMS screening assay. Note 
that by applying the adjusted BioMS identification approach in which ten times more 
rhSHBG was used, more low level and/or low affinity steroids are identified. For 
example, in the rapid identification approach, only β-norT was identified in sample 
16 and no β-bol was found. By applying the adjusted BioMS identification procedure, 
both steroids were found in sample 16 and in sample 21 the gestagen progesterone 
was additionally identified. In sample nr 15 however, the combination of a low level 
of β-bol plus its much lower affinity caused the identification of β-T only, both in the 
direct analysis and in the adjusted BioMS identification approach. For the same 
reasons, α-norT was not identified in sample 16. The results in Table 2 also stress 
the consequences when only LC-MS/MS without rhSHBG is applied to find steroids. 
Sample 18 was reported as blank by the LC-MS/MS method, however the YAB found 
a compound having bioaffinity and it was suggested that androst-4-ene-3β-17β-diol 
was present in the “blank” sample. Both the fast and the adjusted BioMS identification 
approaches identified androst-4-ene-3β-17β-diol in sample 18. This compound 
was not found by the targeted LC-MS/MS method as the MRM transitions for this 
compound were not acquired [11]. Moreover, in sample 19, 20 and 22 the steroid 
β-1-T was identified by the BioMS identification approach with the chip-UPLC-Q-ToF-
MS. This steroid was found in sample 19 following the adjusted BioMS identification 
procedure (see Table 2). β-1-T was also screened suspect by YAB and subsequently 
identified with parallel LC-fractionation plus ToF-MS in sample 22, but YAB did not 
identify β-1-T in samples 19 and 20 because these samples were not subjected to 
that laborious identification approach. Also an estrogen, 17β-estradiol (E2) was found 
in sample 19 but only using a very sensitive GC-MS/MS instrument (see appendix 4.4 
for GC-MS/MS conditions). Additionally, for the identification of estrogenic compounds 
in dietary supplements a new BioMS method is being developed which uses the 
estrogen receptor in combination with GC-MS. A supplement screened negative 
was spiked with the designer steroid THG in order to demonstrate the potential of 
the method for early discovery of designer steroids in dietary supplements. First the 
sample was screened suspect by the BioMS screening. Next, the same extract was 
injected onto chip-UPLC-Q-ToF-MS and the designer steroid THG was identified 
based on accurate mass and specific product ions (all identifications results shown in 
appendix 4.3 and appendix 4.5). Since the chip-UPLC-Q-ToF-MS identification set-up 
was quite sensitive, its use for BioMS screening was briefly explored. To investigate 
this, four blank and four suspect sample extracts were injected onto the chip-UPLC-
Q-ToF-MS and by measuring the T-D3 product ions in accurate product ion scanning 
mode, the four blank extracts displayed much higher eluted amounts of T-D3 (30±5 
pg) compared to the four suspect samples (5±1 pg) (see Figure 2). These results 
demonstrate that screening can even be performed using the chip-UPLC-Q-ToF-MS 
used for identification. However, in this study BioMS screening with UPLC-QqQ-MS 
was preferred as the run time of the latter is much shorter (2 min vs 15 min).   
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* LoD of LC-MS/MS is 0.01 mg unit-1 (all LC-MS/MS data were adopted from Van 
Poucke et al. [11])         
** + = screened suspect, - = screened as negative 
*** β-E2 identified on basis of retention time and two specific MRM transitions with 
GC-MS/MS (see appendix 4.4 for GC-MS conditions).
Conclusions
For rapid screening, a novel radiolabel-free BioMS assay was developed for 
rhSHBG binders in dietary supplements featuring high-throughput (the entire the 
sample treatment, BioMS assay and measuring time was 4h for 96 tests) and the 
possibility to use the same biopurified extract for subsequent identification using 
chip-UPLC-Q-ToF-MS with full scan accurate mass measurement. Any strong 
binder, including unknown designer steroids, can be successfully identified on basis 
of retention time, accurate mass and product ion spectra. To identify additionally 
less potent rhSHBG binders in dietary supplements, ten times more rhSHBG can 
be applied in an adjusted bioaffinity procedure. Only weakly binding steroids might 
remain undetected when present at low levels. The steroid β-1-T was identified in 
three samples previously found negative in targeted LC-MS/MS. In the literature, in 
field of doping control, various targeted and untargeted proteome profiling strategies 
and gene reporter assays are described, however, these strategies should be 
viewed only as a screening tool as their biorecognition elements cannot be applied 
in identifying previously screened compounds [30]. Our results demonstrate that, in 
contrast to the proteome profiling strategies and reporter gene assays [2, 31], the 
presented BioMS approach is generic and very fast as both multiple androgens, an 
estrogen and a gestagen were identified using solely one transport protein. Thus 
the bioaffinity screening plus identification approach can be a powerful tool for 
early warning of unknown emerging rhSHBG bioactive designer steroids in dietary 
supplements and contribute to fight doping in sports. 
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Appendix 4.1
Chemicals
17α-testosterone (4-androsten-17α-ol-3-one, α-T), 17β-testosterone (4-androsten-
17β-ol-3-one, β-T), 17β-testosterone-D3 (4-androsten-17β-ol-3-one-16,16,17-d3, 
T-D3), 17β-estradiol (1, 3, 5(10)-estratrien-3,17β-diol, β-E2), 17α-estradiol (1, 3, 
5(10)-estratrien-3,17α-diol, α-E2), 17β-estradiol-3-glucuronide (1, 3, 5(10)-estratrien-
17β-ol-3-glucuronide, β-E2-glu), 17β-estradiol-3-sulphate (1, 3, 5(10)-estratrien-
17β-ol-3-sulfate, β-E2-sul), 17β-testosterone-glucuronide (4-androsten-3-one-
17β-glucuronide, β-T-glu), dihydrotestosterone (5α-androstan-17β-ol-3-one, 
DHT), zearalenone (zea) α-zearalanol (α-zear), β-zearalanol (β-zear), 4-chloro-
testosterone (4-androsten-4-chloro-17β-ol-3-one, Cl-T), equol (3,4-dihydro-3-(4-
hydroxyphenyl)-2H-1-benzopyran-7-ol), estrone (1, 3, 5(10)-estratrien-3-ol-17-one, 
E1), testosterone-17-acetate (4-androsten-3-one-17β-acetate, T-Ac), testosterone-
17-cypionate (4-androsten-3-one-17β-cypionate, T-cyp), testosterone-17-decanoate 
(4-androsten-3-one-17β-decanoate, T-dec), progesterone (4-pregnen-3,20-dione, 
proges.), 16-dehydroprogesterone (4,16-pregnadien-3,20-dione, dehydroproges.) 
and cortisol (4-pregnene-11β,17α,21-triol-3,20-dione) were purchased from 
Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands). 17α-1-testosterone (1,(5α)-
androsten-17α-ol-3-one, α-1-T), 17β-1-testosterone (1,(5α)-androsten-17β-ol-3-
one, β-1-T), (4-androsten-4-chloro-3,17-dione, CLAD), 17α-19-nortestosterone 
(4-estren-17α-ol-3-one, α-norT), 17β-19-nortestosterone (4-estren-17β-ol-3-one, 
β-norT), 17β-boldenone (1,4-androstadien-17β-ol-3-one, β-bol), 17α-boldenone 
(1,4-androstadien-17α-ol-3-one, α-bol), dehydroepiandrosterone (5-androsten-3β-
ol-17-one DHEA), androst-4-ene-3β-17β-diol, tetrahydrogestrinone 13,17-diethyl-
17-hydroxy-18,19-dinor-17-pregn-4,9,11-trien-3-one, THG) and 5α-androstane-3β-
17β-diol and its seven other isomers were purchased from Steraloids (Newport, RI, 
US). Acetonitrile (ACN) and methanol (MeOH) were from Biosolve (Valkenswaards, 
The Netherlands). Formic acid (HCOOH), ethanol (EtOH), EDTA (Triplex), HEPES, 
sodium azide (NaN3), imidazole and sodium chloride (NaCl) were purchased from 
Merck (Whitehouse Station, NJ, USA). The 2-(N-Morpholino) ethanesulfonic acid 
(MES) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC) 
were from Sigma Aldrich Chemie (Zwijndrecht, The Netherlands). Six times His-
tagged full-length recombinant human SHBG (purified, 96 kDa dimer) was purchased 
from Generi Biotech s.r.o. (Hrdadec Kralove, Czech Republic). 
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Appendix 4.2
 
Average amounts (n=2) of T-D3 label recovered from different volumes of rhSHBG-
coated beads after pre-incubation with 5 ng of the label and measured by UPLC-
QqQ-MS.
Chapter 4
138
A
pp
en
di
x 
4.
3
Th
eo
re
tic
al
 a
nd
 e
xp
er
im
en
ta
l e
xa
ct
 m
as
se
s,
 m
as
s 
er
ro
rs
, r
et
en
tio
n 
tim
es
 a
nd
 e
le
m
en
ta
l c
om
po
si
tio
n 
of
 β
-n
or
T,
 α
-T
, β
-T
, a
nd
ro
st
-
4-
en
e-
3β
-1
7β
-d
io
l 
an
d 
1-
β-
T 
in
 s
ta
nd
ar
d 
so
lu
tio
ns
 a
nd
 i
n 
bi
op
ur
ifi
ed
 d
ie
ta
ry
 s
up
pl
em
en
t 
ex
tra
ct
s 
w
ith
 c
hi
p-
U
P
LC
-Q
-T
oF
-M
S
 
fo
llo
w
in
g 
sc
re
en
in
g.
M
ea
su
re
m
en
t
t R
E
xp
er
im
en
ta
l
Th
eo
re
tic
al
M
as
s 
er
ro
r
E
le
m
en
ta
l 
co
m
po
si
tio
n
A
cc
ur
at
e 
m
as
s 
pr
od
uc
t i
on
 s
ca
nn
in
g 
 
(m
in
)
[M
+H
]+
[M
+H
]+
(p
pm
)
[M
+H
]+
(m
/z
)
β-
T
st
an
da
rd
6.
07
28
9.
21
7
28
9.
21
7
0
C
19
H
29
O
2
97
.0
63
, 1
09
.0
65
sa
m
pl
e 
15
6.
07
28
9.
21
6
 
-3
C
19
H
29
O
2
97
.0
61
, 1
09
.0
61
β-
no
rT
st
an
da
rd
5.
52
27
5.
20
3
27
5.
20
1
+7
C
18
H
27
O
2
10
9.
06
3,
 1
45
.0
61
sa
m
pl
e 
16
5.
53
27
5.
20
3
+7
C
18
H
27
O
2
10
9.
06
1,
 1
45
.0
60
β-
T
st
an
da
rd
6.
07
28
9.
21
7
28
9.
21
7
0
C
19
H
29
O
2
97
.0
64
, 1
09
.0
62
sa
m
pl
e 
17
6.
06
28
9.
21
6
 
-3
C
19
H
29
O
2
97
.0
65
, 1
09
.0
65
an
dr
os
t-4
-e
ne
-3
β-
17
β-
di
ol
 
st
an
da
rd
5.
83
27
3.
22
1
[M
-H
2O
+H
]+
-4
C
19
H
29
O
1
25
5.
21
0,
 8
1.
07
2
sa
m
pl
e 
18
5.
82
27
3.
22
1
27
3.
22
2
-4
C
19
H
29
O
1
25
5.
20
9,
 8
1.
07
3
β-
T
st
an
da
rd
6.
06
28
9.
21
7
28
9.
21
7
0
C
19
H
29
O
2
97
.0
68
, 1
09
.0
64
sa
m
pl
e 
19
6.
06
28
9.
22
0
 
+1
0
C
19
H
29
O
2
97
.0
67
, 1
09
.0
66
Screening and identification of steroids
139
β-
T
st
an
da
rd
6.
06
28
9.
21
7
28
9.
21
7
0
C
19
H
29
O
2
97
.0
65
, 1
09
.0
61
sa
m
pl
e 
20
6.
08
28
9.
21
6
-3
C
19
H
29
O
2
97
.0
67
, 1
09
.0
63
β-
1-
T
st
an
da
rd
6.
51
28
9.
21
6
28
9.
21
7
-3
C
19
H
29
O
2
18
7.
14
5,
 2
05
.1
55
sa
m
pl
e 
20
6.
49
28
9.
21
6
-3
C
19
H
29
O
2
18
7.
15
0,
 2
05
.1
57
β-
T
st
an
da
rd
6.
08
28
9.
21
7
28
9.
21
7
0
C
19
H
29
O
2
97
.0
64
, 1
09
.0
61
sa
m
pl
e 
21
6.
08
28
9.
21
6
-3
C
19
H
29
O
2
97
.0
67
, 1
09
.0
67
α-
T
st
an
da
rd
6.
70
28
9.
21
6
28
9.
21
7
-3
C
19
H
29
O
2
97
.0
63
, 1
09
.0
67
sa
m
pl
e 
21
6.
72
28
9.
21
6
 
-3
C
19
H
29
O
2
97
.0
65
, 1
09
.0
66
β-
1-
T
st
an
da
rd
6.
52
28
9.
21
7
28
9.
21
7
0
C
19
H
29
O
2
18
7.
14
6,
 2
05
.1
55
sa
m
pl
e 
22
6.
48
28
9.
21
6
 
-3
C
19
H
29
O
2
18
7.
14
2,
 2
05
.1
53
TH
G
st
an
da
rd
7.
33
31
3.
21
5
31
3.
21
7
-6
C
21
H
29
O
2
24
1.
16
1,
 1
59
.0
83
sp
ik
ed
 s
am
pl
e
7.
35
31
3.
21
5
 
-6
C
21
H
29
O
2
24
1.
15
5,
 1
59
.0
86
Chapter 4
140
Appendix 4.4
3800 GC Varian 1200 L GC-MS/MS conditions
Derivatization of β-E2. Twenty-five microliters of N-methyl-N-
trimethylsilyltrifluoroacetamide solution was added to dried samples and incubated 
during 1 hour at 60°C. After incubation the mixture is evaporated to dryness under 
a stream of nitrogen at 55°C and the residue was dissolved in 50 µL of isooctane.       
GC conditions.
•   injection 1 µl pulsed splitless at 260°C
•   initial oven temperature 110°C (1 minute)
•   temperature is increased by 20°C min-1 to 260°C, remaining time: 0.5 minutes.
•    increasing 1°C min-1 to 266°C, followed by increasing of 20°C min-1 to 340°C.    
    Total runtime: 20 minutes.
•   temperature transfer line 330°C
•   constant flow mode, 1.1 mL min-1 helium
•   temperature ion volume 250°C
GC column: stationary phase: VF-17ms, film thickness (µm): 0.25 L (m) x ID (mm) x 
OD (mm): 30 x 0.25 x 0.39, from Agilent Technologies (Santa Clara, CA, USA).
MS/MS conditions: Electron Impact (EI) source was at -70 eV and 250°C while 
following multiple reaction monitoring (MRM) transitions were measured for β-E2 
using argon as collision-induced dissociation gas; m/z 416.2 → m/z 285.2, m/z 416.2 
→ m/z 326.2 (using collision energy 7 and 6 V respectively).
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Receptor-based high-throughput screening and 
identification of estrogens in dietary supplements using 
bioaffinity liquid-chromatography ion mobility mass 
spectrometry
Aqai, P., N. Gómez Blesa, H. Major, M. Pedotti, L. Varani, V.E.V. Ferrero, W. Haas-
noot, M.W.F. Nielen, Analytical and Bioanalytical Chemistry,
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Abstract 
A high-throughput bioaffinity liquid chromatography-mass spectrometry (BioMS) 
approach was developed and applied for the screening and identification of 
recombinant human estrogen receptor α (ERα) ligands in dietary supplements. 
For screening, a semi-automated mass spectrometric ligand binding assay was 
developed applying 13C2,15N-tamoxifen as non-radioactive label and fast ultra-high-
performance–liquid chromatography–electrospray ionization–triple-quadrupole-MS 
(UPLC-QqQ-MS), operated in the single reaction monitoring mode, as a readout 
system. Binding of the label to ERα-coated paramagnetic microbeads was inhibited 
by competing estrogens in the sample extract yielding decreased levels of the 
label in UPLC-QqQ-MS. The label showed a high ionisation efficiency in positive 
electrospray ionisation (ESI) mode, so the developed BioMS approach is able to 
screen for estrogens in dietary supplements despite their poor ionisation efficiency in 
both positive and negative ESI modes. The assay was performed in a 96-well plate, 
and all these wells could be measured within 3 h. Estrogens in suspect extracts 
were identified by full-scan accurate mass and collision-cross section (CCS) values 
from a UPLC-ion mobility-Q-time-of-flight-MS (UPLC-IM-Q-ToF-MS) equipped with 
a novel atmospheric pressure ionisation source. Thanks to the novel ion source, this 
instrument provided picogram sensitivity for estrogens in the negative ion mode and 
an additional identification point (experimental CCS values) next to retention time, 
accurate mass and tandem mass spectrometry data. The developed combination of 
bioaffinity screening with UPLC-QqQ-MS and identification with UPLC-IM-Q-ToF-
MS provides an extremely powerful analytical tool for early warning of ERα bioactive 
compounds in dietary supplements as demonstrated by analysis of selected dietary 
supplements in which different estrogens were identified. 
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Introduction
In 2006, the nutritional supplement market was worth US$ 60 billion and is growing 
continuously [1]. Supplements are widely available in local stores and on the Internet 
and easy to order for (professional) athletes to enhance their performance and for 
ordinary people. However, several investigations have shown the deliberate and 
unintentional addition of (pro)hormones to supplements [2-7]. Labels of these 
supplements are often incomplete or incorrect [4,7]. The presence of anabolic 
steroids in supplements is banned in the European Union (EU) and USA. Despite this, 
various supplements are easily accessible to consumers. Geyer et al. described that 
21% of supplements purchased in the EU contained anabolic steroids [7]. Generally, 
they assumed that the presence of steroids in supplements is a result of accidental 
cross-contamination during either manufacturing or packaging [7]. As an example 
of deliberate addition of steroids to herbal supplements, Toorians et al. presented 
in their study the presence of diethylstilbestrol (DES) in a supplement marketed on 
the Internet for prostate problems [4]. Due to the high intake of DES (4.1 ± 0.1 mg 
g-1) through these pills, the male consumer of this herbal supplement developed 
abnormally large mammary glands. In modern laboratories, gas chromatography-
mass spectrometry (GC-MS) and liquid chromatography (LC)-tandem mass 
spectrometry (MS/MS) are used for the fast, sensitive and specific detection of steroids 
[8-10], appetite suppressors [11], mycotoxins [12] and pharmaceuticals [13] in dietary 
supplements. In order to achieve the highest sensitivity and selectivity, both GC-MS 
and LC-MS/MS are set up in pre-selected ion or ion transition acquisition modes 
[14-17,9]. In this way, only known compounds can be measured, and new estrogenic 
compounds may escape from routine testing and remain undetected. Alternatively, 
biorecognition-based assays, using, e.g. the estrogen receptor (ER), are used for 
rapid screening of estrogenic compounds. However, non-immobilised ER tends to be 
very sensitive to slight changes in, e.g. temperature, salt concentration and pH [18]. 
Usami et al. [19] developed a surface plasmon resonance (SPR)-based biosensor 
assay in which 17β-estradiol (E2) was used as a ligand, human recombinant ERα 
for biorecognition and test chemicals as competitors. By means of this biosensor 
assay, dissociation constants for the binding of estrone (E1), β-E2, estriol (E3), 
tamoxifen (Tamo), DES, bisphenol A (BPA) and 4-nonylphenol were determined. 
Blair et al. [20] determined the relative binding affinity for a large group of chemicals 
by using an ERα competitive ligand binding assay. In this radio receptor assay, ER 
was obtained from rats, and [3H]-E2 was used as the competing label. The obvious 
disadvantages of this assay include the use of a radiolabel and the long assay time 
of 24h. The combination of a bioaffinity extraction with MS detection could serve as 
a powerful tool for the identification of known and unknown estrogenic compounds. 
Choi et al. developed a screening assay for ligands of the estrogen receptor based 
on magnetic microparticles and LC-MS [21]. Although this method was capable of 
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screening genistein and daidzein in botanical extracts, the throughput of this method 
was low, and a high amount of the costly estrogen receptor was required due to 
the low affinity of the phytoestrogens [22,23]. De Vlieger et al. [24] developed an 
on-line dual post-column estrogen receptor affinity assay based on fluorescence 
(limit of detection (LOD) 4.7 nM) and parallel detection by MS (LOD 40 nM) for 
quantification and identification purposes of estrogenic compounds. However, in 
order not to decrease receptor activity by the LC mobile phase gradient, a make-up 
gradient had to be added post-column in order to dilute the organic solvent content, 
thus complicating the setup. To decrease protein consumption and to omit the make-
up gradient, pre-column bioaffinity MS methods have been described in literature as 
well [25-28]. Niessen et al. developed an off-line competitive MS binding assay for 
determining the binding affinity of dopamine receptor ligands using spiperone as a 
label [27]. That binding assay was presented as a possible alternative to radiolabeled 
assays; however, since only the unbound fraction of the marker was measured, 
at best, indirect information was obtained about the bound ligands. Moreover, 
because of the use of a non-volatile buffer, an additional SPE step was required 
prior to LC-MS detection. Due to the solid-phase extraction (SPE) step and the 
absence of microtiter plates, high-throughput screening was not feasible. Zepperitz 
et al. described a competitive MS binding assay in which the γ-aminobutyric acid 
transporter-bound fraction of the label was measured after elution with methanol 
[25]. Although that method had the potential for high-throughput characterisation 
of new drug candidates, the format was used for kinetic measurements in buffer 
only, and no screening in real samples was performed. By the lengthy (30-60 min) 
filtration steps during wash and dissociation steps, the method became longer and 
less straightforward. In general, these off-line pre-column bioaffinity MS methods are 
focused on determining affinities, and no screening or identification is performed for 
food or environmental contaminants [25-28]. In a previous bioaffinity MS (BioMS) 
study, a mass spectrometric ligand binding assay was presented in pre-column format 
in which recombinant human sex hormone-binding globulin (rhSHBG) and LC-MS 
were used for screening and identification of androgenic and estrogenic (designer) 
steroids in dietary supplements [29]. Although that method was rapid and able to 
identify (un)known rhSHBG binders in supplements, the screening of estrogens 
other than β-E2 was not feasible due to the low affinity; moreover, identification of 
this estrogen could only be achieved following derivatisation and GC-MS/MS. In 
the present work, a semi-automated high-throughput BioMS method is presented in 
which the recombinant ligand binding domain (LBD) of human ERα and dedicated 
modes of fast ultra-high performance liquid chromatography (UPLC)-MS are used 
for screening and identification of estrogenic steroids in dietary supplements. Since 
estrogens have poor ionisation efficiencies in both positive and negative electrospray 
ionisation (ESI) modes [30,31], a label having excellent ionisation efficiency in ESI 
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is required for the rapid screening of estrogens. Therefore, a mass spectrometric 
ligand binding assay was developed based on 13C2,15N-tamoxifen as label, which has 
a high ionisation efficiency in positive ESI and fast UPLC-electrospray ionisation-
triple-quadrupole-MS (UPLC-QqQ-MS), operated in the single reaction monitoring 
(SRM) mode, as readout system for the detection and quantification of the non-
radioactive label. The LBD of ERα was immobilised covalently and non-covalently 
onto paramagnetic microbeads using two different surface chemistries. To identify 
the estrogens, a UPLC-ion mobility-Q-ToF-MS equipped with a novel atmospheric 
pressure ion source [32] was used to obtain adequate ionisation efficiency, retention 
time, collision cross-section (CCS) values and high-resolution full-scan accurate 
mass data. This novel ion source was evaluated for the first time in negative ion 
mode. Several dietary supplements were screened for ER binders, and, in suspect 
samples, different estrogens were identified to demonstrate the applicability of this 
newly developed ERα-based BioMS approach. 
Materials and method
Materials
Tamoxifen (2-{4-[ (1Z)-1,2-diphenylbut-1-en-1-yl] phenoxy}-N,N-dimethylethanamine, 
Tamo), 13C2,15N-tamoxifen (tamoxifen-15N,N,N-dimethyl-13C2 (13C2,15N-Tamo)), 
zearalenone (Zon), BPA, naringenin (Nar), β-sitosterol (β-Sito), 2-(N-morpholino) 
ethanesulfonic acid (MES) and N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
hydrochloride (EDC) were purchased from Sigma-Aldrich Chemie (Zwijndrecht, The 
Netherlands). 17β-estradiol (β-E2), 17α-estradiol (α-E2), 17α-ethinyl estradiol (EE2), 
estrone (E1) and diethylstilbestrol (DES) were purchased from Steraloids (Newport, 
RI, US). Acetonitrile (ACN) and methanol (MeOH) were from Biosolve (Valkenswaard, 
The Netherlands) and formic acid (HCOOH), EDTA (Triplex), HEPES, sodium azide 
(NaN3), imidazole and sodium chloride (NaCl) from Merck (Whitehouse Station, NJ, 
USA). The purified recombinant his-tagged wild-type ligand binding domain (LBD) 
of the human estrogen receptor α (ERα, 25 kD) was kindly provided by Dr Luca 
Varani of the Institute for Research in Biomedicine (Bellinzona, Switzerland). The 
LBD was over-expressed in E.Coli, refolded from inclusion bodies and purified with 
His-tag affinity and size exclusion chromatography. LoBind Tubes were provided 
by Eppendorf (Hamburg, Germany) and LoBind 96-well micro flat bottom plates 
(655161) and 96-well micro V-shaped bottom plates (651201) by Greiner Bio-One 
B.V. (Alphen a/d Rijn, The Netherlands). Water purification was performed using 
a Milli-Q system (Milipore, Bedford, MA, USA). SiMAG-Carboxyl microbeads 
(product number 1402-1, 1 µm diameter) and SiMAG-IDA/Nickel microbeads 
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(product number 1512-1, 1 µm diameter) were supplied by Chemicell GmbH (Berlin, 
Germany). The Milliplex magnet Handheld Magnetic Separator Block for 96-well flat-
bottom plates was purchased from Milipore, the microtiter plate vari-shaker from 
Dynatech (Alexandria, VI, USA), the REAX2 head-over-head shaker from Heidolph 
(Schwabach, Germany) and the automatic magnetic wash station BioPlexTM pro II 
from BioRad Laboratories B.V. (Veenendaal, The Netherlands). 
Instrumentation
Ultra-high performance liquid chromatography–triple-quadrupole mass 
spectrometry
A Waters (Milford, MA, USA) Acquity Ultra-Performance LC (UPLC) system, 
consisting of a degasser, a binary gradient pump, an auto sampler (at 10 °C) and a 
column oven (at 50 °C), was used. The injection volume was 10 μL and the analytical 
column an Acquity UPLCTM BEH 1.7 μm C18, 50 x 2.1 mm I.D. from Waters. The 
UPLC system was coupled to a Micromass (Manchester, UK) Quattro Platinum 
tandem mass spectrometry (QqQ) system equipped with an ESI source used in 
positive ion mode. The two mobile phases consisted of (A) H2O/HCOOH (99.9/0.1%, 
v/v) and (B) ACN/HCOOH (99.9/0.1%, v/v) and the flow rate was 0.3 mL min-1. The 
gradient started at 30% B for 0.30 min, increased sharply to 95% B in 0.10 min with 
a hold for 1.10 min and returned to the initial state in 0.05 min with a final hold of 0.45 
min. The total run time was 2 min only. The UPLC was interfaced with the ESI MS/MS 
instrument without a flow split. The ESI capillary voltage was +2.7 kV, and the cone 
voltage was 30 V. The desolvation gas was nitrogen (700 L/h) with a temperature of 
350 °C, the source temperature was 120 °C, and the collision-induced dissociation 
gas was argon at a pressure of 2.5 × 10−3 mbar. Data acquisition for 13C2,15N-Tamo, 
which was used as label in this study, was performed in SRM mode at transition m/z 
375.2→ m/z 75.3 using collision energy 25eV. 
Ultra-high performance liquid chromatography–ion mobility–quadrupole–time-of-
flight  mass spectrometry
Chromatography was performed on an Acquity UPLC system consisting of a 
degasser, a binary gradient pump, an auto sampler (at 10 °C) and a column oven 
at 50 °C. The UPLC system was coupled to a Synapt G2-S (Waters) ion mobility-
quadrupole-time-of-flight-MS (IM-Q-ToF-MS) system equipped with a novel 
atmospheric pressure ionisation (API) source. In this API source design [32], a high-
velocity droplet stream is impacting on a high-voltage electrode (see also appendix 
5.2). The injection volume of the sample from a 384-well plate was 10 μL and the 
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analytical column was an Acquity UPLCTM BEH 1.7 μm C18, 50 x 2.1 mm I.D. 
from Waters. The mobile phase consisted of (A) H2O/NH4OH (99.9/0.1%, v/v) and 
(B) MeOH/NH4OH (99.9/0.1%, v/v), in order to support negative ion formation for 
estrogens. After injection, separation was done using gradient elution at a constant 
flow rate of 0.6 mL min-1. The gradient started at 30% B for 0.3 min followed by a 
linear increase to 95% B in 0.1 min with a hold of 1.1 min and from 95% to 30% 
B in 0.05 min with a hold of 0.45 min, prior to the next injection. The prototype ion 
source was operated in the negative ion mode at 150 °C and a voltage of -4 kV with 
a cone voltage of -40 V. In order to get extra structural information, MSe was applied, 
which means simultaneous scans at low (20 eV) and high collision energy (ramped 
from 20 to 55 eV) in separated data acquisition functions. Additionally, in order to 
measure specific product ions at the highest sensitivity, the Q-ToF-MS was also 
operated in accurate mass product ion scanning mode. The ion mobility separation 
was performed under the following conditions: trap collision energy -4.0 V, transfer 
collision energy -2.0 V, IM gas N2, IMS gas flow 90 mL min-1; IM wave height -40 
V; IM wave velocity 800 m/s. As lock mass, a solution of leucine-enkephalin was 
continuously introduced by a separate lock mass probe at a flow rate of 10 μL min-
1. For accurate mass calibration of the m/z axis, m/z 554.2615 was used as a lock 
mass in negative ion mode.
Methods
The protocols for immobilisation of the ERα LBD on the two types of paramagnetic 
beads are described in appendix 5.1
Sample preparation
The primary extraction of steroids from dietary supplements was based on the 
procedure described by Rijk et al. [33], which was simplified by omitting the SPE 
and evaporation steps. The dietary supplements were ground, and 0.05 gram was 
weighed into a 10 mL plastic tube. To this tube, 2 mL MeOH and 2 mL H2O were 
added for extraction of steroids. First, the tubes were placed in an ultra-sonic bath 
for 10 min, followed by 15 min head-over-head mixing. The tubes were centrifuged at 
3000 x g for 10 min, the supernatant was transferred into glass vials and diluted five 
times with  PBST buffer (9 g NaCl,  0.76 g Na2HPO4, 0.17g KH2PO4, 2 mL Tween-20 
25%  in 1 L H2O) from which 100 µL was used in the BioMS assay for screening and 
identification purposes. 
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BioMS screening
First, 100 µL of PBST was added to each well of a 96-well flat-bottom plate, followed 
by the addition of 6 µL of ERα-coated  Ni2+- or COOH-beads. Then, the Milliplex 
magnetic plate (Millipore, Bedford, MA, USA) was used to magnetise the beads 
against the well wall in one min after which the supernatants were removed. 
Next, 0.5 ng of label (13C2,15N-Tamo) in 100 µL PBST (with or without addition of 
competing estrogens) was added to the wells. To construct dose-response curves, 
various competitors were added between 0 and 1000 ng. In case of screening of 
supplement extracts, 0.5 ng of label in 100 µL supplement extract (five times diluted) 
was added to the beads in the wells. Following the addition of the label, the mixture 
was incubated for 15 min on a shaker at 500 rpm (Dynatech Alexandria, VI, USA). 
To remove the unbound label and unbound competitors, the automatic magnet wash 
station was used to wash the 96-well plate three times with PBST buffer. After the 
wash cycle, 70 µL PBST buffer were added to each well, and the content of each 
well was transferred by an eight-channel pipette into a new 96-well flat-bottom plate. 
This step was done prior to the elution step, in order to exclude non-specific binding 
of competitors to the surface of the well-plate. The well-plate was placed on the 
magnetic plate, and after 1 min, the supernatants were removed. To elute all bound 
label and bound competitors, 50 µL of elution solution (H2O/ACN/HCOOH, 49/50/1 
%, v/v/v) was added to the wells, and the plate was shaken for 2 min (500 rpm). With 
the help of the magnetic plate, the supernatants with all the eluted compounds were 
transferred to a 384-well plate for rapid UPLC-QqQ-MS screening. The total duration 
of this BioMS assay procedure was 30 min for 96 samples. Dose-response curves 
were fitted using the five-parameter curve fitting in the GraphPad Prism software of 
GraphPad Software Inc. (La Jolla, CA, USA).
Bioaffinity isolation prior to chemical identification
The bioaffinity isolation procedure deviates from the BioMS screening by the use of 
five times more ERα-coated beads without label. So, 30 µL of ERα-coated beads 
(either Ni2+ or COOH) was added to the plate. After diluting the primary supplement 
extract in PBST, 100 µL were added to the plate, incubated for 15 min, and the same 
procedure was followed as described for the screening, except that the UPLC-IM-Q-
ToF-MS was used for identification. The total duration of this bioaffinity purification 
procedure was <30 min for 96 samples.  
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Results and Discussion
BioMS screening assay
The principle of the BioMS screening assay is based on competition between the 
13C2,15N-Tamo label and any known or unknown estrogenic compound in a sample 
for binding to the LBD of the ERα coupled to paramagnetic microbeads. The amount 
of label recovered by the elution solution decreases if a competing ERα binder, e.g. 
β-E2, is present in a sample. The limit of detection (LOD) of the 13C2,15N-Tamo label in 
the UPLC-QqQ-MS was determined as 500 fg on-column (S/N > 6). This estrogenic 
compound was chosen because of its very high ionisation efficiency in ESI+ due to 
the high proton affinity of its tertiary amine substructure. This is in sharp contrast to 
other estrogens, of which most are phenolic and show poor ionisation in both ESI+ 
and ESI–. During the development of the semi-automated BioMS screening assay, 
various parameters were optimised, such as LC conditions for the label, relative 
amounts of label and receptor required for reproducible measurements, influence of 
buffer composition and incubation, wash and elution conditions. After testing different 
amounts of label with different amounts of beads and elution solvents (data not 
shown), the optimum amount of added label was 0.5 ng per test when using H2O/
ACN/HCOOH (49/50/1 %, v/v/v) as the elution solvent. The optimum amounts of the 
two types of beads, oriented non-covalent immobilised His-tagged ERα onto Ni2+-
coated paramagnetic beads versus non-oriented covalent coupled ERα onto COOH-
coated paramagnetic beads, were investigated (see appendix 5.3). The absolute 
eluted amounts of label increased with increasing amounts of the two types of ERα-
coated beads (from 1 to 45 pg using 2 to 10 µL of ERα-coated Ni2+-beads and from 2 
to 55 pg using 2 to 10 µL of ERα-coated COOH-beads). The amount of label found in 
a negative control without any ERα-coated beads was close to the LOD, which proved 
that only the ER was responsible for capturing the label. The results in appendix 
5.3 demonstrate that, when ERα is immobilised in a non-oriented covalent manner, 
slightly higher label yields are obtained. It is important to note that the immobilisation 
procedure of Ni2+-beads is shorter than with COOH-beads (1 versus 3 h, see the 
appendix 5.1). The stability of ERα-coated beads stored at 4 °C was determined to be 
2 weeks for both bead types, which is in sharp contrast to non-immobilised ERα, which 
is stable for <1 day at 4 °C [18]. Further experiments proved that 6 µL of both types 
of ERα-coupled beads yielded reproducible label recoveries and, in the presence of 
estrogens, good competition. This means that, with each immobilised bead stock, 
83 tests can be performed, however, multiple bead stocks can easily be prepared 
in parallel. Typical reconstructed UPLC-QqQ-MS chromatograms of the eluted label 
from non-oriented covalently coupled ERα-coated beads (Figure 1) illustrate the fast 
analysis, with a total run time of 2 min, and the effect of a competitor on the amount 
of label measured with the BioMS screening assay. 
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Figure 1. Reconstructed UPLC-QqQ-MS SRM chromatograms showing the peak areas and retention 
time of the label (13C2,15N-Tamo) eluted from 6 µL of ERα-coated COOH beads in the absence (▲) and in 
the presence of 1 ng (▼) and 10 ng (•) of β-E2 as the competitor.  
Dose-response curves were constructed with ERα-coated COOH-beads for different 
estrogenic compounds in buffer (Figure 2). 
Figure 2. Normalized average dose-response curves (n=2) for α-E2 (▲), β-E2 (▼), EE2 (●), DES (x) and 
BPA (+) in PBST buffer obtained by the BioMS screening assay using 6 µL of ERα-coated COOH beads 
and UPLC-QqQ-MS.
Sensitivities at 50% inhibiting concentration (IC50) were found to range from 4 
ng mL-1 (0.4 ng absolute) for EE2 as the strongest binder to 550 ng mL-1 (55 ng 
absolute) for BPA as the weakest binder, and all curves illustrate good precision of 
the method. For clarity, the dose-response curves of E1, E3, Tamo, Zon and Nar are 
not shown in this figure, but the calculated IC50 values are given in Table 1. The same 
dose-response curves were made with Ni2+-beads and in Table 1, all IC50 values are 
summarised. 
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In dietary supplements, intentionally added estrogenic compounds are typically 
present at high levels (60 to 1,800 µg g-1) [4,9] which would correspond to  final 
concentrations in the BioMS screening assay between 0.15 and 4.5 µg mL-1 which 
is far above the IC50 values obtained with the estrogens in the BioMS screening. 
The developed BioMS assay showed in general lower sensitivities compared with 
alternative receptor-based assays in the literature, such as the yeast estrogen 
bioassay (YEB), the tritium-label displacement method and the fluorescent 
polarisation (FP) competitive inhibition assay [22,34,20,35,36]. However, the BioMS 
sensitivities are more than adequate for the screening of estrogenic compounds 
in dietary supplements. Relative binding (RB) values for various ERα competitors 
(see Table 1) were calculated by dividing the IC50 value of β-E2 (RB=1) by those 
of other competitors and RB values <1 represent binders having  lower affinity 
towards ERα. In literature, affinities of ERα binders were investigated by the FP 
competitive inhibition assay, the SPR-based biosensor assay, the YEB and tritium-
labelled displacement approaches [22,34,20,35,36]. The calculated RB values 
from our BioMS screening method and the values obtained from literature compare 
generally well (Table 1): Similar weak and strong binders are found in the BioMS 
assay (EE2>β-E2>DES=E1>E3>BPA). The slightly lower IC50 values obtained with 
COOH-beads than those with the Ni2+-beads are possibly due to the influence of the 
different immobilisation approaches. 
BioMS screening of estrogens in dietary supplements
To investigate the performance of our new BioMS screening, 13 different dietary 
supplements, previously analyzed for the presence of estrogens by another BioMS 
method using sex hormone-binding globulin (SHBG) as a biorecognition element 
[29] and LC-MS/MS [9] or LC-Q-ToF-MS [4], were screened again using the newly 
developed BioMS screening method based on ERα (Figure 3). From the 13 dietary 
supplements, samples 1-10 were previously screened as blanks, and samples 11-
13 were expected to contain estrogenic compounds. Sample 11 is a herbal food 
supplement marketed as ‘a non-estrogenic mixture’ for the treatment of mild prostate 
cancer and is described by its manufacturer as a pharmaceutical that is tested for 
toxicity in a trial with prostate cancer patients. However, this supplement showed a 
strong effect in the yeast estrogen bioassay [4] and by using LC-ToF-MS method, 
this was caused by very high levels of DES (4.1 ± 0.1 mg g-1). Sample 12 is a suspect 
dietary supplement that was ordered via the Internet, intercepted by the Belgian 
inspection at the post-office and when analyzed with conventional LC-MS/MS, the 
results revealed the presence of several steroids including β-E2 [9]. Indeed that 
steroid was also screened suspect with the SHBG-based BioMS approach [29]. The 
third suspect sample (sample 13) was a birth control pill containing 30 µg EE2 per 
pill.
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Figure 3. BioMS screening results of blank (sample 1 to 10) and positive (sample 11 to 13) dietary 
supplements (using ERα-coated Ni2+- (black bars) and COOH-beads (grey bars)). Data are the mean of 
duplicate analysis (dash line shows the level of decision for both bead types). 
Figure 3 shows the screening results of the BioMS using both ERα-coated Ni2+- and 
COOH-beads. The BioMS assay results show that the blanks gave average eluted 
amounts of label of 51±10 and 42±7 pg using ERα-coated COOH- and Ni2+-beads, 
respectively. Decision levels calculated from these data (average minus 3 times SD) 
indicate that label levels below 21 pg pinpoint to suspect samples for both types of 
beads. Indeed, the known suspect samples gave eluted amounts of label below that 
decision level (7±4 and 6±2 pg for the ERα COOH- and Ni2+-beads, respectively). 
Since phytosterols and phytoestrogens may occur in sports supplements, the 
potential binding of these compounds to ERα was investigated. The labels of 
supplements 3 and 8 declared the presence of 10 mg of phytosterols β-sitosterol, 
campesterol and stigmaterol. As these supplements were screened as blanks, no 
false-positive results are obtained in the BioMS screening by the presence of 10 
mg/pill phytosterol in dietary supplements. The affinities of phytoestrogens such as 
daidzein, genistein, enterolactone and equol are reported to range from very low 
affinity to no affinity towards ERα [22,23] causing no false positive results in the 
BioMS screening. Phytoestrogens such as genistein and daidzein bind to ERα when 
high amounts of ERα are used (e.g. 20 µg) [21], however in the BioMS screening, 
<0.6 µg was used. The results show that the BioMS screening assay using 13C2,15N-
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Tamo as a label and fast UPLC-QqQ-MS as a read-out system is fit for purpose of 
screening any (un)known estrogens in dietary supplements. 
BioMS chemical identification of estrogens
In this study, a UPLC-IM-Q-ToF-MS system equipped with a novel API source was 
used. The ionisation mechanism is based on a high-velocity droplet stream impacting 
on a high-voltage electrode. An image of the novel ion source is included in appendix 
5.2. A major advantage of such a “multi-source” is that it ionises a wide range of 
polarities in a single chromatographic run without switching between ESI and APCI. 
Compared to state-of-the-art ESI, higher ionisation efficiencies were obtained in 
both negative (see appendix 5.4) and positive ion modes [32]. The UPLC-IM-Q-ToF-
MS system also acquires ion mobility drift time data from which CCS values can be 
derived, which offer an additional orthogonal identification point next to retention 
time, accurate mass and MS/MS data. The experimental CCS values and can be 
compared with the theoretical CCS values from modelling software (e.g. MOBCAL). 
As an example, Figure 4 shows typical UPLC-IM-Q-ToF-MS reconstructed accurate 
mass ion chromatograms, highlighting the fast and good separation, even for isobaric 
estrogen isomers, including the accompanying ion mobility drift times. Additionally, 
Figure 5 illustrates a 3D view of retention times and ion mobility drift times of a 
standard mixture of DES, EE2 and β-E2.
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Figure 4. Reconstructed UPLC-IM-Q-ToF-MS ion chromatograms (within ± 0-2 ppm window) of (A) DES, 
(B) EE2 and (C) the isomers β-E2 and α-E2 (all standards, 1 ng on-column) and of DES (D) in the extract 
of suspect sample nr 11. 
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Figure 5. 3D view of retention and ion mobility drift times (within m/z 200-350) of a standard mixture of 10 
ng mL-1 β-E2, EE2 and DES analyzed by the UPLC-IM-Q-ToF-MS system.  
In Table 2, all identification results for estrogens in the suspect dietary supplements 
obtained by UPLC-IM-Q-ToF-MS are summarised and compared with literature 
data [4,9]. All suspect samples were subjected to identification using both ERα-
coated Ni2+- and COOH-beads, and two different biopurified extracts were prepared: 
“screening extracts” (using the normal amount of beads plus label) and “dedicated 
identification extracts” (i.e. five times more beads without the addition of label). The 
screening extracts were used for rapid identification, and the identification extracts 
were prepared to increase the chance to detect compounds having very low RB 
values in the BioMS approach. In the three positive samples of Figure 3, β-E2, EE2 
and DES were identified on basis of retention time, accurate mass and MS/MS 
spectra (in accurate product ion scanning mode), ion mobility drift times and CCS 
values. 
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Table 2 demonstrates that both in screening and identification extracts, β-E2 (in 
sample 12), EE2 (in sample 13) and DES (in sample 11) were identified. This means 
that, for screening and identification of strong ERα-binders, the leftover from the 
screening extract is sufficient for unambiguous identification. Only a slight difference 
was observed between the results obtained with screening and identification extracts. 
Measuring the screening extracts in MSe mode, only the most abundant product 
ion was detected for β-E2, EE2 and DES (m/z 145.065, 145.071 and 251.113, 
respectively). However, when the identification extracts were measured in MSe 
mode, two specific ion products were detected for β-E2 (m/z 145.065, 183.080), EE2 
(m/z 145.071, 159.086) and DES (m/z 251.113, 237.087) [37,38]. In contrast to the 
MSe results, in accurate mass product ion scanning mode, the two specific product 
ions for each estrogen were measured in both screening and identification extracts. 
Furthermore, no significant difference was observed between the identification 
results obtained with ERα-coated Ni2+- or COOH-beads. By using the drift times, 
experimental CCS values were calculated based on polyalanine calibration and 
compared with theoretical CCS value for β-E2 (Table 2). The latter was adapted 
from Shimizu et al. [39] who used MOBCAL with Trajectory Method to calculate a 
theoretical CCS value of 99.38 Å2, only 7% higher than the experimentally determined 
CCS value for β-E2 (92.27 Å2) in this work. It is important to note that the theoretical 
CCS values are significantly affected by error ratios in the modelling, especially for 
small molecules [40,41]. The experimental CCS values of the estrogens in standard 
solutions were similar to the experimental CCS values in the suspect samples 
(only 1–2% deviation). Increasing CCS values were calculated for increasing larger 
molecules: DES (m/z 267.1385: 91.20 Å2), β-E2 (m/z 271.1698: 92.27 Å2) and EE2 
(m/z 295.1169: 96.36 Å2). Although CCS values for DES and β-E2 are close to each 
other, further discrimination between these estrogens was easily achieved with the 
help of retention time and accurate mass acquired in full-scan mode with UPLC-IM-
Q-ToF-MS. 
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Conclusions
In this study, we demonstrated that, by using 13C2,15N-Tamo as ESI+ label in a mass 
spectrometric ligand binding assay, the developed BioMS approach is able to screen 
(un)known estrogens despite their poor ionisation efficiency in ESI [31,30]. For 
rapid screening, ERα was successfully immobilised using either oriented or non-
oriented approaches onto paramagnetic microbeads, and the BioMS assay was 
successfully demonstrated by screening for the ERα ligands DES, EE2 and β-E2 in 
dietary supplements. The method features ultrahigh-throughput (the entire sample 
treatment, BioMS assay and measuring time was <3h for 96 tests) and the possibility 
to use even the leftover from the BioMS screening extract for subsequent rapid 
(<5h for 96 tests) identification using UPLC-IM-Q-ToF-MS. This instrument provided 
excellent sensitivity using a novel API source and an additional identification point 
(experimental CCS value) next to retention time, accurate mass and MS/MS data. 
Thus, the combination of rapid bioaffinity screening using UPLC-QqQ-MS and 
identification with UPLC-IM-Q-ToF-MS is an extremely powerful analytical tool for 
early warning of ERα bioactive steroids in dietary supplements.
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Appendix 5.1
Covalent immobilisation of ERα
SiMAG-carboxyl paramagnetic microbeads of 1 µm (having a maghemite core and 
a non-porous silica surface containing propyl linkers on which carboxyl groups are 
immobilised) were used in this study because of their proven high coupling efficiency 
for proteins. The LBD of the ERα was immobilised randomly by covalent bond 
formation between its amino groups and the carboxyl groups on the bead surface. 
For this immobilisation, the carbodiimide coupling protocol of Chemicell (“Covalent 
Coupling Procedure in SiMAG-Carboxyl by Carbodiimide Method”) was used. In short, 
the beads suspended in storage solution were vortexed for 15 min and 200 µL of the 
bead stock was transferred to a LoBind tube which was then placed in the magnetic 
rack for 1 min. The supernatant was removed and the pellet was washed twice with 
1 mL 0.1 M MES buffer (pH 5) using the magnetic rack. For activation of the bead 
surface, the pellet was resuspended in 0.25 mL MES containing 10 mg EDC (prepared 
freshly). This mixture was mixed by rotating for 10 min at room temperature (RT). 
After the activation of the beads, the mixture was washed twice with 1 mL MES buffer 
and resuspended again in 0.25 mL MES buffer. Subsequently, 50 µg of the LBD of 
ERα was added to the activated beads and this mixture was incubated for 2 h by 
mixing with the rotator at RT. After incubation, the unbound ERα in the supernatant 
was removed by using the magnetic rack and the beads with covalently coupled ERα 
were washed three times with 1 mL PBS (5.4 mM Na2HPO4, 1.3 mM KH2PO4, 150 mM 
NaCl, 3 mM KCl, pH 7.4). Finally, the ERα-coated beads were resuspended in 0.5 mL 
of PBS containing 0.05% sodium azide and stored at 4 °C. 
Non-covalent immobilisation of ERα
 
SiMAG-IDA/Nickel paramagnetic microbeads of 1 µm (having a maghemite core and 
a non-porous silica surface on which Ni2+-metal complex is formed with iminodiacetic 
acid) were used for oriented non-covalent immobilisation of the LBD of ERα. The 
immobilisation is based on the His-tag sequence of the ER which binds to the Ni2+ 
cations on the beads. The protocol of Chemicell (“Purification of 6xHis-tagged proteins 
with magnetic SiMAG-IDA/Nickel particles”) was used with slight modifications. In 
short, the beads were vortexed for 15 min and then 1 mL of the SiMAG-IDA/Nickel 
bead stock is transferred to a LoBind tube which was then placed in the magnetic rack 
for 1 min. The supernatant was removed and the pellet was washed three times with 
0.5 mL Wash & Binding buffer ((WB buffer) 500 mM NaCl, 100 mM HEPES, 20 mM 
imidazole, pH 8.0). After the last wash step, the beads were resuspended in 0.5 mL of 
WB buffer. Subsequently, 50 µg of ERα was added to the beads and mixed gently for 
30 min at RT. After incubation, the unbound ERα in the supernatant was removed and 
the beads with non-covalently bound ERα were washed three times with WB buffer. 
Finally, the ERα-coated beads were resuspended in 0.5 mL of PBS containing 0.05% 
sodium azide and stored at 4 °C.
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Appendix 5.2
Photograph of a novel API source prototype showing the high-velocity droplet stream 
impacting on a high-voltage electrode. 
Appendix 5.3
Average eluted amounts (n = 2) of 13C2,15N-Tamo label from different volumes of 
ERα-coated Ni2+-beads (black bars) and COOH-beads (grey bars) suspensions 
incubated with 0.5 ng of the label and measured by UPLC-QqQ-MS.
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Appendix 5.4
 
Peak areas obtained with the novel API source in negative ionisation mode (grey 
bar) relative to ESI in negative mode (black bars) for estrogen standards at the 10 
ng mL-1 level. 
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General discussion 
Looking at the history of monitoring programs, it is quite imaginable that in sports and 
animal farming new unknown compounds are being used which are at the moment 
undetectable in the existing screening or confirmatory methods [1-5]. Therefore, 
the main goal in this thesis was to develop bioaffinity mass spectrometry (BioMS) 
concepts for the screening and identification of known and unknown contaminants 
in the environment and food. In Chapter 2, such a concept is described by using 
fluorescent labeled superparamagnetic microbeads coated with specific anti-
ochratoxin A (OTA) monoclonal antibodies (Mabs) in a novel direct inhibition flow 
cytometric immunoassay (FCIA) for high-throughput screening (HTS) of ochratoxins 
in wheat and cereal samples at relevant levels. The same anti-OTA Mabs-coated 
beads were used for immunoaffinity isolation prior to identification by nano-ultra 
performance-liquid chromatography-quadrupole-time-of-flight-mass spectrometry 
(nano-UPLC-Q-ToF-MS) in full scan accurate mass mode. In this mode, next to OTA, 
the analogue ochratoxin B was identified in cereal samples. By using nano-UPLC-
Q-ToF-MS, not only the consumption of costly bioreagents decreased significantly, 
it was also made plausible that unlike targeted MS MRM mode, full scan accurate 
mass MS is able to detect known and unknown contaminants in affinity purified 
extracts. Next to the advantages of this approach, there was the serious issue 
of the expensive Luminex®-compatible paramagnetic beads. For screening, the 
consumption of the antibody-bound beads was negligible (1000 beads or €0.04/
sample). However, this amount of beads did not capture ochratoxins at detectable 
amounts for the nano-UPLC-Q-ToF-MS system. Therefore, 350 times more coupled 
beads had to be used for the identification which raised the bead costs to €14/
sample excluding the Mabs costs. In that approach, the nano-UPLC-Q-ToF-MS 
system was used after an immunoaffinity extraction and that system presented 
several challenges which included leakages (which were not detectable due to the 
low flow rate), clogging and serious dead volumes between connections which all 
contributed to difficult handling of the system and relatively poor chromatographic 
performance. For screening multiple mycotoxins, such as fumonisins, zearalenone 
and aflatoxins, in one assay, Mabs for each mycotoxin could be used for specific 
bioisolation. These Mabs can be immobilized on different Luminex®-bead sets 
making the simultaneous screening of several mycotoxins possible. Following the 
screening, the same Mabs-coated beads could be used in a simultaneous bioisolation 
procedure of the mycotoxins for identification purposes with LC-MS. Similarly, the 
described screening method may be extended to screen masked or conjugated 
mycotoxins, which can escape routine methods [6, 7], by using other or additional 
biorecognition elements. For the analysis of thyroid transporter ligands, a BioMS 
concept is described in Chapter 3 with three different analytical purposes: screening, 
confirmation and identification. In order to avoid the usage of any fluorescent reporter 
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molecule and expensive Luminex®-compatible paramagnetic beads, a stable 
isotopic thyroid hormone 13C6-L-thyroxine was used as label in a competitive inhibition 
format and the biomolecule recombinant transthyretin (rTTR) was used immobilized 
onto inexpensive paramagnetic microbeads and in solution using cut-off filters. For 
screening and confirmation of endocrine disrupting chemicals (EDCs) in process 
water (at ppt level) and urine (at ppb level), a fast UPLC-triple quadrupole (QqQ)-MS 
was used as readout system and for identification nano-UPLC-Q-ToF-MS in full scan 
mass mode. All extracts were biopurified using the same biorecognition element in 
screening, confirmation and identification. However, due to the use of test tubes in 
the assay, HTS was not feasible regardless whether rTTR-coated beads were used 
or cut-off filters. In best case, 40 samples could be assayed and measured in 8 hours 
despite the short runtime of the measurement (2 min/sample) with UPLC-QqQ-MS. 
This problem could be overcome by switching to 96-well plate assay format. Another 
challenge in this method was to screen thyroxine (T4) in water at ppt level (i.e. ng 
L-1). The IC50 values of T4 obtained with the competitive inhibition assay was 1000 
times too high for screening at ppt level. This challenge was tackle by applying a 
lengthy solid-phase extraction (SPE) procedure consisting of two different SPE 
columns to concentrate T4 from ppt level to ppb level. Although this SPE procedure 
made the screening of T4 possible, the total sample preparation time was increased 
significantly as the procedure including evaporation steps needed >5 hours. Since 
the same nano-UPLC-Q-ToF-MS system was used as described in Chapter 2, the 
same issues with the nano-UPLC were experienced for the identification of EDCs 
in full scan accurate mass mode. In this research, the screening of several EDCs 
is demonstrated while the list of hazardous EDCs found in the environment is long. 
For example, recently, the German section of Friends of the Earth published a study 
which concluded that nearly a third of cosmetic products in Germany, Austria and 
Switzerland contain EDCs such as parabens [8]. The described screening method 
should be extended to a large group of EDCs. This could be achieved by using new 
TTR types. By using different mutant types of TTR, a wide range of EDCs could be 
detected while maintaining the single-isotope label based screening approach. By 
using mutant types of TTR, the detection of new emerging EDCs will be possible 
while the measurement time is kept short (i.e. 2 min/sample) by using LC-MS for 
screening instead of conventional GC-MS. In Chapter 4, a generic high-throughput 
BioMS approach was developed and applied for the screening and identification of 
known and unknown recombinant human sex-hormone binding globulin (rhSHBG)-
binding designer steroids in dietary supplements. In this method, screening was 
performed using 17β-testosterone-d3 as stable isotopic MS label and the previously 
described paramagnetic microbeads were used for immobilizing rhSHBG onto the 
bead surface. The same UPLC-QqQ-MS system was used for screening while 
for identification chip-UPLC-Q-ToF-MS was used for superior chromatographic 
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performances and sensitivity. The latter system did not have the typical practical 
issues as the nano-LC system. The entire sample treatment, BioMS assay and 
measuring time was 4h for 96 tests. Next to multiple androgens, an estrogen and 
a gestagen, also the steroid β-1-T was screened and identified in three samples 
previously found negative in targeted LC-MS/MS. Additionally, the designer steroid 
tetrahydrogestrinone was screened and identified in a spiked dietary supplement. 
Any strong binder was successfully identified on basis of retention time, accurate 
mass and product ion spectra. To identify additionally less potent rhSHBG binders in 
dietary supplements, ten times more rhSHBG was applied in an adjusted bioaffinity 
procedure. This BioMS approach is generic and very fast as multiple androgens, 
an estrogen and a gestagen were identified using solely one transport protein. To 
test the applicability of this BioMS approach to screen and identify SHBG binders 
in bovine urine, the affinity of various natural occurring hormones in bovine urine 
were tested. It was found that some of these natural compounds have high affinity 
towards SHBG. Due to this, screening bovine or human urine for steroids is not 
possible, but, screening of calf urine should be feasible since the calf urine contains 
natural hormones at lower levels [9]. The screening of calf urine using SHBG was 
not tested yet in this research. Further, it was found that steroid metabolites in bovine 
urine, cannot be screened as they showed very low or no affinity towards SHBG. 
Another matrix, which could contain SHBG binders making the screening of steroids 
impossible, is feed. This matrix contains large amount of ingredients originating 
from plants which contain equol [10, 11]. This compound is a metabolite from the 
isoflavone daidzein and showed a relative binding affinity of 0.4 towards SHBG 
while 17β-testosterone has a relative binding affinity of 1. As a future experiment, the 
coupling of the TrizaicTM interface to an UPLC-QqQ-MS should be investigated. By this 
coupling, superior chromatographic performances and sensitivities can be achieved 
for e.g. steroids, while confirmatory or quantification analysis in agreement with EU 
legislation is feasible. Since SHBG was able to bind few estrogens, another high-
throughput bioaffinity LC-MS approach was developed in Chapter 5 for estrogens in 
dietary supplements using the estrogens receptor α (ERα). The highly unstable ERα 
was stabilized by immobilizing it onto the surface of paramagnetic microbeads and 
with this method, instead of GC-MS, UPLC-QqQ-MS was used for the screening of 
estrogens by using a suitable LC-MS-compatible label. In this way derivatization and 
a long run time, which are related to GC-MS, were avoided [12, 13]. The identification 
of estrogens in ERα-purified supplement extracts was achieved by using a UPLC-ion 
mobility (IM)-Q-ToF-MS which gave next to retention times, experimental accurate 
mass, MS/MS data also specific drift times. To extend this BioMS to other matrices 
such as bovine urine or feed, there are serious limitations which are similar to the 
SHBG BioMS method. Both in bovine urine and in feed, there are ERα-binders, i.e. 
natural hormones in bovine urine and phytoestrogens in feed, which could interfere 
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with the screening. Moreover, if the ERα is not produced in-house or delivered by 
partners, the assay costs of this method are very high. The commercial price of 50 
µg ERα is >€1000 which can be used for screening of only 80 samples. The use of 
IM helps to identify known and unknown compounds. Not only, the commercially 
available UPLC-IM-Q-ToF-MS system adds an additional identification point in drift 
times, it also proved to be simple in use. Another advantage is the separation of 
isomers of contaminants by IM which could make the chromatographic separation of 
compounds less important [14, 15]. By this, fast chromatography could be feasible 
which contributes to high-throughput measurement.  
Future Perspectives
Generally, the described BioMS methods were able to screen contaminants at 
>10 ppb level. Only compounds having high affinity towards the biorecognition 
element could be screened at <10 ppb level. Regarding the EU legislation for certain 
compounds, screening at low ppb levels is required. To improve the sensitivity of 
the BioMS screening methods, there are two major factors which influence the 
sensitivity. The sensitivity of the screening instrument is important. The lower the 
limit of detection (LoD) of the isotope label is, the lower amount of the biorecognition 
element is required during screening. When the amount of biorecognition element is 
decreased during screening, lower amounts of competing contaminants are needed 
to compete with the label. In this thesis, the LoDs of isotope labels were generally at 
the low pg levels and the concentration of the used biorecognition element were at 
low nM levels. If the label LoD would be at <fg levels and with that the biorecognition 
element concentration at <pM, screening at 1 ppb level might be achieved. Another 
way to improve the BioMS screening sensitivity is to choose an isotope label which 
has low relative binding (RB) affinity towards the biorecognition element. In the 
BioMS screening of SHBG-binders, 17β-testosterone-d3 was used as label which 
was one of the strongest binders (RB value of 1). By selecting a weaker binder, e.g. 
β-boldenone having an RB value of 0.6 as label, lower amounts of competing SHBG-
binders are needed to compete with the label which could improve the screening 
sensitivity. It is important to note that the choice of isotope label having a low RB 
value and the amount of biorecognition element could increase the rate of false non-
compliant results. In order to be able to screen feed samples, which contain high 
levels of phytoestrogens, for steroids, a specific sample treatment step is required to 
separate the phytoestrogens from the steroids. Since phytoestrogens have similar 
molecular structures as 17β-estradiol or other steroids, it is difficult to separate them 
during a chemical extraction procedure. Therefore, following a primary extraction of 
the feed sample, a bioaffinity extraction procedure could be applied which can isolate 
the most abundant phytoestrogens such as isoflavones or coumestans. After this 
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procedure, the feed extract which should contain low amounts of phytoestrogens can 
be subjected to the BioMS screening methods. To investigate the feasibility of BioMS 
to screen steroid metabolites, the affinity of testosterone-glucuronide or estradiol-
sulphate which are present in bovine urine were determined. It was found that these 
metabolites had no affinity or very low affinity towards SHBG or ERα. A specific 
hydrolysis step, which converts the metabolites back to the parent compound, might 
enable the screening of steroid metabolites [16-18]. In general, all the concepts 
presented in this thesis, can easily be extended for screening and identification 
of a wide range of contaminants. In a next research, to develop a comprehensive 
screening method, combining various biorecognition elements in one assay is an 
interesting next step. Coccidiostats are the only veterinary drugs still permitted to be 
used as feed additives to treat poultry for coccidiosis. Currently, LC-MS is used for 
multi-analyte screening of coccidiostats in chicken liver [19], eggs and feed [20, 21]. 
In the literature a five-plex flow cytometric-based screening assay is described for 
coccidiostats in eggs and feed which used polyclonal antibodies [22]. These antibodies 
could be used in a BioMS screening for coccidiostats at relevant levels. This BioMS 
screening method could use one kind of paramagnetic beads on which five different 
polyclonal antibodies are immobilized separately. Each antibody-coated bead assay 
requires an isotope label which can be measured with a fast UPLC-QqQ-MS system 
for screening of known and unknown cross-reacting coccidiostats. The subsequent 
identification could be performed, following a bioisolation procedure using the same 
antibody-coated beads in combination with an LC-MS in full scan accurate mass 
mode. A multi-sulfonamide antibody having equal affinity towards sulfamethoxazole 
and sulfadiazine was used to develop a biosensor screening assay for serum and 
plasma samples obtained from the broilers [23]. This multi-sulfonamide antibody 
proved to have affinity towards ten sulfonamides in total which makes it an interesting 
biorecognition element. Using this antibody immobilized onto magnetic beads for 
BioMS screening of sulfonamides, only one suitable isotope label is required. This 
means that the UPLC-QqQ-MS run time remains short (e.g. 2 min/sample) making 
high-throughput screening more feasible. After screening, the same antibody-coated 
beads can be used for isolating the sulfonamides for identification purposes. The 
β2-adrenergic receptor binds several β-agonists including clenbuterol, salmeterol 
and salbutamol [24]. At RIKILT, a radiolabel assay is developed for the screening 
of β-agonists in feed. To avoid the use of radiolabel, this method could be replaced 
by a BioMS screening assay. As isotope label clenbuterol-d6 could be used which 
can be measured at pg level with UPLC-QqQ-MS and LC-MS operated full scan 
accurate mass mode could be used for identifying β2-adrenergic receptor binders 
in biopurified feed extracts. By using anti-mycotoxin Mabs, TTR, β2-adrenergic 
receptor and SHBG and their accompanying MS labels, the bioactivity-based 
screening of mycotoxins, EDCs, β-agonists, androgens, estrogens and gestagens 
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could be feasible by measuring merely several labels in single reaction monitoring 
(SRM) mode. This approach will be rapid not only in terms of assay time but also 
the LC-MS run time could be 2 min/sample while the screening of a wide range of 
compounds is achieved. In this way, also the rapid screening of contaminants which 
are not LC-MS compatible will be possible avoiding any derivatization or lengthy 
GC-MS run time. This comprehensive BioMS screening method is able to screen 
both known and unknown cross-reactive contaminants in food and environmental 
samples. The same biorecognition elements as in screening could be used for 
subsequent identification of contaminants using chip-UPLC-IM-Q-ToF-MS. 
The results described in this thesis demonstrate the power of bioactivity-based 
screening combined with mass spectrometric identification. This ideal combination 
proved to be suitable to screen and identify contaminants which otherwise would 
be missed by conventional instrumental analysis. By further improving these 
bioaffinity mass spectrometry concepts, by multiplexing and validation, existing 
food and environmental contaminants can be monitored comprehensively while 
maintaining the abilities to detect new emerging contaminants. Consequently, these 
new bioaffinity mass spectrometry concepts present new tools for the screening 
and identification of emerging yet unknown food and environmental contaminants to 
ensure consumer’s health and fair play in sports. 
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Summary
Our environment is constantly threatened by large amounts of man-made chemicals 
and natural substances. Parts of these substances accumulate and contaminate soil 
and surface water, affecting the organisms living in it and eventually contaminate the 
food chain. The European Union (EU) has imposed regulations and obliged EU 
member states to monitor for possible contaminants in the environment and food. 
For this, highly sophisticated mass spectrometry (MS) techniques are developed 
which can screen >100 contaminants in a single run. For rapid and inexpensive 
screening of contaminants, bioactivity-based screening assays are applied, however, 
identification of compounds based on their chemical-physical properties is not 
possible. As both methods cannot identify emerging and unknown bioactive 
contaminants, there is a need for new tools and concepts. This thesis describes new 
bioaffinity mass spectrometry concepts for the screening and identification of food 
and environmental contaminants. For this, various biorecognition elements, such as 
an antibody, transport proteins and a receptor were used for bioaffinity isolation 
procedures of contaminants from various matrices. Several liquid-chromatography 
MS (LC-MS) systems were used in either pre-selected mass mode for screening or 
in full scan accurate mass mode for identification of contaminants. In Chapter 2, a 
concept is demonstrated using superparamagnetic microbeads coated with 
monoclonal antibodies (Mabs) in a novel direct inhibition Luminex® flow cytometric 
immunoassay (FCIA) plus immunoaffinity isolation prior to identification by nano-
ultra-performance-LC-quadrupole-time-of-flight-MS (nano-UPLC-Q-ToF-MS). As a 
model system, the mycotoxin ochratoxin A (OTA) and cross-reacting mycotoxin 
analogues were analyzed in wheat and cereal samples, after a simple extraction, 
using the FCIA with anti-OTA Mabs coated microbeads. In the immunomagnetic 
isolation method, a higher amount of beads was used to trap ochratoxins from 
sample extracts. Following a wash step, bound ochratoxins were dissociated from 
the Mabs prior to separation plus identification with nano-UPLC-Q-ToF-MS system. 
In screened suspect naturally contaminated samples, OTA and its non-chlorinated 
analogue ochratoxin B were successfully identified by full scan accurate mass 
spectrometry as a proof of concept for identification of unknown but cross-reacting 
emerging mycotoxins. Due to the miniaturization and bioaffinity isolation, this concept 
might be applicable for the use of other and more expensive bioreagents such as 
transport proteins and receptors for screening and identification of known and 
unknown (or masked) emerging food contaminants. In another study, a new 
competitive inhibition concept was developed in which LC-MS was used for both 
screening and identification. In this concept, Luminex was no longer used for 
screening as Luminex®-compatible microbeads are expensive and the use of the 
fluorescent reporter molecule was a disadvantage. Therefore, in Chapter 3 new 
inexpensive paramagnetic beads were used together with a stable isotopic mass 
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spectrometric label for the analysis of thyroid transporter ligands. A triple bioaffinity 
mass spectrometry (BioMS) concept was developed aiming at three different 
analytical objectives: rapid screening of any ligand, confirmation of known ligands in 
accordance with legislative requirements and identification of emerging yet unknown 
ligands. These three purposes shared the same bio-recognition element, recombinant 
thyroid transport protein transthyretin (rTTR), and dedicated modes of LC-MS. For 
screening, a rapid and radiolabel-free competitive inhibition MS binding assay was 
developed with fast UPLC-electrospray ionization-triple-Q-MS (UPLC-QqQ-MS) as 
readout system. It used the non-radioactive stable isotopic thyroid hormone 13C6-L-
thyroxine as label of which the binding to rTTR is inhibited by any ligand such as 
thyroid drugs and thyroid endocrine disrupting chemicals (EDCs). The rTTR was 
either used in solution or immobilized on paramagnetic microbeads. The 
concentration-dependent inhibition of the label by the natural thyroid hormone 
L-thyroxine (T4), as a model analyte, was demonstrated in water at part-per-trillion 
and in urine at part-per-billion level. For confirmation of identity of known ligands, 
rTTR was used for bioaffinity purification for confirmation of naturally present free T4 
in urine. As a demonstrator for identification of unknown ligands, the same rTTR was 
used again, but in combination with nano-UPLC-Q-ToF-MS and urine samples 
spiked with the model ‘unknown’ EDCs triclosan and tetrabromobisphenol-A. This 
study highlighted the potential of BioMS using one affinity system, both for rapid 
screening as well as for confirmation and identification of known and unknown 
emerging thyroid EDCs. However, this BioMS concept was considered low-
throughput. Therefore, in Chapter 4, a switch was made from low-throughput to 
high-throughput screening and identification. A generic high-throughput BioMS 
approach was developed and applied for the screening and identification of known 
and unknown recombinant human sex hormone-binding globulin (rhSHBG)-binding 
steroids in dietary supplements. For screening, a semi-automated competitive 
inhibition binding assay was combined with fast UPLC-QqQ-MS. The assay was 
performed in a 96-well plate and combined with the fast LC-MS, 96 measurements 
could be performed in 4 h. The concentration-dependent inhibition of the label by 
steroids in dietary supplements was demonstrated. Following an adjusted bioaffinity 
isolation procedure, suspect sample extracts were injected into a chip-UPLC 
(NanoTileTM)-Q-ToF-MS system for full scan accurate mass identification. Next to 
known steroids, 1-testosterone was identified in three of the supplements studied 
and the designer steroid tetrahydrogestrinone was identified in a spiked supplement. 
The generic steroid-binding assay can be used for high-throughput screening of 
androgens, estrogens and gestagens in dietary supplements to fight doping. When 
combined with chip-UPLC-MS, it is a powerful tool for early warning of unknown 
emerging rhSHBG bioactive designer steroids in dietary supplements. In Chapter 5, 
another high-throughput BioMS method was developed and applied for the screening 
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and identification of recombinant human estrogen receptor α (ERα) binders in dietary 
supplements. For screening, a semi-automated competitive inhibition binding assay 
was developed based on 13C2,15N-tamoxifen as a label and using fast UPLC-QqQ-
MS operated in the single reaction monitoring (SRM) mode as a readout system. 
The label, showed a high ionization efficiency in positive electrospray ionization 
(ESI) mode, so the developed BioMS approach was able to screen for estrogens in 
dietary supplements despite their poor ionization efficiency in both positive and 
negative ESI modes. The assay and the LC-MS measurements could be performed 
within 3 h for 96 tests. Estrogens in suspect extracts were identified by full scan 
accurate mass and collision-cross section (CCS) values from a UPLC-ion mobility 
(IM)-Q-ToF-MS equipped with a novel atmospheric pressure ionization source. 
Thanks to the novel ion source, this instrument provided picogram sensitivity for 
estrogens in the negative ion mode and an additional identification point (experimental 
CCS values) next to retention time, accurate mass and MS/MS data. The developed 
combination of bioaffinity screening with UPLC-QqQ-MS and identification with 
UPLC-IM-Q-ToF-MS provides an extremely powerful analytical tool for early warning 
of ERα bioactive compounds in dietary supplements as demonstrated by analysis of 
real-life supplement samples. In the last chapter (Chapter 6) the results obtained in 
this research are summarized and discussed and the future perspectives of the 
developed concepts are described. All the concepts presented in this thesis, can 
easily be extended for screening and identification of a wide range of contaminants. 
In a next research, to develop a comprehensive screening method, combining 
various biorecognition elements in one assay should be investigated. The results in 
this thesis demonstrate the power of bioactivity-based screening combined with 
mass spectrometric identification. This combination proved to be suitable to screen 
and identify contaminants which otherwise would remain undetected by conventional 
instrumental analysis. By Improving these bioaffinity mass spectrometry concepts, 
by multiplexing and validation, existing food and environmental contaminants can be 
monitored comprehensively while maintaining the abilities to detect new emerging 
contaminants. 
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Samenvatting
Ons milieu wordt constant bedreigd door grote hoeveelheden door de mens 
geproduceerde chemicaliën en natuurlijke stoffen. Bepaalde delen van deze stoffen 
accumuleren en contamineren de grond en oppervlaktewater waardoor organismen 
die in dit milieu leven worden getroffen en hierdoor wordt ook de voedselketen 
gecontamineerd. De Europese Unie (EU) heeft verplichte wetgeving opgelegd aan 
de EU-lidstaten om mogelijke contaminanten in voedsel en milieu te monitoren. Ten 
behoeve hiervan zijn er uiterst geavanceerde massaspectrometrie (MS) technieken 
ontwikkeld die >100 contaminanten kunnen screenen in een enkele meting. Voor 
snelle en goedkope screening van contaminanten worden doorgaans bioactiviteit-
gebaseerde screening testen toegepast die de identiteit van componenten niet 
kunnen vaststellen op basis van chemisch-fysische eigenschappen. Beide methoden 
kunnen opkomende onbekende bioactieve contaminanten niet identificeren en 
daarom is er behoefte aan nieuwe tools en concepten. Dit proefschrift beschrijft 
nieuwe bioaffiniteit MS concepten voor de screening en identificatie van voedsel- en 
milieucontaminanten. Hiervoor zijn verschillende bioherkenningselementen, zoals 
een antilichaam, transporteiwitten en een receptor gebruikt voor de bioactieve 
isolatie van contaminanten uit verscheidene matrixen. Meerdere 
vloeistofchromatografie-MS (LC-MS) systemen zijn gebruikt of in vooraf 
geselecteerde massa mode voor het screenen of in full scan accurate massa mode 
voor het identificeren van contaminanten. In Hoofdstuk 2 is een concept 
gedemonstreerd waarin superparamagnetische microbeads, die bedekt waren met 
monoklonale antilichamen (Mabs), werden gebruikt in een nieuwe directe verdringings 
Luminex® flow cytometrische immunoassay (FCIA) en dezelfde microbeads werden 
ook toegepast in een immunoaffiniteits isolatiemethode voor identificatie met nano-
ultra-performance-LC-quadrupool-time-of-flight-MS (nano-UPLC-Q-ToF-MS). Als 
een modelsysteem zijn de mycotoxine ochratoxine A (OTA) en de kruis-reagerende 
mycotoxine analogen geanalyseerd in tarwe en ontbijtgranen na een simpele 
extractie waarin de FCIA en anti-OTA Mabs bedekte microbeads werden gebruikt. In 
de immunomagnetische isolatiemethode werden grotere hoeveelheden beads 
gebruikt om de ochratoxinen te extraheren uit het monster. Na een wasstap werden 
de gebonden ochratoxinen gedissocieerd van de Mabs voorafgaande de scheiding 
en identificatie met het nano-UPLC-Q-ToF-MS systeem. In de verdacht gescreende 
natuurlijk gecontamineerde monsters, werden OTA en zijn niet-gechloreerde analoog 
ochratoxine B geïdentificeerd met behulp van full scan accurate MS als bewijs van 
het concept voor de identificatie van onbekende maar kruis-reagerende mycotoxines. 
Door de miniaturisatie en de bioaffiniteitisolatie, kan dit concept toegepast worden 
met andere bioreagentia zoals transporteiwitten en receptoren voor de screening en 
identificatie van bekende en onbekende (gemaskeerde) voedselcontaminanten. In 
een andere studie, werd een nieuw competitieve verdringingsconcept ontwikkeld 
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waarin LC-MS zowel voor screening als voor identificatie werd gebruikt. In dit 
concept, werd Luminex® niet meer toegepast voor de screening, vanwege de hoge 
prijzen van de Luminex®-compatibele microbeads en daarnaast was het gebruik van 
een fluorescente reporter molecuul ook een nadeel. Derhalve, werden in Hoofdstuk 
3 nieuwe goedkope paramagnetische beads gebruikt in combinatie met een stabiel 
isotoop MS label voor de analyse van thyroide transporter liganden. Een drievoudig 
bioaffiniteit MS (BioMS) concept werd ontwikkeld gericht op drie verschillende 
analytische doeleinden: snelle screening van elke ligand, bevestiging van bekende 
liganden in overeenstemming met de wettelijke vereisten en identificatie van 
aankomende onbekende liganden. Deze drie doeleinden deelden samen hetzelfde 
bioherkenningselement, het recombinante thyroide transporteiwit (rTTR), en 
specifieke LC-MS modes. Voor screening, werd een snelle radiolabel-vrije 
competitieve MS binding verdringingsassay ontwikkeld met snelle UPLC-electrospray 
ionisatie-triple-Q-MS (UPLC-QqQ-MS) als detectiesysteem. Deze methode gebruikte 
het niet-radioactieve isotopische thyroide hormoon 13C6-L-thyroxine als label waarvan 
de binding met rTTR verdrongen kon worden door elke ligand zoals thyroide 
medicijnen of thyroide hormoonverstorende chemicaliën (EDCs). De rTTR werd 
zowel in oplossing als geïmmobiliseerd op paramagnetische microbeads gebruikt. 
De concentratie-afhankelijke verdringing van het label, door het natuurlijke thyroide 
hormoon L-thyroxine (T4) als model analyt, is gedemonstreerd op part-per-trillion 
(ppt) niveau en in urine op part-per-billion (ppb) niveau. Voor bevestiging van de 
identiteit van bekende liganden werd rTTR gebruikt voor een bioaffiniteit zuivering 
voor de bevestiging van het natuurlijk aanwezige vrije T4 in urine. Ter demonstratie 
van identificatie van onbekende liganden werd hetzelfde rTTR wederom gebruikt in 
combinatie met nano-UPLC-Q-ToF-MS en urinemonsters gespiket met de model 
‘onbekende’ EDCs triclosan en tetrabromobisfenol-A. Deze studie benadrukte de 
potentie van BioMS waarin een affiniteitssysteem werd gebruikt voor snelle 
screening, bevestiging en identificatie van bekende en onbekende aankomende 
thyroide EDCs. Echter, dit BioMS concept was als low-throughput beschouwd en 
daarom werd in Hoofdstuk 4 een omschakeling gemaakt van low-throughput naar 
high-throughput screening en identificatie. Een generieke high-throughput BioMS 
methode werd ontwikkeld en toegepast voor de screening en identificatie van 
bekende en onbekende recombinante human sex hormone-binding globulin 
(rhSHBG) gebonden steroïden in voedingssupplementen. Voor screening werd een 
semi-geautomatiseerde competitieve verdringings bindingassay gecombineerd  met 
een snelle UPLC-QqQ-MS. De assay werd uitgevoerd in een 96-wellsplaat en 
gecombineerd met de snelle LC-MS konden 96 metingen worden gedaan binnen 4 
uur. De concentratie-afhankelijke verdringing van de label door steroïden in 
voedingssupplementen is gedemonstreerd. Na een aangepaste bioaffiniteits 
isolatieprocedure werden verdachte monsterextracten geïnjecteerd op een chip-
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UPLC (NanoTileTM)-Q-ToF-MS systeem voor full scan accurate massa identificatie. 
Naast de bekende steroïden, werd 1-testosterone geïdentificeerd in drie 
voedingssupplementen en de designer steroïde tetrahydrogestrinon werd 
geïdentificeerd in een gespikete supplement. De generieke steroïde-binding assay 
kan gebruikt worden voor high-throughput screening van androgenen, estrogenen 
en gestagenen in voedingssupplementen om doping tegen te gaan. Wanneer de test 
gecombineerd kan worden met chip-UPLC-MS, is deze een sterke tool voor 
vroegtijdige waarschuwing voor aankomende onbekende rhSHBG bioactieve 
designer steroïden in voedingssupplementen. In Hoofdstuk 5 werd een andere 
high-throughput BioMS methode ontwikkeld en toegepast voor de screening en 
identificatie van recombinante human estrogene receptor α (ERα) binders in 
voedingssupplementen. Voor screening werd een semi-geautomatiseerde 
competitieve verdring bindingassay ontwikkeld gebaseerd op 13C2,15N-tamoxifen als 
label en snelle UPLC-QqQ-MS ingesteld op single reaction monitoring (SRM) mode 
als detectiesysteem. Het gebruikte label vertoonde een hoge ionisatie-efficiëntie in 
positieve electrospray ionisatie (ESI) mode en daarom kon de ontwikkelde BioMS 
methode estrogenen screenen in voedingssupplementen ondanks hun slechte 
ionisatie-efficiëntie in zowel negatieve als positieve (ESI) modes. De assay samen 
met de LC-MS metingen konden worden uitgevoerd binnen 3 uur voor 96 monsters. 
Estrogenen in verdachte extracten werden geïdentificeerd met behulp van full scan 
accurate massa en collision-cross section (CCS) waarden werden verkregen van 
een UPLC-ion mobility (IM)-Q-ToF-MS voorzien van een nieuwe atmosferische druk 
ionisatiebron. Dankzij deze nieuwe ionisatiebron werden met dit instrument 
gevoeligheden op pictogram niveau behaald in negatieve ionisatie mode met een 
additionele identificatiepunt (experimentiele CCS waarden), naast retentietijden, 
accurate massa en MS/MS data. De ontwikkelde combinatie van bioaffiniteit 
screening met UPLC-QqQ-MS en identificatie met UPLC-IM-Q-ToF-MS verschaft 
een zeer sterke analytische tool voor vroegtijdige waarschuwing voor ERα bioactieve 
componenten in voedingssupplementen zoals het gedemonstreerd werd door de 
analyses van real-life supplementen. In het laatste hoofdstuk (Hoofdstuk 6) zijn alle 
behaalde resultaten in dit onderzoek samengevat en bediscussieerd en toekomstige 
perspectieven van de ontwikkelde concepten zijn beschreven. Alle gedemonstreerde 
concepten in dit proefschrift kunnen gemakkelijk uitgebreid worden voor de screening 
en identificatie van een breed scala aan contaminanten. In een volgend onderzoek, 
dient het combineren van verschillende bioherkenningselementen in één test 
onderzocht te worden voor omvangrijke screening en identificatie van contaminanten. 
De beschreven resultaten in dit proefschrift demonstreerden de kracht van 
bioactiviteit-gebaseerde screening gecombineerd met MS identificatie. Deze 
combinatie toonde aan dat het geschikt is voor screening en identificatie van 
contaminanten die anders gemist zou worden door conventionele instrumentele 
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analyses. Door verdere verbetering van deze bioaffiniteits-MS concepten door 
multiplexen of validatie, kunnen bestaande voedsel- en milieucontaminanten 
uitgebreid worden gemonitord terwijl de capaciteiten voor de detectie van nieuwe 
aankomende contaminanten worden behouden. 
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